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Nanoparticles have garnered much attention in pharmaceutical and biomedical 
fields because their small size and high surface area facilitate drug absorption, improve 
access to cells and organs, and enhance optical imaging. However, delivery of 
nanoparticles to the body is not always feasible or effective. Here, nanoparticle 
assemblies (flocs or clusters) for pulmonary drug delivery and biomedical imaging in 
cells are shown to facilitate delivery, interactions with cells, and manipulation of optical 
properties of inorganic/organic nanocomposites.  The formation of aggregates by 
physical techniques and their mechanisms are described in detail.   
For pulmonary delivery, particles with aerodynamic diameters between 1-5 μm 
deposit efficiently in the deep lungs.  However, crystalline, non-porous, poorly water 
soluble drugs of this size require long dissolution times, limiting absorption by the body.  
Therefore, drug dissolution must be “decoupled” from deposition to improve absorption.  
To address this challenge, drug nanoparticles were dispersed within 4-μm water droplets 
when administered via nebulization or as micron-sized flocs using a pressurized metered 
 viii
dose inhaler (pMDI).  Upon deposition in aqueous media, the aerosolized nanoparticle 
assemblies dissociated into constituent nanoparticles, raising the available surface area 
for dissolution and increasing dissolution rates, relative to solid particles.  Poorly water 
soluble drug nanoparticles were prepared using a controlled precipitation (CP) or thin 
film freezing (TFF) process, in which stable nanoparticles (30-300 nm in diameter) with 
high potencies (>90 wt% drug) were produced by rapidly nucleating drug solutions in the 
presence of strongly adsorbing polymers or by freezing, respectively.  Amorphous, 
nanoparticles prepared by CP produced stable aqueous dispersions with high fine particle 
fractions (FPF) of 77% and total emitted doses (TED) of 1.5 mg/min upon nebulization.  
CP and TFF also produced anisotropic particles (aspect ratios >5), which formed stable 
suspensions in a hydrofluoroalkane propellant.  Inefficient packing of anisotropic 
particles formed loose, open flocs that stacked upon each other to prevent settling.  Upon 
pMDI actuation, atomized propellant droplets shear apart and template portions of the 
floc to yield porous particles with high FPFs (49-64%) and TEDs (2.4 mg/actuation).        
The controlled assembly of gold nanoparticles into clusters is also of great interest 
for biomedical imaging and therapy because clusters exhibit improved near infrared 
absorbance (where blood and tissue are most transparent), relative to single spherical 
particles, and can biodegrade into clearable particles.  Gold nanoparticles (5 nm) were 
assembled into clusters between 30 to 100 nm in diameter with high gold loadings, 
resulting in strong NIR absorbance.   The assembly was kinetically controlled with 
weakly adsorbing polymers by manipulating electrostatic, van der Waals, steric, and 
depletion forces. Furthermore, clusters assembled with a biodegradable polymer 
deaggregated back into primary particles in physiological media and within cells.  This 
kinetic assembly platform is applicable to a wide variety of fields that require high metal 
loadings and small particle sizes. 
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Chapter 1:  Introduction 
 
Nanoparticles are of great interest for pharmaceutical and biomedical 
applications, especially in areas such as drug delivery and biomedical imaging because of 
their small size, high surface area, and tunable properties1.  Extensive research on 
nanoparticle formation processes has been conducted to improve drug delivery because it 
has been reported that 40% of drugs currently being developed by the pharmaceutical 
industry have poor water solubility, which can lead to low bioavailability2, 3.  For these 
poorly water soluble drugs, their absorption into the body is limited by their slow 
dissolution rates in bodily fluids4.  Dissolution rates may be enhanced by reducing 
particle size, which increases the surface area for adsorption, A, and decreases the 










     (1.1) 
 
where M is the mass of undissolved drug, t is time, D is the average diffusion coefficient, 
and ∆C is the difference between the equilibrium concentration of the drug adjacent to 
the particle surface and the concentration in the bulk.  Furthermore, when the sizes of 
nanoparticles are reduced to < 50 nm, the biological pathways in targeted cells can 
undergo profound changes6-11.  Nanoparticles < 30 nm in diameter become comparable to 
the size of small viruses, antibodies, membrane receptors, and other biomolecules, which 
can penetrate cell membranes and leaky vasculature in cancerous tumors more efficiently 
than particles >50 nm 6-11.  Particle in this size range are of significant interest for 
therapeutic and imaging applications. 
Common drug nanoparticle formation techniques include mechanical milling12 
and high pressure homogenization13, 14, which often require long processing times, risk 
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contamination with impurities, and offer little control over the morphology of the final 
product15.  The formation of nanoparticles of poorly water soluble drugs by precipitation 
from solution, however, offers more control over the production of amorphous versus 
crystalline drugs, high drug loadings, as well as high process yields16-26.  Two of the 
nanoparticle formation processes that were used in this research include controlled 
antisolvent precipitation (CP)18-20 and thin film freezing (TFF)23-25.  In the case of CP, 
high surface area particles are produced by generating large levels of drug supersaturation 
to induce rapid nucleation of the drug in the presence of amphiphilic polymeric 
stabilizers, which mitigate particle growth19, 20(Figure 1.1).  Briefly, a poorly water 
soluble drug, dissolved in an organic solvent that is miscible with water, is introduced to 
an aqueous solution containing stabilizers.  Upon mixing of the two phases, 
supersaturation of the drug leads to nucleation and precipitation.  The large interfacial 
area produced by the nucleating surfaces provides a strong driving force for the 
adsorption of the stabilizers to the newly formed particle surfaces.  The hydrophilic 
blocks of the amphiphilic stabilizers preferentially orient towards the drug/water interface 
and provide steric stabilization, thus minimizing growth by condensation or coagulation.  
In the TFF process, a drug solution is dripped onto on a cryogenically cooled surface to 
form a thin film that freezes within one second23, 26(Figure 1.2).  Cooling of the feed 
solution as it freezes leads to the nucleation of drug particles.  Particle aggregation is 
minimized due to the restricted mobility of particles in the frozen state.  In this process, 
nanoparticles may be formed with or without surfactants or stabilizers, as freezing rates 
dictate nucleation rates.  For both nanoparticle formation processes, increased nucleation 
rates, produced by increasing levels of supersaturation or by increasing cooling rates in 
CP and TFF, respectively, facilitate the formation of smaller particles.  
Similar mechanisms used to produce organic pharmaceutical nanoparticles have 
been applied in this thesis to the synthesis of inorganic nanoparticles.  For gold 
nanoparticles, increasing nucleation rates result in the formation of smaller nanoparticles, 
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just as observed during the production of the drug nanoparticles.  Gold nanoparticles are 
generally synthesized by reduction of soluble precursors27-31.  Reactions conducted using 
stronger reducing agents, such as sodium borohydride compared to sodium citrate, or at 
elevated temperatures, ~97 compared to 25oC, resulted in the production of smaller 
nanoparticles, less than 5 nm in diameter, due to  increased reaction rates and thus 
nucleation rates28, 30, 32.  Gold nanoparticles synthesized in aqueous media at room 
temperature or using citrate as the only reducing agent are generally greater than >25 nm 
in diameter29-31. 
For nanoparticles with various morphologies, strategies may be designed to 
efficiently deliver them to the appropriate location in the body and to maximize their 
therapeutic function.  Although nanoparticles possess many desirable properties that have 
been reported to enhance therapeutic and imaging applications, efficient delivery of these 
nanoparticles to a specific location in the body is not trivial due to their extremely small 
size.  Furthermore, in some situations, nanoparticle assemblies possess more desirable 
properties compared to single, isolated nanoparticles.  Two such cases will be discussed, 
where clusters of nanoparticles are used to improve pulmonary drug delivery as well as 
facilitate efficient imaging/photothermal therapy of cells and tissues.  In the case of 
pulmonary delivery, nanoparticles may be efficiently delivered to the deep lungs within 
micron-sized aggregates33-35.  These nanoparticle assemblies were achieved by spray 
drying nanoparticle dispersions and carefully controlling the time for the spray dried 
droplet to evaporate and the time for particles within the droplet to diffuse to the air-
water interface.  The time was varied by manipulating spray drying conditions 
(temperature, concentration of particles in the feed, solvent, etc ….) to control the 
cluster’s porosity, and thus aerosol properties.  Upon deposition in aqueous media, the 
assemblies were shown to deaggregate into its constituent particles, which would 
facilitate drug dissolution.   
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For bimedical applications, clusters of gold nanoparticles possess more desirable 
optical properties for imaging of cells and photothermal therapy than single, isolated gold 
nanoparticles36-39.  Gold nanoparticles conjugated with anti-EGFR monoclonal antibodies 
have been shown to form clusters during cell uptake.  When the targeted gold binds to the 
EGFR receptors on cells, they are taken up by the cell, into endosomes, which clusters 
them together36-38.  Upon cluster formation, the surface plasmon resonance (SPR) of the 
gold shifts into the near infrared region (NIR), where blood, water, and tissues absorb 
minimally, which facilitates efficient imaging and photothermal therapy of targeted cells 
and leaves untargeted cells unharmed.  Therefore, the development of robust, broadly 
applicable assembly methods for nanocluster assembly of organic and inorganic 
nanoparticles is of interest to improve the efficiency of nanoparticle delivery to the body 
as well as to take advantage of improved optical properties of clusters of metal 
nanoparticles.       
 
1.1 PULMONARY DELIVERY  
 
Pulmonary delivery is an attractive route of drug administration because it is non-
invasive and offers advantages of an enormous absorptive surface area (140 m2), thin 
absorptive membrane (0.1 – 0.5 μm), highly vascularized epithelium, and avoidance of 
first pass metabolism40.  Effective treatment of respiratory diseases, such as asthma and 
chronic bronchitis, by pulmonary drug delivery methods has been well established.40, 41  
More recently, research on the aerosol delivery of systemic drugs has resulted in several 
pulmonary insulin products42-46.  Thus, pulmonary drug delivery is versatile in its ability 
to treat diseases both locally and systemically.  Furthermore, aerosol drug delivery 
provides a promising alternative to conventional oral treatments (where drug doses may 
be  5-10 times higher than pulmonary doses, due to extensive drug metabolism in the 
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stomach/intestines40, 47) and parenteral treatment (which is more invasive and thus, less 
patient compliant). 
Drug particles may be delivered to the lungs by nebulization, pressurized metered 
dose inhaler (pMDI), or dry powder inhaler (DPI).  Nebulization, in which a drug 
solution or suspension is aerosolized into droplets for inhalation using a vibrating mesh 
screen or piezoelectric device, is easy to use and is the most capable method of delivering 
large drug doses48, up to 300 mg, in one sitting due to its ease of administration49.   
However, nebulizers are expensive and not portable, and thus not ideal for treating 
diseases that may require sudden, immediate treatment, such as asthma50, 51.  pMDIs and 
DPIs are more appropriate treatment options for these types of diseases because they are 
portable.  pMDIs remain the most popular form of pulmonary drug delivery because they 
are the least expensive of the three options, reliable, and provide effort-independent 
dosing 52, 53.   
  To achieve high deposition of drug particles in the alveoli of the lungs, where 
drug absorption is most efficient as a consequence of extremely thin membranes (0.1 – 
0.2 μm)40, aerosolized particles must possess an aerodynamic diameter (da) between 1-5 
μm.  Particles larger than 5 μm tend to deposit in the throat or upper airways whereas 
smaller, sub-micron particles are often exhaled during expiration without appreciable 
deposition54, 55.  Crystalline, non-porous, poorly water soluble drugs of the appropriate 
size for efficient alveoli deposition require long dissolution times, limiting absorption by 
the body.  Furthermore, these slow-dissolving particles are readily cleared by alveolar 
macrophages, the lung’s primary defense mechanism against foreign matter, within 
several hours after deposition40, 56, 57.  Clearly, there exists a conflict between particles 
with optimal size for deep lung deposition and optimal size for efficient drug absorption 
(Figure 1.3).  To address this challenge, drug nanoparticles may be “packaged” into 
micron-sized assemblies that, upon deposition in aqueous media, are able to dissociate to 
undergo rapid dissolution, as will be described in chapters 2-4. 
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1.1.1 Delivery of nanoparticles to the lungs by nebulization  
Aerosolized droplets emitted from nebulizers may be tuned to 1-5 μm in diameter, 
the ideal size range for deep lung delivery 58.  Therefore, in order to efficiently delivery 
nanoparticles to the lungs, they may be delivered within the nebulized droplets, which are 
already optimized for deep lung deposition.  Nebulization of poorly water soluble drugs 
dissolved in organic solvents, such as ethanol or propylene glycol, has been shown to 
efficiently deliver large drug doses directly to the lungs, on the order of 300 mg/dose40, 49, 
59, 60.  However, the prolonged and consistent exposure of organic solvents to the lungs 
often caused severe lung irritation during clinical trials, limiting its long-term viability61.  
To avoid the use of potentially irritating organic solvents, aqueous nanoparticle 
dispersions may be prepared for nebulization.  In addition to the previously mentioned 
advantages of nanoparticles versus microparticles regarding enhanced dissolution rates 
and reduced macrophage clearance, the delivery of nanoparticles is further advantageous 
for nebulization compositions because smaller nanoparticles are more stable against 
flocculation and settling, relative to microparticle dispersions.  Furthermore, 
nanoparticles may be distributed more uniformly throughout  the 1-5 μm carrier droplets 
than microparticles, as shown in Figure 1.4, which facilitates the delivery of larger doses, 
as well as more uniform drug distribution throughout the alveoli, which can enhance 
absorption rates62, 63.  
Previous studies have demonstrated the advantages of pulmonary delivery of 
nanoparticle dispersions63-66.  Nebulization of nanoparticle dispersions of milled 
budesonide63 as well as itraconazole, formed by spray freezing into liquid (SFL)64, 65 and 
TFF66, yielded optimal aerosol properties for deep lung deposition by utilizing the 
aerosolized micron-sized water droplet as a vehicle to efficiently deliver the nanoparticles 
to the lungs.  Furthermore, nebulization of itraconazole nanoparticles, produced using 
SFL and TFF, to a mouse model yielded high lung tissue to serum ratios, demonstrating 
 7
superior local therapy in the lungs while minimizing systemic levels, relative to oral or 
parenteral delivery 65, 66, which is highly desirable to reduce toxicity concerns.  However, 
these previous studies required at least 40 wt % of excipient to effectively stabilize the 
drug nanoparticles in an aqueous dispersion.  Chapter 2 will examine an alternative 
particle formation technique to produce stable poorly water soluble drug nanoparticles 
with higher drug potencies.   
 
1.1.2  Delivery of nanoparticles to the lungs using a pressurized metered dose 
inhaler (pMDI)  
pMDIs are commonly formulated as suspensions due to the low solubilities of 
many drugs and proteins in hydrofluoroalkane (HFA) propellants67.  The traditional 
methods used to stabilize colloidal particles in water have not been successful in HFA 
because of the lack of efficient electrostatic and steric repulsive forces.  Electrostatic 
stabilization in HFA is negligible compared to the van der Waals (VDW) attractive 
forces, due to ion pairing that results from the low dielectric constants68, 69.  Steric 
stabilization is also severely limited because the hydrogenated tails of FDA-approved 
surfactants are poorly solvated by HFA, due to its low polarizability52, 67, 70-72.  Therefore, 
drug loadings in pMDI formulations have been restricted to 1-5 wt% to minimize 
flocculation and settling that may lead to irreversible particle aggregation67.   Despite the 
low drug loadings, suspensions of milled or spray dried particles, which are most 
commonly delivered using pMDIs, often flocculate and settle within minutes67, 73, 74.  This 
rapid particle settling often results in an increase in da and inconsistent dosing between 
actuations, as evidenced by the low fine particle fractions (percentage of delivered 
particles estimated to deposit in the deep lungs40) between 5-30% 75 and respirable doses 
between 30-200 μg/actuation40, 73, 75 that are typical of pMDI compositions.  The low 
respirable doses achieved by pMDIs limit their ability to treat systemic diseases, as 
required doses for drugs such as insulin and some anti-cancer agents are 1-10 mg/dose76.  
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Therefore, pMDI administration has been limited to the delivery of high potency (low 
dose) drugs.   
To improve pMDI performance, reduced particle flocculation and settling in 
HFAs have been demonstrated with hollow, porous particles, which possess excellent 
suspension stability in HFAs with no visible settling up to four hours73.  The porous 
structure allows the HFA to permeate and fill the particle, minimizing the density 
difference between the suspended particles and the surrounding HFA, and thus reducing 
VDW attraction forces77.  Additionally, the hollow, porous particles achieved high FPFs 
when delivered using a pMDI,  ranging from 40-70% for a wide variety of drugs 73, 77-79.  
However, their high porosity, as well as the high excipient levels required to produce 
their porous morphology, limits their drug mass/particle loading, capping their maximum 
respirable dose at ~300 μg/actuation67.  Therefore, the production pMDIs capable of 
delivering high drug doses requires the development of a stabilization mechanism that 
does not rely on colloidal stabilization of particles in HFA.  This concept is explored in 
chapters 3 and 4 using anisotropic particles.   
 
1.2 CONTROLLED ASSEMBLY OF NANOPARTICLE CLUSTERS FOR BIOMEDICAL 
IMAGING AND THERAPY  
 
Clusters of metal nanoparticles have been shown to possess different optical 
properties than isolated nanoparticles due to a change in their surface plasmon resonance 
when packed closely together80.  For a variety of applications, robust and widely 
applicable synthetic strategies are needed to pack high levels of functionality (i.e. high 
metal loadings) into clusters with an overall size smaller than ~30 to 100 nm.  Clustering 
of gold nanoparticles is of extreme interest for imaging and therapeutic applications, such 
as photothermal therapy, because the surface plasmon resonance (SPR) of gold may be 
shifted  to the near-infrared region (NIR), where soft tissues and blood are most 
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transparent, upon tight packing between gold particles within a cluster81-83.  Presently 
available gold nanoparticles that absorb in  the NIR possess hollow or non-spherical 
geometries and are typically larger than 50 nm84-90, above the threshold size of 
approximately 5.5 nm required for efficient renal clearance from the body 91.  These 
nanoparticles are essentially non-biodegradable since the metallic bonds between atoms 
are inert, and thus concerns about their accumulation and long-term toxicity91, 92 have 
restricted their translation into clinical practice.  Therefore, the assembly of gold 
nanoparticles into clusters using a biodegradable polymer, which possess the potential to 
deaggregate into clearable particles, offers a significant improvement over currently 
available materials for imaging processes.   
To regulate their size, clusters are most often formed by thermodynamic self 
assembly.  A “bricks and mortar” technique was developed by Rotello and co-workers to 
template the assembly of metal nanoparticles into clusters using polymers, proteins, and 
DNA80, 93 and Glotzer et al. used polymer-tethered nanoparticles to demonstrate cluster 
assembly 94.  Gold nanoparticles have also been assembled in the cores of block 
copolymer micelles95-98 and on the surface of micelles99, 100.  Amphiphilic gold Janus 
spheres, containing hydrophobic and hydrophilic domains self-assemble into clusters101-
104 upon manipulation of pH or solvent quality.  For thermodynamically driven cluster 
assembly, high concentrations of strongly interacting templating agents are required.  
Therefore, a significant amount of these templating agents often remain in the final 
cluster, typically limiting the metal loading well below 50 wt%.   
Kinetic assembly of clusters, in contrast to thermodynamic self assembly, may 
achieve extremely high metal loadings by manipulating electrostatic interactions between 
charged particles.  For example, variation of pH or ionic strength of dilute dispersions of 
citrate-capped gold nanoparticles screens electrostatic repulsion and induces cluster 
growth105, 106.  Lysine-107-110 and cysteine-111 capped gold nanoparticles at high loadings 
aggregate reversibly in response to changes in charge with pH.  Despite the ability of 
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these gold clusters to exhibit strong NIR absorbance, cluster growth and shape in each of 
these cases was difficult to control, due to the absence of a stabilizing agent and often 
produced irregularly shaped aggregates greater than several hundred nanometers in 
diameter.  Therefore, a conflict arises in both thermodynamically- and kinetically-
controlled assembly between the need for sufficient levels of stabilizers to produce small 
clusters <50 nm while simultaneously achieving high metal loadings for high 
functionality.  To address this conflict, the ability to simultaneously control cluster size 
and optical properties by mediating VDW, electrostatic, steric, and depletion forces will 




In many situations, nanoparticle assemblies possess more desirable properties 
over single, isolated nanoparticles.  Assemblies of nanoparticles may be more efficiently 
delivered to the desired location in the body and for, inorganic metal nanoparticles, 
possess improved optical properties in a clustered state versus isolated nanoparticles.  
The primary goals of this dissertation are (1) to demonstrate enhanced pulmonary 
delivery of nanoparticles to the lungs by facilitating their delivery as micron-sized 
assemblies and (2) to demonstrate the assembly of gold nanoparticles into clusters of 
controlled size and optical properties for improved biomedical imaging and therapy 
applications.  The kinetically controlled assembly of both organic and inorganic 
nanoparticles will be demonstrated to provide efficient delivery of nanoparticles to the 
body as well as improved function.  Control over cluster formation and also their break-
up will be discussed.  The assembly of these clusters is driven by attractive van der Waals 
forces. The size and morphology of the clusters will be shown to influence their delivery 
and functional properties.  In contrast to thermodynamic assembly methods, which 
require strong interactions between the particles and a templating agent that results in low 
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particle loadings within the cluster, the kinetic assembly of clusters facilitates high drug 
or metal nanoparticles loadings to maximize functionality.   
For the first goal of this dissertation, there are two key objectives.  First, the 
stability and aerosol performance of nebulized dispersions of a poorly water soluble drug 
was investigated.  The nanoparticles for nebulization were produced by CP.  The effect of 
drug/surfactant levels during the formation process on particle size and crystallinity was 
examined in order to determine the optimal level of surfactant required to stabilize small 
nanoparticles (<300 nm) while maintaining high drug potencies.  Furthermore, the 
mechanism behind drug absorption of these nanoparticle dispersions in the lungs was 
examined by developing a model to examine the dissolution and permeation of poorly 
water soluble drugs in lung tissue.  For the second objective, this dissertation describes 
the concept of forming stable nanoparticle suspensions of both proteins and poorly water 
soluble drugs in HFAs by using anisotropic particles.  Anisotropic particles form loose, 
open flocs in HFA, due to their inefficient packing relative to spherical particles, which 
are able to stack upon each other and prevent settling to form stable suspensions.  The 
mechanism by which the atomized HFA droplets, formed upon pMDI actuation, template 
the flocs into aerosolized particles to achieve high fine particle fractions in pulmonary 
delivery is described.  The particle morphologies for pMDI delivery, produced using CP 
and TFF, were rods, thin plates, and needles of varying size and aspect ratios.  The effect 
of particle size and shape on suspension stability and aerosol properties, as well as the 
extension of this concept to deliver higher doses, on the order of milligrams/actuation, is 
also examined.  Furthermore, the ability of these nanoparticle assemblies to deaggregate 
upon deposition in aqueous media to facilitate drug dissolution, relative to a non-porous 
particle of similar size, is also discussed. 
For the second goal of this dissertation, the kinetic assembly of 5 nm constituent 
gold particles into clusters, with tunable sizes between 30 nm to 100 nm, which manifest 
intense NIR absorbance and strong optical contrast in live cells is described.  The 
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combination of high gold particle volume fractions during the cluster formation process 
and the inclusion of a weakly adsorbing polymeric stabilizer to mediate interactions 
between gold primary particles facilitates the production of clusters with high gold 
loadings and close-spacing between the gold particles in the cluster.  These properties 
enable strong NIR absorbance.  The mechanism by which the clusters nucleate and grow 
is described in terms of the electrostatic, van der Waals, steric and depletion forces.  
When a biodegradable polymeric stabilizer is used in the cluster formation process, 
nanoclusters deaggregate completely into the constituent 5 nm primary gold particles 
upon degradation of the polymer binder under physiologically relevant conditions in 
solution and in live cells.  This general concept for the assembly of hybrid 
polymer/inorganic nanoclusters combines advantages of the biodegradability of a 
polymer binder/stabilizer with the strong imaging contrast and therapeutic capabilities 
afforded by the NIR-active closely-spaced metal nanoparticle assembly.   
 
1.4 DISSERTATION OUTLINE 
 
The first half of this dissertation focuses on the formation and stabilization of 
nanoparticle assemblies for pulmonary drug delivery applications.  In chapter 2, stable, 
aqueous dispersions of a poorly water soluble drug were nebulized to demonstrate the 
successful delivery of nanoparticles to the lungs.  Aqueous colloidal dispersions of 
amorphous poorly water soluble drug nanoparticles were produced by controlled 
antisolvent precipitation and stabilized using only 10% wt of a polymeric stabilizer.  
Rapid nucleation rates and efficient stabilization of the particles by adsorbed polymer 
minimized crystal growth within the dispersion to yield average particle sizes of ~300 nm 
with over 80% by volume of the particles smaller than 1 μm.  The small size of the drug 
nanoparticles, relative to the micron-sized droplet, made them ideal for delivery via 
nebulization because they could uniformly disperse throughout the micron-sized 
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aerosolized droplet, whose aerodynamic diameter was controlled by the nebulizer. The 
nebulized dispersion yielded a mass median aerodynamic diameter (MMAD) of 2.5 μm 
and a FPF of 72%, indicating that the dispersion possessed optimal aerodynamic 
properties for deep lung deposition. Dissolution of the amorphous nanoparticles produced 
supersaturation values 18 times the drug’s aqueous equilibrium solubility.  The 
nebulization of the nanoparticle dispersion to mice produced therapeutic lung levels and 
systemic concentrations below toxic limits. Therefore, the sizes of the aerosolized 
aqueous droplets were optimal to efficiently delivery the drug nanoparticles to the lungs, 
and, upon deposition, the amorphous drug nanoparticles could disperse and facilitate 
rapid dissolution.  A dissolution/permeation model was developed to characterize the 
effects of particle size, solubility, and drug dose on the absorption half-lives of poorly 
water soluble drugs in the alveoli.  The in-vitro and in-vivo data, as well as the 
dissolution/permeation model, indicate that nebulization of amorphous nanoparticle 
suspensions  has the potential to enhance lung epithelial absorption markedly for poorly 
water soluble drugs, relative to respiratory delivery of crystalline, micron-sized particles.  
In contrast to chapter 2, in which nanoparticles were stabilized in an aqueous 
dispersion for nebulization, nanoparticles are purposely flocculated to form micron-sized 
assemblies for delivery by a pMDI in chapter 3.   A novel concept for the formation of 
stable protein (bovine serum albumin, BSA) suspensions in a HFA propellant for pMDI 
delivery, which is based on purposely forming flocs of particles, is presented.  Rod-
shaped BSA particles with an aspect ratio of 24, produced by TFF, formed highly open, 
low density, space-filling flocs, held together weakly by VDW forces, in HFA that were 
stable against settling for over one year at a drug concentration of 10 mg/mL.  In contrast, 
spherical particles produced by milling formed dense aggregates in HFA at the same drug 
loading settled within one minute.  Therefore, the pMDI suspension stability is dependent 
on the geometry of the suspended particles, and not on surfactants or stabilizers.  Upon 
pMDI actuation, the atomized HFA droplets were shown to break apart and template the 
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weakly associated, highly open, friable flocs.  Evaporation of the HFA droplet produced 
capillary forces that compacted the templated floc to produce porous particles with 
optimal mass median aerodynamic diameters (MMAD) for deep lung delivery.  The 
pMDI suspensions composed of anisotropic particles produced aerosol particles with 
geometric diameters on the order of 10 µm with low densities, on the order of 0.2 g/cm3, 
which enabled optimal MMADs between 3-4 μm, high fine particle fractions (47%), and 
a delivered dose up to 0.7 mg/actuation.   
The novel concept of purposely forming flocs for efficient pMDI delivery, 
presented in chapter 3, was extended to another drug system, as well as to the delivery of 
higher drug doses in chapter 4.  Anisotropic particles of a poorly water soluble drug, 
itraconazole (Itz) were also shown to form stable suspensions in HFA as well as to yield 
aerosol particles possessing optimal aerodynamic sizes for deep lung deposition.  The 
effects of particle size, shape and aspect ratio on floc formation and structure, as well as 
aerodynamic properties upon pMDI delivery were examined.  In comparison to the BSA 
nanorods that possessed an aspect ratio of 24, the ability of the Itz particles of different 
morphologies, which include thin, rectangular plates (maximum dimension of 600 nm, 
aspect ratio of 10) and long, needle-shaped crystals (maximum dimension of 8 µm, aspect 
ratio of 5), to form stable suspensions of open flocs in HFA is examined.  In addition, the 
ability of these lower aspect ratio particles to produce appropriately-sized aerosol 
particles for deep lung delivery is also discussed.  This concept of floc formation for 
pMDIs was further explored by studying the ability of these pMDI compositions to 
handle higher drug loadings, up to 50 mg/mL, in terms of suspension stability and aerosol 
performance.  Despite the factor of 5 increase in drug loading, stable suspensions in 
HFA, optimal MMADs between 3-4 μm, and high FPFs up to 64%, while delivering total 
emitted doses up to 3.5 mg/actuation, were achieved.  Finally, improved dissolution rates 
for the aerosolized, porous flocs of the poorly water soluble drug, Itz, relative to dense 
aggregates of milled particles, is also described.  This novel concept of forming 
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extremely stable pMDI suspensions without stabilizers, based on the flocculation of 
anisotropic particles, is of practical interest because it encompasses a wide-range of drug 
classes, demonstrates increased deliverable doses from a pMDI, and enhances the 
dissolution of particles that are delivered to the lungs. 
In contrast to the flocculation methods presented in chapters 3-4 where loose, 
open flocs were desirable, chapters 5-6 discusses the assembly of gold nanoparticles into 
tight, closely-spaced clusters for applications in biomedical imaging and therapy.  In 
chapters 3-4, weak VDW interactions between anisotropic particles, in which the contact 
areas between particles was small, facilitated the formation of  open, low density flocs.  
For the clusters of spherical gold nanoparticles, much more dense assemblies were 
formed, as expected, due to more efficient packing of spherical particles.  Chapter 5 
introduces a novel platform for the kinetically-controlled assembly of 5 nm gold particles 
into ~100 nm metal/polymer biodegradable nanoclusters with strong NIR absorbance for 
multimodal applications.  The small size of the clusters is shown to enable efficient 
uptake by macrophage cells, while close-spacing between gold nanoparticles within the 
clusters facilitates strong NIR scattering and absorption.  The nanoclusters are bound 
together with a biodegradable triblock copolymer of polylactic acid and polyethylene 
glycol, PLA(2K)-b-PEG(10K)-b-PLA(2K), enabling cluster deaggregation under 
physiological conditions to release the constituent clearable gold nanoparticles.  The 
ability of the clusters to deaggregate minimizes concerns of systemic toxicity and particle 
accumulation.  The nanocluster size and spacing between constituent gold nanoparticles 
are controlled by regulating particle concentration during cluster formation, as well as 
mediating interactions between ligand-coated gold cores and the biodegradable polymer 
binder.  Key aspects in this chapter are to demonstrate the ability of these nanoclusters to 
be taken up by live macrophage cells and to deaggregate into clearable particles within 
the cells. 
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By elucidating a detailed mechanism by which these clusters are formed, 
nanocluster properties, such as size and interparticle spacing, may be tuned.  A 
mechanism to describe nanocluster formation, growth, and assembly in terms of the 
electrostatic, VDW, steric and depletion forces is presented in chapter 6.  Nanoclusters 
with high gold loadings are produced upon the nucleation of electrostatically stabilized 
gold nanoparticles at high volume fractions in the presence of a weakly adsorbing 
polymer.  Polymer adsorption to the gold nanoparticles reduces particle charge and thus 
weakens electrostatic repulsion, facilitating cluster growth by VDW forces.  The 
purposeful nucleation of clusters by polymer adsorption also enables regulation of cluster 
size because the adsorbed polymer provides steric stabilization to the growing cluster.  
Therefore, cluster growth is controlled by simultaneously increasing gold and polymer 
concentrations using physical processes, such as solvent evaporation or mixing.  Along 
with high gold particle volume fractions, depletion forces, which exclude the weakly 
adsorbed polymer from the cluster interior, facilitate low polymer loadings and close 
spacing between gold particles.  Exclusion of the polymer to the cluster exterior provides 
sufficient steric stabilization to prevent unregulated cluster growth, enabling the tuning of 
the cluster size down to only ~30 nm.  Therefore, the key to controlling both cluster size 
and interparticle spacing within the cluster is the inclusion of a weakly adsorbing 
polymer that simultaneously facilitates cluster nucleation and provides steric stabilization 
to the nucleating cluster.  The generality of this kinetically controlled nanocluster 
assembly method, capable of producing clusters with high metal loadings and sizes 
between 30-100 nm, demonstrates great promise , as the ability to pack high levels of 
functionality into small clusters is applicable for a wide range of fields, including sensors, 









Figure 1.1 Controlled precipitation of drug particles in the presence of amphiphilic 
molecules19.   
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Figure 1.2 (A) Schematic of the TFF process and (B) photograph of the frozen drug 






Figure 1.3 Nanoparticle formulations may enhance bioavailability by minimizing 
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Figure 1.4 Schematic to demonstrate that nanoparticles are more evenly distributed 
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Chapter 2:  Amorphous Cyclosporin  Nanodispersions for Enhanced 
Pulmonary Deposition and Dissolution 
Aqueous colloidal dispersions of amorphous cyclosporin A (CsA) nanoparticles, 
intended for pulmonary delivery, were formed by controlled antisolvent precipitation and 
stabilized with 10% polysorbate 80.  Dissolution of the dispersion of CsA nanoparticles 
produced supersaturation values 18 times the aqueous equilibrium solubility.  
Nebulization of the dispersion to mice produced therapeutic lung levels and systemic 
concentrations below toxic limits. The sizes of the aerosolized aqueous droplets are 
optimal for deep lung deposition, whereas the amorphous drug nanoparticles facilitate 
rapid dissolution.  A dissolution/permeation model was developed to characterize the 
effects of particle size, solubility, and drug dose on the absorption half-lives of poorly 
water soluble drugs in the alveolar epithelium.  For crystalline 3 μm particles with a 
solubility of 1 μg/mL, the half-life for absorption was estimated to be 500 minutes.  The 
half-life may be reduced to less than 1 minute by increasing the solubility by a factor of 
100 with an amorphous form as well as by decreasing the particle size ten fold. The in-
vitro and in-vivo data, as well as the dissolution/permeation model, indicate that 
nebulization of amorphous nanoparticle suspensions  has the potential to enhance lung 
epithelial absorption markedly for poorly water soluble drugs, relative to respiratory 





2.1  INTRODUCTION 
 
Pulmonary drug delivery has been a popular form of therapy for asthma and has 
become increasingly attractive for cystic fibrosis, lung cancer, immunosuppression, 
tuberculosis, pulmonary hypertension, and diabetes1-5.  The advantages of this non-
invasive delivery route include: (1) an enormous absorptive surface area of 140 m2 and 
vasculature that facilitate rapid delivery of large drug doses, (2) targeted lung therapy 
with reduced systemic side effects relative to other routes of administration, and (3) 
avoidance of hepatic first-pass metabolism3.  As a result, pulmonary drug doses can be 
80-90% lower than a required oral dose in some cases3, 6.   
Recently, nanoparticle formulations of poorly water soluble drugs have been 
developed for respiratory delivery to raise dissolution rates and thus enhance 
bioavailability 7, 8.  The reduced macrophage uptake of nanoparticles, relative to larger 
particles,  also minimizes pulmonary clearance3, 9-11.  Phagocytosis is most prevalent for 
particles with diameters of approximately 1 μm and is reduced for particles smaller than 
500 nm and larger than 3 μm3, 10, 11.  Alveolar macrophage uptake of 1 μm particles has 
been observed as early as 15 minutes after nebulization12.  Evora et al. reported up to 
65% of macrophages had phagocytosed 3 μm particles within one hour after incubation 
in a cell culture13.  Furthermore, 30-60% of 1-3 μm particles have been observed to be 
phagocytosed 2-4 hours post aerosolization, with complete pulmonary clearance of 
particles within 24 hours 11, 14, 15.  Large, porous particles, with diameters of 5-20 μm, 
have also been delivered to the lungs because of their ability to evade macrophage 
clearance16-18. 
Although nanoparticles offer the benefit of enhanced dissolution, the particles are 
predominantly exhaled after inspiration, without appreciable deposition, as a 
consequence of their low inertia 19-21.  Tsapis and Edwards formed “Trojan particles” 
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composed of polystyrene nanoparticle aggregates in the form of a hollow sphere with a 
favorable aerodynamic diameter to address this challenge9.  The nanoparticles were 
released upon contact with a dissolution medium such as alveolar fluid, offering the 
potential for rapid dissolution.  Nebulization of aqueous nanoparticle dispersions is an 
alternative approach22-24.  The aqueous droplet diameters may be tuned to 1-5 μm, the 
ideal range for deep lung delivery 3.  Nanoparticle dispersions are more stable against 
flocculation and settling relative to microparticle dispersions, particularly for low 
molecular weight steric stabilizers such as polysorbate 80.  Furthermore, nanoparticles 
have been shown to be distributed more uniformly throughout  the 1-5 μm carrier 
droplets than microparticles 7, 25, 26.  Suppose the volume fraction, f, of particles in the 
solvent is 0.01.  Then only about 1/100 of 3 μm carrier droplets will contain a 3 μm 
particle.  In contrast each carrier droplet would contain about ten 300 nm particles 








f/NN =   (2.1) 
 
Thus, nanoparticle colloidal dispersions, relative to microparticle colloidal 
dispersions, have the potential to increase the rate of drug absorption by promoting more 
uniform drug distribution throughout the alveoli22, 26.  Furthermore, aerosol impactor 
studies show improvements in fine particle fractions (percentage of the emitted dose that 
deposits within the region of therapeutic benefit 26) for nebulization of dispersions of 
nanoparticles relative to micron-sized particles 7, 26, 27.   
Methods of forming drug nanoparticles for inhalation include encapsulation into a 
polymer 28-30, liposome 31, solid lipid nanoparticle (SLN) 32, or complexation into 
cyclodextrin 33-35.  Despite the benefits of these techniques, the drug/excipient ratio is 
limited in some cases and the long-term cytotoxic effects of the excipients must be 
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considered.  Ostrander et al. roller-milled beclomethasone dipropionate in an aqueous 
dispersion with a surfactant for approximately 4 days to produce 164 nm particles.  
Nebulization of aqueous dispersions of these nanoparticles delivered higher emitted doses 
with much higher fine particle fractions relative to the commercial microparticle product 
(34.8% and 56-72%, respectively)26.  Likewise, phase I clinical trials of a nebulized 
crystalline nanobudesonide (75-300 nm) aqueous dispersion yielded double the 
maximum plasma concentrations in approximately half the time when compared to a 
microparticle inhalation dispersion with a mean diameter of 4.4 μm.  The higher peak 
plasma levels were attributed to faster systemic absorption resulting from more rapid 
dissolution and a higher fine particle fraction 22, 36.  However, milling is not suitable for 
all drugs because it has been shown to produce partially amorphous drug domains 
complicating control of crystalline morphology, and thus the drug stability 37. 
Recent studies in our laboratories have demonstrated the advantages of pulmonary 
delivery of both amorphous and crystalline dispersions of nanoparticles.  Nebulization of 
nanoparticle aggregates of itraconazole, formed by spray freezing into liquid (SFL) and 
evaporative precipitation into aqueous solution (EPAS), yielded fine particle fractions 
between 71 – 85% in in-vitro studies and high lung concentrations in mice 23, 24.  
Furthermore, high lung tissue to serum ratios demonstrated superior local therapy in the 
lung while minimizing systemic levels, relative to oral or parenteral delivery 24.  To 
further advance this delivery approach, it would be desirable to examine a variety of 
classes of poorly water soluble drugs and to more fully understand the effect of particle 
deposition in the lungs and the role of supersaturation on particle dissolution and 
absorption mechanisms. 
CsA, a cyclic undecapeptide, is of interest for immunosuppression in patient 
populations that have undergone organ transplantation procedures3, 38, treatment of 
autoimmune diseases38, and the management of chronic and inflammatory conditions, 
such as asthma39.  CsA is highly lyophilic and very poorly water soluble with an 
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octanol/water partition coefficient (i.e. log P) of 4.3 40, and a solubility of 7.3 μg/mL in 
water41, 42.  The delivery of sufficient amounts of CsA to lung tissue with oral or 
parenteral formulations can cause severe systemic side effects as a result of renal and 
liver toxicity 43-45. Furthermore, the bioavailability of oral CsA formulations has been 
highly variable in clinical trials 46.  
Studies have been conducted to maximize drug levels in the lung and minimize 
systemic toxicity by nebulizing CsA solutions in ethanol to rats 47-50.  Effective 
immunosuppression has also been observed in human lung transplant recipients with 
CsA-propylene glycol solutions, which produced enhanced lung concentrations relative 
to oral delivery 51-54.  However, patients developed severe lung irritation even after 
receiving anesthesia, signifying limitations for long-term use 55.  Other studies have 
shown successful production and nebulization of CsA nanoparticles by liposomal 56, 57 
and cyclodextrin 39 encapsulation.  These methods can be limited by unknown toxicity 
effects3, 31, 34, low drug loading, or drug leakage, in the case of liposomal encapsulation31, 
32, 58.   
The primary objectives of the current study were (1) to nebulize stable amorphous 
nanoparticle dispersions of CsA to achieve high fine particle fractions and high levels of 
absorption into the lung epithelium, (2) to achieve higher and, thus, more favorable lung 
tissue to serum levels relative to oral and parenteral techniques, and (3) to more fully 
understand the deposition, dissolution, and absorption mechanisms for these 
nanodispersions.  Relative to previous pulmonary studies of nanoparticle dispersions, 
new features of this study were to raise the drug/surfactant ratio to 10:1, examine the 
stability of the dispersions with respect to particle size and crystallization, investigate in 
vitro the degree of supersaturation produced in pH 7.4 dissolution media, and to examine 
the impact of delivering amorphous drug nanoparticles on lung absorption with a 
dissolution/permeation model.  The amorphous nanoparticles were formed by controlled 
antisolvent precipitation59 with small amounts of polysorbate 80, which adsorbed on the 
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surface of the particles and arrested growth.  The surfactant orients preferentially at the 
drug-water interface and not throughout the particle.  Thus only a small amount of 
surfactant is needed to stabilize the particle, corresponding to a high drug/surfactant 
ratio60, 61.  The model provides a general framework for understanding dissolution and 
permeation for poorly water soluble drugs with solubilities ranging from 1 to 100 μg/mL.  
Furthermore, this model highlights the benefits of high supersaturation levels for 
amorphous particles and small particle sizes.  The uniform distribution of the drug 
particles in the aqueous droplets is shown to have the potential to influence the 
distribution of drug concentration in the alveoli.  Finally, the model is used to estimate 
drug absorption half-lives as a function of supersaturation, particle size, and dose, relative 
to the time for the onset of macrophage uptake, which can be as little as 15 minutes after 
nebulization12.  




U.S.P. grade cyclosporin A (CsA) and polysorbate 80 (T80) were purchased from 
Spectrum Chemical (Gardena, CA).  B.P. grade itraconazole (ITZ) was acquired from 
Hawkins, Inc. (Minneapolis, MN).  HPLC grade acetonitrile (ACN), diethyl ether, n-
hexane, ACS grade hydrochloric acid (12.1 N), and methanol were used as received from 
Fisher Chemicals (Fairlawn, NJ).  Sodium hydroxide pellets were obtained from EM 
Science (Gibbstown, NJ).   
 
2.2.2 Controlled antisolvent precipitation into aqueous solution 
The precipitation process used to produce nanoparticle dispersions of CsA was 
based on previously established methods59, 62.  Deionized (DI) water (50 g) containing an 
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appropriate amount of polysorbate 80  constituted the antisolvent phase into which 15 g 
of methanol containing 3.2% w/w CsA was injected.  Vacuum distillation was used to 
reduce the methanol to very low residual levels in the aqueous dispersion.  Nanoparticle 
dispersions were characterized directly after precipitation or were stored at 4oC.  If dry 
powder was required for characterization techniques, the aqueous dispersion was frozen 
drop-wise into liquid nitrogen and lyophilized using a Virtis Advantage Tray Lyophilizer 
(Virtis Company, Gardiner, NY) with 24 hours of primary drying at -40oC followed by 
36 hours of secondary drying at 25oC.  Dried powders were stored in a dessicator under 
vacuum.   
 
2.2.3 Particle size analysis 
The size distribution of CsA particles in aqueous dispersion was measured by 
static light scattering with a Malvern Mastersizer-S (Malvern Instruments, Ltd., 
Worcestershire, UK).  Approximately 4-5 mL of an 8.4 mg/mL dispersion was diluted 
with 500 mL of pure DI water to obtain an obscuration between 10-15%. 
The size distribution of CsA particles after nebulization was measured by 
dynamic light scattering (DLS), as the sample size was too small for static light 
scattering.  Approximately 5 mL of the CsA/T80 in water dispersion (8.4 mg/mL) were 
nebulized using an Aeroneb® Pro micropump vibrating mesh nebulizer (Aerogen Inc., 
Mountain View, CA) for 15 minutes.  The aerosol mist was captured in a 100 mL pyrex 
beaker containing about 10 mL of DI water.  The contents of the beaker were analyzed by 
a custom-built DLS apparatus 63.  The scattering angle was 90º, and the data were 
analyzed with a digital autocorrelator (Brookhaven BI-9000AT) with 522 real time 
channels and a non-negative least-squares (NNLS) method (Brookhaven 9KDLSW32).  
Measurements were made over a period of 2 minutes.  Reported average diameters 
correspond to the maximum of the distribution. 
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2.2.4 Scanning electron microscopy (SEM) 
Aqueous dispersions were diluted by approximately one-tenth using pure DI 
water, then flash frozen onto aluminum SEM stages pre-cooled in liquid nitrogen.  In 
certain experiments, the aqueous dispersions were centrifuged (Sorvall, model RC-5C, 
Newtown, CT) for 10 minutes at 17,000 RPM at 4oC.  The supernatant, containing the 
excess surfactant, was decanted, and the remaining particles were reconstituted with DI 
water to yield a concentration of approximately 1 mg/mL.  The reconstituted dispersions 
were flash frozen onto SEM stages pre-cooled in liquid nitrogen.  Subsequently, the 
stages were lyophilized.  The remaining particles were sputter coated with gold-
palladium for 30 seconds using a K575 sputter coater (Emitech Products, Inc., Houston, 
TX).  Micrographs were taken using a Hitachi S-4500 field emission scanning electron 
microscope (Hitachi Ltd., Tokyo, Japan) at an accelerating voltage of 10-15 kV. 
 
2.2.5 Brunauer-Emmett-Teller (BET) surface area measurement 
Specific surface areas of powder were measured using a BET apparatus 
(Quantichrome Instruments, Nova 2000 version 6.11 instrument, Boynton Beach, FL) 
with nitrogen as the adsorbate gas.  Weighed powder was added to a 9 mm Quantichrome 
bulb sample cell and degassed for a minimum of 8 hours.  Six points were taken over a 
range of relative pressures from 0.05 to 0.35.  The data were analyzed with the Brunauer-
Emmett-Teller equation using Nova Enhanced Data Reduction Software (Version 2.13). 
 
2.2.6 X-ray diffraction (XRD) 
The crystallinity of the dried powders was determined from X-ray diffraction 
patterns obtained using CuKα1 radiation with a wavelength of 1.5404 Ǻ at 40 kV and 20 
mA from a Philips PW 1720 X-ray generator (Philips Analytical Inc., Natick, MA).  
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Dried powder was pressed onto a glass slide to from a level surface.  A 2Ө step size of 
0.05o and a dwell time of 9 seconds were used from 5-50 2Ө degrees.    
 
2.2.7 Temperature modulated differential scanning calorimetry (mDSC) 
A 2920 modulated DSC (TA Instruments, New Castle, DE) was used to 
characterize drug crystallinity.  The drug powders were placed in hermetically sealed 
aluminum pans and then purged with 150 mL/min of nitrogen.  An amplitude of 1oC, 
period of 1 minute, and an underlying heating rate of 5oC/min from 25oC to 200oC were 
used.  Glass transition temperatures (Tg’s) were reported as the inflection point in 
thermograms and were determined using TA Universal Analysis 2000 software. 
 
2.2.8 Density measurements 
A Micromemeritics AccuPyc 1330 helium pycnometer (Norcross, GA) was used 
to determine powder density.  Weighed powder was added to a 10 cm3 sample holder.  
Mean values and standard deviations were obtained from three measurements. 
 
2.2.9 Dissolution 
Dissolution rates were measured by adding the nanoparticle dispersion (8.4 mg 
CsA/mL) to pH 7.4 phosphate buffer with 0.02% w/v SDS at 37.2oC.  The amount of the 
amorphous drug added was above the equilibrium solubility of the drug in its crystalline 
state, thus supersaturated solutions were formed.   Dissolution media (50 mL) were 
preheated in 100 mL dissolution vessels (Varian Inc., Cary, NC) placed in a VanKel 
VK6010 Dissolution Tester with a Vanderkamp VK650A heater/circulator (VanKel, 
Cary, NC).  The dispersions of the drug nanoparticles were added drop-wise to the 
dissolution media at a rate of approximately 10 drops/min over approximately 2.5 
minutes.   This slow addition technique was used to reduce the presence of excess 
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particles, which may act as heterogeneous sites for nucleation of the supersaturated 
solutions and facilitate precipitation61.  Prior to the addition of the last five drops of the 
dispersion, the dissolution media was clear.  Subsequent addition produced slight 
turbidity and drug addition was terminated.  At this point, the final dose was 240 μg CsA/ 
mL of dissolution media.  In the case of bulk CsA dissolution, dispersions were produced 
by adding the as received drug powder to a 0.084% w/v polysorbate 80 in DI water 
solution and sonicating for 2-3 minutes using a Branson Sonifier 450 (Branson 
Ultrasonics Corporation, Danbury, CT) with a 102 converter and tip operated in pulse 
mode at 35 W.  The dispersions were then added to the dissolution media as described 
above.  Sample aliquots (1.5 mL) were taken at various time points and immediately 
filtered using a 0.02 μm syringe filter.  It was assumed that drug that passed through the 
filter was dissolved as the filter pore size was more than 10 times smaller than the 
average particle diameter.  The filtrate (0.8 mL) was diluted with 0.8 mL of acetonitrile.  
The drug concentration in all samples was quantified by HPLC.   
 
2.2.10  Aerosol particle size analysis using a cascade impactor 
An aliquot (5 mL) of the CsA/T80 in water dispersion (8.4 mg/mL) was nebulized 
using an Aeroneb® Pro micropump nebulizer for 10 minutes at an air flow rate of 28.3 
L/min.  A non-viable eight-stage cascade impactor (Thermo-Andersen, Smyrna, GA) was 
used to determine aerodynamic droplet size distributions and to quantify total emitted 
dose (TED), fine particle fraction (FPF), mass median aerodynamic diameter (MMAD), 
and geometric standard deviation (GSD).  FPF was defined as the percentage of particles 
with an aerodynamic diameter less than 4.7 μm.  Fiberglass filters (81 mm diameter) 
(ThermoFisher Scientific, Franklin, MA) were set atop each impactor plate to absorb the 
aerosolized suspensions and prevent overload of the plates.  Each stage was rinsed with a 
known volume of ACN.  Each filter was placed in a separate container with a known 
volume of ACN and allowed to soak for at least 30 minutes.  Samples were filtered using 
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a 0.2 μm syringe filter prior to quantification of drug concentrations with a high 
performance liquid chromatography (HPLC) method64. 
 
2.2.11  Pulmonary dosing to mice  
Aerosols were delivered to twelve male ICR mice (Harlan Sprague Dawley Inc., 
Indianapolis, IN) weighing 25-30 g via nebulization with an aqueous 8.4 mg/mL CsA 
dispersion using a nose-only dosing chamber (Figure 2.1).  The study protocol was 
approved by the Institutional Animal Care and Use Committee (IACUC) at the 
University of Texas at Austin, Austin, TX.  All animals were maintained in accordance 
with the American Association for Accreditation of Laboratory Animal Care.  Mice were 
acclimated in restraint tubes (Batelle, Columbus, OH) for 15 minutes/day for 2 days prior 
to dosing.  Approximately 3 mLs of the CsA dispersion were nebulized over a 15 minute 
period.  Two mice were sacrificed at each time point (0.5, 1, 3, 6, 12, and 24 hours after 
the end of aerosolization) by CO2 narcosis.  Whole blood (~ 1 mL aliquots), obtained by 
cardiac puncture, and lung tissue was extracted for analysis by HPLC.  The amount of 
inhaled drug to reach the mouse was estimated to be ~3.5 mg CsA /kg body weight as 







where Cchamber is the drug concentration in the dosing chamber, RMV (rate minute 
volume) is the volume of air inhaled in one minute, estimated by the animals’ body 
weight, D is the duration of the exposure, F is the fine particle fraction (defined as the 
percentage of particles with an aerodynamic diameter less than 5.4 μm), and W is the 














animals’ body weight.  Cchamber was estimated to be 30 mg/L by using average TED’s 
from Anderson Cascade Impactor tests and the nose only dosing chamber volume to 
calculate the chamber concentration after each minute of nebulization and then taking the 
average of the concentrations over the 15 minute nebulization time. The optimal particle 
size for deep lung exposure in mice is approximately 3 μm23, 67, comparable to the value 
of 1-3 μm for humans. Given the similarity of these values,  Fukaya et al.39 chose a FPF 
cut-off of 5.4 μm for mice, a typical value for humans. 
 
2.2.12  Whole blood and lung extraction and chromatographic analysis 
Calibration standards, whole blood, and homogenized lung samples were 
analyzed as described  previously64.  Briefly, normal saline (1 mL) was added to each 
harvested lung sample, which was homogenized using a rotor stator.  An aliquot of a 40 
μg/mL itraconazole in methanol solution (50 μL) was added to 450 μL of homogenized 
lung as an internal standard.  A 95/5 v/v diethyl ether/methanol mixture (1.1 mL) was 
added to the samples.  The samples were shaken on a mechanical shaker for 15 minutes 
and centrifuged at 6000 rpm for 5 minutes.  An aliquot (900 μL) of the ether/methanol 
phase was pipetted to a new vial.  This process was repeated.  Both supernatant aliquots 
were added to the same vial.  The sample vials were placed in an aluminum heating block 
(60oC) under a stream of nitrogen for ~30 minutes until dry.  Methanol (450 μL), 0.025 
M HCL (225 μL), and n-hexane (900 μL) were added to each sample.  The samples were 
shaken for 5 minutes and centrifuged at 6000 rpm for 5 minutes.  The n-hexane layer was 
discarded.  Ether (450 μL) and 0.025M sodium hydroxide (450 μL) were added to each 
sample.  The samples were shaken for 10 minutes and centrifuged as before.  The ether 
layer was transferred to a new vial.  An additional 450 μL of diethyl ether was added to 
each sample and the shaking and centrifugation process was repeated.  The ether layer 
was transferred to the same vial as the ether supernatant from the previous step.  The 
samples were evaporated to dryness under the conditions mentioned previously.  The 
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samples were reconstituted with 250 μL of mobile phase (ACN/water 70/30 v/v), vortex 
mixed for 1 minute, and centrifuged at 6000 rpm for 5 minutes.  A 150 μL aliquot was 
pipetted into HPLC vials with low volume inserts.  CsA was extracted from whole blood 
samples using the same process.  Each sample was analyzed using a Shimadzu LC-10 
HPLC system (Columbia, MD) equipped with a Hypersil C18 column (5 μm, 150 x 
4.6mm) (Thermoelectron Corporation, Waltham, MA) protected by a C-18 guard column 
(5 mm, 7.5 x 4.6 mm) (Alltech Associates Inc., Deerfield, IL) heated to 75oC.  The CsA 
and Itz peak eluted at 7.8 and 4.0 minutes, respectively, at a flow rate of 1 mL/min, 
injection volume of 100 μL, and an absorption wavelength of 225 nm.  A 
noncompartmental model was used to determine pharmacokinetic parameters for the lung 
tissue concentration profile using WinNonlin version 4.1 (Pharsight Corporation, 
Mountain View, CA).  The whole blood concentration profile was evaluated using a one-




2.3.1  In-vitro characterization of CsA dispersion 
2.3.1.1  Morphology and size distribution for high potency nanoparticle dispersions 
made by controlled antisolvent precipitation 
Aqueous nanodispersions of CsA intended for pulmonary delivery were formed 
by controlled antisolvent precipitation.  Due to the lung’s sensitivity to foreign material 
and to limit disruption of the molecular monolayer of lung surfactant, minimal amounts 
of excipient are desired 68.  Thus, the mass of polysorbate 80 added to the aqueous phase 
during precipitation was varied to determine the  smallest amount of surfactant required 
to stabilize nanoparticles59.  Static light scattering results (Figure 2.2) show that a CsA to 
polysorbate 80 ratio of 1 to 0.1 produced particles with an average diameter of 300 nm, 
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despite the very small amount of surfactant.  Drug loading was kept constant at ~8.4 mg 
CsA/mL.  Although a small secondary peak between 2-3 μm was observed (accounting 
for about 20% of the particles by volume), over 80% of the particles had a diameter of 1 
μm or less.  For smaller amounts of surfactant extensive growth was present.   Therefore, 
all further results in this paper refer to an 8.4 mg CsA/mL dispersion with a CsA/T80 
ratio of 1/0.1.   
To confirm the static light scattering results, SEM images of the 1/0.1 CsA/T80 
powder were taken.  Primary nanoparticles on the order of 300 nm with bridging between 
the particles were observed (Figure 2.3A).  However, upon removal of excess polysorbate 
80 from the formulation by centrifugation, the lyophilized drug particles appeared to be 
relatively spherical in shape without the bridges between particles (Figure 2.3B).  Thus, 
the presence of polysorbate 80, a liquid at room temperature, during drying most likely 
facilitated the formation of the interconnecting bridges between the primary particles.  
The particle sizes in Figure 2.3B are representative of the upper end of the size 
distribution, as the centrifugation process for removal of excess surfactant also removed 
the majority of the smaller nanoparticles.  To further verify that the bridging observed 
between nanoparticles resulted from the drying process, DLS was used to determine the 
hydrodynamic diameter of the CsA/T80 particles.  The average diameter of 311 nm 
(Figure 2.4), corresponded with sizes given by static light scattering.  Thus, the DLS 
results and the SEMs in Figure 2.3B indicate that the interconnecting bridges between the 
particles in Figure 2.3A appear to be an artifact of polysorbate 80’s presence during 
drying and are not indicative of the drug particle morphology while in aqueous 
suspension.  In contrast to the spherical nanoparticles produced by controlled antisolvent 
precipitation, large high aspect ratio plates were observed for the bulk drug particles with 
lengths greater than 15 μm and a large polydispersity (Figure 2.3C).   
The particle sizes obtained from SEM and measured by static and dynamic light 
scattering may be compared with values inferred from BET surface area measurements.  
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The BET surface area of the CsA/T80 powder was ~9.5 m2/g, which corresponds to an 
effective particle diameter of ~490 nm, assuming monodisperse particles.  This calculated 
diameter is modestly higher than the results from light scattering.  The difference in size 
could result from aggregation of the particles during drying as indicated in the bridging 
between primary particles in the SEMs.  Overall, the difference between the sizes 
determined by SEM, light scattering, and BET are relatively small.  The small size of the 
primary particles formed by the controlled antisolvent precipitation process is within the 
desired range for the pulmonary experiments. 
To further complement the particle sizing techniques mentioned above, Stokes’ 








=   (2.5) 
 
where r is the particle radius, ρp is the particle density, ρmedium is the medium density, and 
η is the medium viscosity.  For the particle concentration of 1% w/v delivered to animals, 
a settling front was not observed over 48 hours.  Therefore, the dispersions were diluted 
to 0.1 % w/v to reduce turbidity in order to discern a settling front.  At this low 
concentration, modifications to Stokes’ settling rate to account for particle interactions 
were not needed.  The calculated Stokes’ settling rate for a particle with an r of 150 nm, 
ρp of 1.3 g/cm3 (as determined by helium pycnometry) in water (ρmedium of 1 g/cm3, and η 
of 0.89 mPa·s) was 0.006 cm/hr (0.1 cm/day).  The observed settling rate was 0.005 
cm/hr.  The similarity between Stokes’ and experimental settling rates infer that the 
CsA/T80 particles are approximately 300 nm in diameter, further supporting the particle 
size results reported above and also indicate minimal aggregation of nanoparticles while 
in dispersion.    
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To understand the fate of particles in the droplets during nebulization, the size 
distribution of the sample emitted from the nebulizer was measured by DLS.  The size 
distribution, by volume, of the nebulizer output was very similar to that of the original 
suspension (Figure 2.4).  Thus, the nebulization process did not cause aggregation of 
nanoparticles in the aerosolized droplets and was capable of delivering nanoparticles to 
the lungs. 
In addition to characterizing the particle size of the CsA/T80 formulation, the 
morphology was determined by XRD.  The XRD pattern for the received bulk powder 
did not show the characteristic peaks of crystalline CsA as reported by Chen et al60 
(Figure 2.5), indicating that the starting material was predominantly amorphous.  The 
amorphous nature of the “as received” bulk CsA was confirmed by DSC (Figure 2.6), 
which did not show a melting point even upon heating to 200oC.  The reported CsA 
melting point is 150oC 69.  However, a Tg at 120oC was observed, which  matches values 
reported in the literature70.  An absence of crystalline peaks was also observed in the 
XRD pattern of 1/0.1 CsA/T80 powder (Figure 2.5), inferring a primarily amorphous 
morphology.     
 
2.3.1.2 Supersaturation of aqueous media with amorphous CsA dispersion 
Particle size reduction of crystalline materials raises the surface area, A, while 
high energy polymorphs including the amorphous state increase the solubility, Csat, 







sat −=              (2.6) 
 
where M is the mass of undissolved drug, D is the diffusion coefficient, h is the boundary 
layer thickness, and C is the concentration in solution.  Dissolution of the CsA/T80 
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dispersion in pH 7.4 phosphate buffer at 37oC was conducted under supersaturated 
conditions.  In Figure 2.7, the drug concentration reached 113 μg/mL in four hours, 15.5 
times the equilibrium solubility of crystalline CsA in pure water at 37oC, which was 
reported as 7.3 μg/mL 41, 42.  After 4 hours, the supersaturation reached a plateau and 
showed no sign of precipitation for up to 4 days, at which the drug concentration reached 
128 μg/mL (data not shown).  Dissolution of bulk powder with polysorbate 80 in the 
same drug to surfactant ratio of 1/0.1 was measured under supersaturation conditions.  
After four hours, the drug concentration was 79 μg/mL (~10.8 times the equilibrium 
solubility) and reached a plateau at 81 μg/mL in 4 days.  Figure 2.7 also illustrates that 
the nanoparticle formulation dissolved much more rapidly than the bulk formulation.  
After 10 minutes, the nanoparticle and bulk particle concentrations were 96 and 13 
μg/mL, respectively.  The high levels of supersaturation maintained after 4 days indicate 
the presence of metastable equilibrium between the slight excess of amorphous particles 
and the dissolved drug. 
 
2.3.1.3 Fine particle fraction determined by Anderson cascade impactor 
The Anderson cascade impactor was used to determine the aerodynamic particle 
size distribution.  The Aeroneb Pro micropump nebulizer  produced an aqueous mist of 
fine droplets with sizes ranging between 1 – 4 μm 23, which falls within the optimal size 
range for effective aerosol delivery (i.e. between 1 and 5 µm)3.  Upon nebulizing an 
aqueous nanodispersion, the physical properties of water dictate the carrier droplet size, 
offering the potential of high fine particle fractions and uniform drug delivery.  An 
MMAD of 2.02 μm with a GSD of 1.83 and a FPF of 77.4% (Table 2.1) were observed.   
To examine storage stability of the dispersion, the cascade impactor experiment 
was repeated after three weeks of storage at 4oC.   The MMAD increased slightly to 2.52 
μm with a GSD of 1.85 and a FPF of 73.9%.  The similar TEDs of about 1450 μg/min 
and high fine particle fractions after three weeks of storage indicate that the particles in 
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the dispersions still have the potential for reaching the deep lung.  The relatively uniform 
data seen in the cascade impactor results for three weeks is consistent with the 
observation of slow settling fronts. 
 
2.3.1.4 Stability of amorphous nanoparticle dispersion after 10 months 
Nebulized dispersions must be stable against particle aggregation and settling to 
achieve uniform drug delivery.  As shown in Figure 2.8, particle size distributions by 
volume (and also by number, not shown) for the CsA/T80 aqueous dispersion did not 
change significantly for up to ten months.  The percentage of particles, by volume, under 
1 μm remained between 85-89%, while the D50 (diameter at which the cumulative sample 
volume was under 50%) was maintained at 300 nm.  Thus, despite the enhanced 
solubility of the amorphous nanoparticles, the mass of drug in the continuous phase is 
trivial when compared to the drug loading in the suspension (<1.5%, based on maximum 
dissolved concentrations achieved in the supersaturation experiments).  The extremely 
low Ostwald ripening may indicate slow addition of the cyclic peptide to the surfactant 
coated particles71.    
In addition to particle size stability, the ability of the CsA/T80 particles to 
maintain an amorphous morphology while in an aqueous dispersion was also 
investigated.  To examine storage stability, the CsA/T80 dispersion was stored for 10 
months at 4oC and was then frozen and lyophilized.  The resultant XRD pattern showed 
that the CsA/T80 nanoparticles remained amorphous over the ten month period (Figure 
2.5).  Furthermore, the DSC scan of the lyophilized nanoparticles did not show a melting 
peak, further indicating that the powder was still amorphous (Figure 2.6).  
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2.3.2 In-vivo characterization of CsA dispersion 
The deposition of CsA/T80 nanoparticles into the deep lungs via nebulization was 
tested in mice.  Lung tissue and blood concentration profiles following a single inhalation 
dose are shown in Figure 2.9, while the corresponding pharmacokinetic parameters are 
summarized in Table 2.2.  Averaged lung levels peaked at 10.5 μg/g of wet lung tissue at 
1 hour, maintaining an average concentration of at least 1.7 μg/g for 24 hours.  Average 
blood levels peaked at 372 ng/mL at 3 hours and slowly declined to 174 ng/mL at 24 
hours.  Areas under the curve (AUCs) were two orders of magnitude higher in the lungs 
than in the blood.   The systemic concentrations were desirable for therapeutic 
immunosuppression levels (100-250 ng/mL 72) in humans, but were well below renal and 
hepatotoxic levels of 800 ng/mL46.  Hence, nebulization of this CsA/T80 formulation has 






2.4.1 Role of surfactant in arresting particle growth during controlled antisolvent 
precipitation 
The controlled antisolvent precipitation process produced particles in the 300-500 
nm size range, which was desirable for achieving stable nanodispersions and high fine 
particle fractions in the cascade impactor.  As the aqueous and organic phases mixed, 
supersaturation was created, promoting rapid nucleation59.  The high hydrophilicity of 
polysorbate 80 (HLB of 15) and hydrogen bonding interactions of the ethylene oxide 
groups with water caused polysorbate 80 to favor the interface between the drug particle 
surface and water, relative to the hydrophobic particle interior61.   The passivation of the 
particle surface by polysorbate 80 hinders particle growth by condensation of molecules 
into the solid phase and by particle coagulation.    
Polysorbate 80 was chosen as the stabilizer as it has been shown to stabilize CsA 
nanoparticles at concentrations of 1.0% and 5.0% w/w in aqueous media 60, 73.  Previous 
pulmonary formulations containing higher concentrations of polysorbate 80 nebulized to 
mice did not show damage, inflammation, or cell mitigation in lung cells based on 
histology analyses in mice 74 .  Additionally, a similar product, polysorbate 20, is utilized 
in a pulmonary recombinant human interferon alpha-2b product developed by Aradigm75.  
However, this is simply a model system to illustrate the benefits of pulmonary 
nanoparticle delivery.  
As shown in Figure 2.2, a CsA to polysorbate 80 ratio of 1 to 0.1 produced 
particles with an average diameter of 300 nm.  Below this drug to surfactant ratio, 
particle growth was excessive, indicating limited steric stabilization and passivation.  
Above this ratio, the surface coverage on the growing particles became sufficient to 
produce the desired particle size of 300 nm, as described by the Damkoler number or 
ratio of mixing time to overall precipitation time.  Additional amounts of polysorbate 80 
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did not significantly reduce the particles size, as can be noted in the particle size 
distribution of the 1/0.5 CsA/T80 formulation.  This type of plateau region in particle size 
has also been observed for itraconazole and naproxen61, 76, 77.  High drug loadings have 
also been achieved for CsA particles produced by evaporative precipitation into aqueous 
solution 60 and rapid expansion from supercritical to aqueous solution73.   
In contrast, CsA to surfactant ratios were on the order of only 1/8 for liposomes 
formulations in which the drug was dissolved in the relatively small volume of the 
bilayers 56, 78.  In liposomal and SLN encapsulations, it is challenging to produce high 
enough drug/lipid ratios for practical use.  The concentrations of aqueous drug-liposomal 
dispersions may be increased to ameliorate this problem.  However, the high viscosities 
of the concentrated dispersions 78, may result in plugging of the  nebulizer jets 58.  The 
integrity of lipid formulations during nebulization is also a concern, as there have been 
numerous reports of drug leakage31, 32, 58, 79.  Polymer and cyclodextrin complexed CsA 
formulations have also been investigated.  The consequences of polymer or cyclodextrin 
internalization by macrophages and subsequent degradation within cells have not been 
determined.  There is also concern about the effects of polymer or cyclodextrin 
accumulation in the lungs and how quickly these agents must degrade to minimize tissue 
irritation 3, 31, 34.   
   
2.4.2 Supersaturation and particle curvature 
The higher solubility of the CsA/T80 nanoparticles (r = 150 nm) relative to the 
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where x is the solubility of dissolved solid, γ is the interfacial tension between the particle 
and the solvent, Vm is the molar volume of the solute, and r is the particle radius.  The 
greater LaPlace pressure for the smaller particles raises the chemical potential and 
solubility.  For a Vm of 0.001 m3/mol and a typical γ of 50 mJ/m2  80 between water and a 
hydrophobic drug, the predicted solubility ratio is 1.3.  The experimentally observed 
value was 1.6.  Thus, it is likely that curvature played a significant role in the 
supersaturation.   
 
2.4.3 Modeling of dissolution and permeation rates of drugs in the lung 
CsA must dissolve in the alveoli and permeate through the epithelial layer into 
lung tissue, before being cleared by macrophages, in order to elicit a therapeutic 
response44, 45, 81.  To better understand drug absorption in the lungs, a transport model has 
been developed to examine the effects of solubility and particle size on drug dissolution 
in lung fluid and subsequent permeation through the epithelial membrane.  The model 
will be used to determine the time for half of the drug to be absorbed, i.e. dissolve in lung 
fluid and permeate the epithelial layer.  For simplicity, the model assumes a 
monodisperse particle size distribution and that the drug is either completely amorphous 
or completely crystalline with a single equilibrium solubility. 
The dissolution rate of CsA spherical nanoparticles was determined by the Noyes-
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where the boundary layer thickness was approximated by the particle diameter.  For 
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 The flux of drug through a membrane is given by J = PΔC = P(C-0) where P is 
the permeability.  The permeate drug concentration for the epithelium was assumed to be 
zero.  A material balance on the dissolved drug in the fluid of a single alveolus includes 














where Np is the number of drug particles deposited in an alveolus, and V and A are the 
volume of lung fluid and surface area for a single alveolus, respectively.  The flux across 
the lung epithelium may be assumed to be constant since the thickness of the mouse lung 
epithelium (0.1-0.4 μm) is small compared to the diameter of a mouse alveolus (31 μm)82, 
83.  Therefore, a planar geometry was used for the permeation in eq. 2.10.  It was assumed 
that the absorption of drug from each alveolus into the lung tissue was independent of 
absorption from other alveoli.     
Equations (2.9) and (2.10) were solved simultaneously using Matlab’s (Natick, 
MA) ode15s solver with the initial conditions of t=0, r=r0 and C=0.  The diffusion 
coefficient was estimated to be 3.8 x 10-6 cm2/s using the Wilke-Chang equation84 based 
upon the properties of CsA.  A value of 1.0 x 10-5 cm/s was used for the permeability 
based on typical measured permeabilities of similar poorly soluble drugs in lung cell 
cultures, which range from 10-6-10-4 cm/s85.  The total number of drug particles deposited 
in the lungs was calculated from an estimated total mass of deposited drug and the 
volume of a single particle.  The value for total drug mass deposited into the lungs was 
approximated from the lung tissue Cmax (1.9 μg) and the corresponding blood 
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concentration (750 ng) from the mouse study.  The number of alveoli in a mouse was 
estimated to be ~2.25 x107 based on a reported alveolar surface area of 680 cm2 82 and 
alveolus diameter of 31 μm83.  Total alveolar fluid volume was estimated to be 8.3 μL, on 
the basis of a human alveolar surface fluid volume of 15 mL 68, 86 and the ratio of human 
lung to mouse lung weight.  The mass of permeated drug, Mpermeated, or drug theoretically 
absorbed by lung tissue from a single alveolus, was determined from the mass of 
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Figure 2.10 illustrates predicted lung tissue absorption times for dissolution and 
permeation for two particle sizes and two drug dosages, M0.  In addition, three solubilities 
were considered (1, 10, and 100 μg/mL) to capture aqueous solubilities for typical poorly 
water soluble drugs including budesonide87, CsA41, and triamcinolone acetonide87.  For a 
12.5 μg drug/g lung dose in Figure 2.10a (chosen based on the CsA Cmax recovered from 
lung tissue at t=1 hr and the corresponding blood concentration given in Figure 2.9) and 3 
μm drug particles, only 1 in 192 alveoli are estimated to receive a particle, assuming 
uniform drug distribution throughout the mice’s lungs.  However, approximately 5 drug 
particles are deposited in each alveolus for 300 nm drug particles.  Thus, values of 1 and 
5 were input for Np to estimate absorption times for 3 μm and 300 nm particles, 
respectively.  The time required for 50% drug absorption is predicted to reach almost 10 
hours for 3μm crystalline very poorly water soluble drugs (aqueous solubility = 1 
μg/mL), such as the anti-asthmatics beclomethasone dipropionate88 and fluticasone 
propionate87.  With an increase in the solubility by a factor of 10, the absorption time 
decreases by an order of magnitude.  Additionally, the combined reduction of particle 
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size to 300 nm along with an increase in solubility to 10 μg/mL, reduces the absorption 
time by 3 orders of magnitude.   
Figure 2.10b shows predicted absorption half lives for drug particles at a drug 
loading of 125 μg drug/g lung, which is comparable to lung levels achieved in clinical 
pulmonary CsA trials54.  At this higher drug loading, 1 in 19 alveoli were estimated to 
receive a 3 μm drug particle, while each alveolus would receive 52 drug particles with 
300 nm diameters.  Thus, for 3 μm particles, increasing the drug loading would increase 
the number of alveoli that receive a drug particle, but the number of particles deposited 
per alveolus, Np, is still unity for the determination of the absorption time.  Therefore, 
predicted absorption times did not change for the 3 μm particles with dosage.  Long times 
are required for large concentrations of drug to permeate in a small fraction of the alveoli 
when Np = 1.  Additionally, dissolution of microparticles is slower than that of 
nanoparticles due to the smaller particle surface area per unit volume.  The absorption 
time increased for the 300 nm particles as the dosage was raised to 125 μg/g since Np and 
the concentration of drug in each alveolus increased, but remained an order of magnitude 
less than the case of microparticles.  For a given mass of deposited drug, the 
nanoparticles are distributed more uniformly throughout the alveoli leading to a much 
larger surface area available for absorption.  For 3 μm particles, a larger mass must 
dissolve and permeate in a localized area, slowing the absorption process.         
To focus on the dissolution resistance independently of the permeability, the half-
lives were predicted for an essentially infinite permeability of 1010 cm/s as shown in 
Figure 2.10c.  Here, the results were the same for both dosages of 12.5 and 125 μg/g.  
Since 300 nm particles undergo rapid dissolution, absorption half lives were not 
significantly affected by the different drug loadings.  Each half life was about an order of 
magnitude shorter than in Figure 2.10a (P=10-5 cm/s), indicating that the absorption was 
limited significantly by permeability.  
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Amorphous nanoparticles with solubilities of 100 μg/mL are predicted by the 
model to dissolve and permeate the epithelial tissue on the order of minutes.  These 
predicted results are in agreement with experimental pulmonary absorption data 
conducted by Schanker and colleagues, which reported absorption half lives for a variety 
of lipophilic drugs (administered as a very dilute solution in phosphate buffer) to be on 
the order of 1 minute89-91.   For CsA, the absorption was substantially lower than for 
typical lipophilic drugs, as was evident in the blood levels in Figure 2.9.  It is probable, 
based on in vitro dissolution results, that CsA dissolved quite rapidly.  However, CsA’s 
high affinity to bind with the intended protein target, cyclophilin, in the lung tissue 
reduced further permeation into the bloodstream.  Handschumacher et al. reported that 
0.96 moles of CsA bound per mole of cyclophilin, indicating a high binding affinity92.  
Observations of prolonged CsA retention in lung tissue in previous studies have also been 
attributed to CsA binding to phospholipids in lung surfactant 54, 93.  For example, upon 
intra-arterial administration, CsA concentrations in the lung were an order of magnitude 
higher than in any of the other organs94.  The lipophilicity of CsA promotes interactions 
with lung surfactant phospholipids leading to avidity for CsA by lung tissue.  High 
binding affinities to proteins in lung tissue have also been attributed to extended drug 
retention in pulmonary tissues for drugs such as fluticasone propionate and amphotericin 
B 95-97.    
 
2.4.4 Comparison of in vivo formulations 
The present CsA/T80 dispersion offers advantages over previously reported CsA 
formulations as shown in Table 2.3 for reducing variability in bioavailability and 
systemic toxicity.  Lung levels in our formulation were similar to those produced by a 
similar intramuscular CsA dose.  However, the blood levels were five times lower49.  An 
oral dose of the commercial CsA product, Neoral, dosed to mice at 10 mg/kg also yielded 
high blood levels, well above the toxic limit for more than 12 hours after dosing98.  In 
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general, doses which produce blood levels below the toxic limit have not been shown to 
provide sufficient absorption into lung tissue 44.  CsA is believed to bind to cyclophilin, a 
cytosolic protein found in lung tissue, to form a complex that inhibits calcineurin.  The 
inhibition of calcineurin blocks T-cell activation, which is responsible for a myriad of 
immune and regulatory responses99, 100.  Thus, for CsA to elicit a therapeutic response, 
sufficient drug levels must be absorbed into the lung tissue. 
Aerosolized formulations of CsA solutions in ethanol yielded extremely high lung 
concentrations in a rat model49, 50, but with extremely high systemic levels 49.  The high 
concentrations of ethanol exposed to the lung could have opened up tight junctions, 
leading to enhanced particle passage into the blood stream101.  A solution formulation 
with propylene glycol, currently in clinical trials, produced lung levels as high as 112 
μg/g by gamma scintigraphy, while maintaining acceptable blood levels 54.  In solution 
formulations, drug particles of unknown size may nucleate and grow upon mixing 
ethanol with lung fluids.  The polydispersity in particle size will influence the dissolution 
rate, absorption, and thus the therapeutic effectiveness, since CsA must dissolve and be 
absorbed before it is cleared44, 45, 81.  Thus, the delivery of amorphous CsA nanoparticles 
have the potential to enhance therapeutic effectiveness over current solution formulations 
by facilitating rapid absorption into the lung tissue without yielding high systemic levels.  
Despite rapid dissolution of the aerosolized CsA nanoparticles, localized therapy was still 
achieved most likely due to CsA’s known affinities for constituents found in pulmonary 
tissue.  Additionally, the large amounts of solvent required for solution formulations may 
not only open up tight junctions and augment CsA levels in the blood, but can in some 
cases cause severe lung irritation.             




CsA amorphous nanoparticle dispersions nebulized to mice produced efficacious 
drug concentrations in both the lung tissue and blood stream, within the therapeutic 
window.  This accomplishment may be particularly useful for lung transplant recipients 
or for those patients requiring non-steroid asthma treatment, where the effectiveness of 
CsA has been limited due to a narrow therapeutic window.  Furthermore, nebulization of 
the CsA nanodispersions with high drug loadings circumvents problems in solution-based 
pulmonary formulations including irritation of lung tissues by organic solvents or large 
amounts of excipients.  It also generates much higher lung tissue concentrations (10.5 μg 
drug/g lung) than oral and parenteral delivery, while maintaining lower systemic toxicity 
levels (370 ng/mL).  Thus, the development of an aerosolized nanoparticle formulation  
to target the deep lungs will not only make CsA a more viable option for treatment of 
lung diseases, but this methodology can also be applied to other drugs that have narrow 
therapeutic windows.   
In nebulization of nanoparticle dispersions, the vast difference in length scales of 
the drug particles and water droplets optimizes, simultaneously, both deposition and 
dissolution in the lung tissue.  The water droplets provide high fine particle fractions 
(77%), whereas the size of the drug particles favors enhanced dissolution.  For 
amorphous CsA, in-vitro supersaturation levels reached up to 18 times the equilibrium 
solubility.  To better understand the drug absorption in the lungs, a 
dissolution/permeation model was developed to characterize the effects of particle size, 
morphology, solubility, and drug dose on absorption half-lives of poorly water soluble 
drugs in the alveolar epithelium.  For a 3 μm drug particle with a solubility of 1 μg/mL, 
the half-life is predicted to decrease from 500 to 5 minutes with an increase in 
supersaturation to 100, which can be achieved by the formation of an amorphous form61, 
or particle size reduction to 300 nm.  Thus, the model indicates that modification of drug 
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properties to enhance drug dissolution can affect drug absorption times markedly.  Due to 
the flexibility of the model, it can also be applied in the development of other pulmonary 
poorly water soluble drug formulations to predict if absorption rates will be sufficient to 
avoid clearance by macrophages.  For CsA, the model predicts rapid absorption into lung 
tissue, where interactions with the lung surfactant and/or the intended protein target 
cyclophilin, inhibited further permeation to the bloodstream.  As a result, favorably high 





Figure 2.1  Schematic of small animal nose-only dosing apparatus: (A) Sketch of dosing 
apparatus, (B) Close-up image of animals’ noses positioned in dosing 
chamber, (C) Illustration of nebulized drug dispersion, in which 




Figure 2.2  Effect of polysorbate 80 concentration on CsA particle size distribution in 
an aqueous dispersion. 
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Figure 2.3 SEM images of (A) CsA:T80 (1:0.1) powder obtained by lyophilization of 
the nanodispersion produced by controlled antisolvent precipitation, (B) the 
same formulation but after removing excess polysorbate 80 prior to 







Figure 2.4  Particle size measurements of the CsA nanodispersion before (A) and after 
(B) nebulization.  In (A), 48% of the particles, by volume, had a diameter of 
296 nm or less.  In (B), 55% of the particles, by volume, had a diameter of 






Figure 2.5  X-ray diffraction (XRD) of CsA:T80 (1:0.1) powders (A-B) and bulk CsA 
(C-D).   Results in (D) were obtained from Chen et al.60.  The dispersion 
was frozen and lyophilized immediately after  precipitation in in (A) and 






Figure 2.6 mDSC thermograms of bulk CsA powder and lyophilized 1/0.1 CsA/T80 
particle dispersions that were stored for 10 months at 4o C.   No melting 
peak was observed for either powder. A Tg at ~ 120oC was observed. 
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Figure 2.7 Supersaturation concentrations of CsA nanoparticle dispersions after 
dropwise addition to pH 7.4 phosphate buffer.  All samples were filtered 
with 0.02μm filters.  The dashed line represents the reported aqueous 





Figure 2.8 Effect of storage time on CsA particle size distribution in an aqueous 
dispersion.  Dispersions were stored at 4oC and sonicated for 5 minutes with 


















Figure 2.9 (A)  Mean lung concentrations (ng CsA/g wet lung tissue) and (B) mean 
whole blood concentrations (ng CsA/mL) over 24 hours for mice dosed with 





Figure 2.10 Predicted absorption half lives (time for 50% of drug to dissolve and 
permeate though lung epithelium) for drug particles of two different sizes 
and two different drug loadings over a range of solubilities (A-B).  In (C), 
absorption half lives are predicted when permeability, P, is very high 
(P=1010 cm/s).  Absorption half-lives were the same for both 12.5 μg/g and 
125 μg/g drug loadings for this high permeability. 
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Table 2.1 Andersen cascade impactor data for a 1/0.1 CsA/T80 dispersion in water 
(8.4 mg/mL) aerosolized using an Aeroneb® Pro micropump nebulizer with 
an airflow rate of 28.3 L/min. 
 
 Initial 3 Weeks Storage 
TED (μg/min) 1452.5 1448.0 
FPF (%) 77.4 73.9 
MMAD (μm) 2.02 2.52 
























Table 2.2 Pharmacokinetic parameters for lung and whole blood concentrations for 
mice dosed with a 1/0.1 CsA/T80 dispersion (8.4 mg/mL) for 15 minutes. 
 
Pharmacokinetic Parameter Lunga Whole Bloodb 
Cmax(ng/mL) 10,500 372.2 
tmax (hr) 1.0 3.7 
t1/2 (hr) 9.6 18.2 
K01 absorption (1/hr) ------ 0.890 
K10 elimination (1/hr) 0.0724 0.038 
AUCinf (ng-hr/mL) 144,400 9665.4 
 
a Based on non-compartmental analysis of lung tissue concentration versus time 



















Table 2.3 Comparison of CsA lung and blood levels from several in-vivo studies  
 














89,000 --- --- --- 3.6 
Nebulized solution 
(ethanol) 49 Rat 175,000 3,500 477,964 27,449 5.0 
Nebulized solution 
(propylene glycol)54  Human 
46,000-
112,000 119-402 --- 715-1565 ~ 4.3 
Intramuscular 
solution (ethanol) 49 Rat 12,500 1600 157,706 17,965 5.0 
Oral (Neoral 
microemulsion) 98 Mouse --- 2557 --- 41,021 10.0 
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Chapter 3:  Templated Open Flocs of Nanorods for Enhanced 
Pulmonary Delivery with Pressurized Metered Dose Inhalers 
A novel concept is presented for the formation of stable suspensions composed of 
very low density flocs of rod-shaped drugs in hydrofluoroalkane propellants for 
pressurized meter dose inhalers (pMDI), and for templating the flocs to achieve high fine 
particle fractions in pulmonary delivery.  The flocculated suspensions in HFA 227 are 
stable against settling for one year.  Bovine serum albumin (BSA) nanorods, ~100 nm in 
diameter and 2.4 μm in length, produced by thin film freezing (TFF), are shown by 
theory and experiment to form space filling flocs with protein particle volume fractions 
of only 0.0020, which are one order of magnitude lower than for flocs composed of 
spheres.  The rods are flocculated reversibly, as they were found to break up into 
individual submicron primary rod particles in a polar solvent acetonitrile.  Actuation of 
the HFA suspension with a pMDI produces high fine particle fractions (38-48%) with an 
emitted dose of 0.7 mg for particles with 3-4 μm aerodynamic diameters ( ad ), as 
determined with an Andersen cascade impactor (ACI).  The atomized 25 μm HFA 
droplets break apart and template the highly open flocs, which are held together by 
extremely weak van der Waals forces.  Upon evaporation of the HFA, capillary forces 
shrink the ~25 μm templated flocs resulting in porous particles with optimal ad  = 3-4 μm 
for deep lung delivery.  The corresponding geometric diameters gd  are on the order of 10 
μm, as shown by SEM and static light scattering measurements.  This novel concept for 
forming extremely stable suspensions of open flocs of rod shaped particles, and 
templating and shrinking the flocs to produce particles for efficient pMDI deep lung 
delivery is applicable to a wide variety of drugs without the need for surfactants or 





Until recently, the delivery of protein therapeutics has been largely limited to 
parenteral delivery due to the chemical and physical instabilities of proteins and 
challenges in permeating biological membranes 1.  Among the non-invasive routes, 
pulmonary delivery offers advantages of large alveolar surface area (~100 m2), rapid 
absorption across the thin alveolar epithelium (0.1-0.5 μm), avoidance of first pass 
metabolism, and sufficient bioavailabilities 1-8.  For pulmonary delivery pressurized 
metered dose inhalers (pMDI) remain the most popular delivery device, relative to dry 
powder inhalers (DPI) and nebulizers, because of low cost, portability, and disposability 
4, 9.  Because most drugs, including proteins, are insoluble in hydrofluoroalkane (HFA) 
propellants, most effort has focused on the design of stable suspensions 10-13, despite 
limited fundamental understanding 4, 11, 14.  Although certain proteins in suspensions may 
potentially be denatured by HFAs 4, the low degree of contact in the solid state with the 
solvent, relative to solutions, is highly beneficial.  For example, suspension-based pMDI 
formulations of insulin, lysozyme, catalase and rhDNase I have been shown to be stable 
15-17.   
To achieve high deposition of aerosolized particles in the deep lung, the 
aerodynamic diameter ( ad ) should range between 1-5 μm 
18.  This size range may be 
produced by milling11, 17, spray drying 3, 19-21, and spray freeze-drying (SFD) 22, 23.  Two 
recent particle engineering processes, spray freezing into liquids (SFL) 24-28, and thin film 
freezing (TFF) 29, were shown to produce high surface area, stable rod-like particles with 
50-100 nm diameters and high aspect ratios, despite slower cooling rates than in SFD.  
The stability of lactate dehydrogenase, based on enzymatic activity, was increased in 
these processes relative to SFD, as a result of a reduction in the surface area of 26, 29 the 
destabilizing gas-liquid interface26, 30.  Limited process yields, in terms of weight of 
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protein, for spray drying (50-70%) 22, 31 and SFD (~80%) 22, 31, 32 are a major concern for 
highly valuable proteins.   
To date, relatively few examples have been given of suspensions with 1-5% 
(w/w) mass loadings in HFAs that are stable against settling on time scales of over 60 s 
11.  To achieve high deposition of aerosolized particles in the deep lung, the aerodynamic 
diameter ( ad ) should range between 1-5 μm 
18.  As the mass loading increases up to and 
above 5% (w/w), particles often aggregate within aerosolized droplets leading to 
unacceptably large  ad ’s. 
11, 33.  Suspensions of cubic or spherical particles formed by 
milling or spray drying often flocculate irreversibly and settle in less than 60 s as 
illustrated in Figure 3.1A 21.  Settling can cause variable dosing between actuations 21, 34.  
As a consequence of these limitations for pMDI suspensions, typical fine particle 
fractions  (FPFs) only reach 5-30% 35.  Although surfactants and cosolvents, such as 
ethanol, may stabilize the suspension, surfactants currently approved by the FDA for 
inhalation are insoluble in HFAs 36, 37.  Surfactant tails are often not solvated well enough 
by HFAs, which have low polarizabilities and van der Waals forces, to provide steric 
stabilization 38, 39.  Thus, a key goal has been to design new surfactant structures by 
achieving a fundamental understanding of the molecular interactions with atomic force 
microscopy and theory 11, 38, 39.   
An alternative approach is to modify the particle morphology to enhance the 
colloidal stability of the primary particles 11, 21, 40.  Large porous particles 40, 41 or hollow 
particles with porous or nonporous shells 21 formed by spray drying were stable against 
settling for at least 4 hours when suspended in HFAs.  Respirable fractions were as high 
as 68%.  Here, the presence of pores filled with HFA decreases the density difference of 
the particle with the surrounding HFA media and reduces van der Waals attractive forces 
between particles 21, 40, 41.   Recently, large porous nanoparticle (LPNP) aggregates, with 
ad  optimized for dry powder inhaler (DPI) delivery 
20, 33, have been formed by spray 
drying aqueous suspensions of submicron particles.  Upon contact with lung tissue, these 
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“Trojan particles” break up into nanoparticles to facilitate dissolution and absorption 20.  
To extend this approach to a pMDI, each LPNP could be stabilized as an individual entity 
in a colloidal dispersion.  Efficient nanoparticle delivery to the deep lung has also been 
achieved with nebulization of nanoparticle dispersions in aqueous media 42.  In all of the 
pMDI methods discussed so far, the goal has been to stabilize a colloidal dispersion of 
primary particles, or of individual LPNP particles in a HFA 11, 14, in many cases with 
surfactant stabilizers. 
The primary objective of this study was to produce aggregates of high aspect ratio 
particles, in this case nanorods, to achieve high fine particle fractions in pMDI delivery 
by: (1) forming stable (against settling) flocculated suspensions of bovine serum albumin 
(BSA) particles, (2) subdividing (templating) the friable flocs upon formation of HFA 
droplets, and (3) shrinking the flocs upon HFA droplet evaporation (Figure 3.1).  Here we 
purposely flocculate asymmetric high-aspect ratio particles without the use of surfactants 
or cosolvents in the HFA to prevent settling.  Thus, this approach is fundamentally the 
opposite of most previous studies where pre-formed primary colloidal particles are 
stabilized in order to prevent flocculation. 11   
The suspension stability and aerosol performance upon actuation from a pMDI 
was evaluated for BSA particles produced by TFF, wet milling and spray drying. The 
addition of cubes or spheres, produced by wet milling or spray drying, to HFA 227 
produced dense flocs that settled rapidly (Figure 3.1A).  In contrast, high aspect ratio 
particles, such as nanorods with 50-100 nm diameters produced by TFF, may be expected 
to pack less efficiently and form much lower density flocs with greater free volume 43-47 
than spheres (Figure 3.1B).  These open flocs stack upon each other and occupy the entire 
vial to prevent settling for months, as illustrated in Figure 3.1B.  The morphology was 
determined by scanning electron microscopy (SEM) of the original particles and after 
solvent removal of particles suspended in HFA 227.  Upon actuation of the pMDI, the 
emitted HFA droplets were on the order of 25 μm.  These 25 μm droplets subdivide and 
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break apart the highly friable open flocs.  We will define this process as “templating” of 
the flocs.  Upon evaporation of the HFA droplet, the compression of the templated flocs 
from capillary forces will be shown to shrink the particles to produce a desirable ad  
(Figure 3.1B).  The ad  values after actuation of the pMDI were determined with an 
Anderson cascade impactor (ACI) and aerodynamic particle sizer (APS) and geometric 
diameters of the aerosol particles ( gd ) with SLS (static light scattering) and SEM 
micrographs.   
In the discussion section, the mechanism of the particle formation is explored in 
detail.  Experimental and calculated settling rates are utilized to characterize particle 
volume fractions and fractal dimensions for flocs composed of either cylindrical (rods) or 
spherical primary particles.  Calculations of van der Waals energies between suspended 
particles are presented to explain floc formation and break up into subdomains upon 
templating the flocs with the HFA droplets.  The calculated particle shrinkage during 




The formation of stable suspensions of purposely flocculated rods depends upon 
the ability of the open flocs to fill large volumes in the vial.  Experimental and theoretical 
studies indicate that rods create extremely low density flocs and thus fill much greater 
space compared to spheres as illustrated in Figure 3.1A 44, 46, 47.  For spheres, the volume 
fraction of primary particles within a floc fφ  is related to the floc diameter 
flocd , primary 
particle diameter pd , and fractal dimension fD , which characterizes the floc structure, 
















dφ  (3.1) 
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Philipse et al. modified eq. 3.1 to account for the packing physics of cylindrical 





















φ  (3.2) 
 
where DLr /=  is the aspect ratio 46.   A comparison of eqs. 1 and 2 indicates that 
fφ may be much smaller for particles with large aspect ratios as shown in Figure 3.1 
leading to flocs that fill a greater volume.  Furthermore, if the attractive contact points of 
the rods prevent close packing during flocculation, the lower Df  for the rods will further 
reduce fφ .  These theoretical predictions will be demonstrated experimentally from 
microscopy, settling rates, and the aerodynamic and geometric diameters. 
 
3.3 MATERIALS AND METHODS 
 
3.3.1 Materials 
Bovine serum albumin (BSA) was purchased from Sigma (St. Louis, MO).  The 
propellant 1,1,1,2,3,3,3-heptafluoroprane (HFA 227) was purchased from Hoechst 
(Frankfurt, Germany) and 2H,3H-Perfluoropentane (HPFP) was purchased from 
SynQuest Labs Inc. (Alachua, FL).  The Micro BCA Protein Assay Reagent Kit was 
obtained from Pierce (Rockford, IL).  The water was deionized by flowing distilled water 
through a series of 2x7 L mixed bed vessels (Water and Power Technologies, Salt Lake 
City, UT) containing 60:40 anionic:cationic resin blends.   
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3.3.2 Powder preparation 
3.3.2.1 Thin film freezing (TFF) 
BSA powders were prepared by the thin film freezing (TFF) process described 
previously 29.  Briefly, 5 mg/mL feed solution of BSA in 10 mM pH = 7.4 potassium 
phosphate buffer was passed at a flow rate of 4 mL/min through a 17 gauge (1.1 mm ID, 
1.5 mm OD) stainless steel syringe needle.  The droplets fell from a height of 10 cm 
above a rotating stainless steel drum (12 rpm) 17 cm long and 12 cm in diameter.  The 
hollow stainless steel drum was filled with dry ice to maintain a drum surface 
temperature of 223 K.  On impact, the droplets deformed into thin films and froze.  The 
frozen thin films were removed from the drum by a stainless steel blade and transferred 
to a 400 mL Pyrex® beaker filled with liquid nitrogen.  The excess liquid nitrogen was 
evaporated in a -80 °C freezer. 
A Virtis Advantage Lyophilizer (The Virtis Company, Inc., Gardiner, NY) was 
used to dry the frozen slurries.  Primary drying was carried out at -40ºC for 36 hrs at 300 
mTorr and secondary drying at 25ºC for 24 hrs at 100 mTorr.  A 12 hour linear ramp of 
the shelf temperature from -40°C to +25°C was used at 100 mTorr. 
 
3.3.2.2 Spray Drying 
Spray drying was performed with a Buchi Model 190 mini spray dryer 
(Brinkmann, Westbury, NY).  A 10 mg/mL BSA feed solution in 10 mM potassium 
phosphate buffer (pH = 7.4) was atomized using a 0.5 mm ID two fluid nozzle with an 
atomizing air flow rate of 200 mL/s.  The liquid protein formulation was pumped through 
the nozzle by a peristaltic pump (VWR, Bridgeport, NJ) at a flow rate of 5 mL/min using 
5 mm ID silicone tubing.  The inlet temperature for the heated aspirator air was set to 
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150ºC at a flow rate of 1000 L/hr.  The resulting outlet temperature from the above 
conditions was 80ºC. 
 
3.3.2.3 Wet Milling 
Bulk BSA powder as received was suspended at 5 mg/mL in acetonitrile.  The 
BSA suspension was placed in a mill filled with 50 ceramic balls approximately 1 cm in 
diameter and milled on a mechanical roller for 24 hours.  The milled BSA suspension 
was dried in the Virtis Advantage Lyophilizer at a shelf temperature of 30ºC for 12 hrs at 
1000 mTorr. 
 
3.3.3 Tapped Density 
Approximately 100-300 mg of protein powder was loaded into a 100 mL 
graduated cylinder.  The tapped density of the protein particles was measured with a 
Vankel tap density meter (Varian, Palo Alto, CA) 
 
3.3.4 Scanning electron microscopy 
SEM images were collected on a Hitachi Model S-4500 scanning electron 
microscope (Hitachi Ltd, Tokyo, Japan).  The samples were prepared in a dry-box.  
Aluminum stages fitted with double adhesive carbon conducting tape were gently dipped 
into sample vials until covered by powder.  Stages were then placed in septum capped 
vials and purged with nitrogen for transfer.  To minimize the time samples were exposed 
to atmospheric moisture the stages were rapidly transferred to a Pelco Model 3 sputter-
coater.  A conductive gold layer was applied and the samples were then quickly 
transferred to the SEM.  Total exposure to the atmosphere was less than 1 minute. 
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3.3.5 Preparation of HFA suspensions 
The various dried BSA powders were placed in 60 mL glass bottles (Qorpak, 
Bridgeville, PA) and pre-cooled in a -80ºC freezer.  HFA 227 was also pre-cooled in a -
80ºC freezer and poured into the bottles containing the protein powders to form 0.7% 
(w/w) suspensions.  The bottles were packed in dry ice and the suspensions were then 
sonicated for 2 min. using a Branson Sonifier 450 (Branson Ultrasonics Corporation, 
Danbury, CT) with a 102 converter and tip operated in pulse mode at 35 W.  Next, 10 mL 
of the cooled protein formulations were dispensed into 17 mL glass pMDI aerosol vials 
(SGD, Paris, France) and fitted with metering valves containing 100 μL metering 
chambers (DF10 RC 150, Valois of America, Inc., Congers, NY).  The vials were then 
allowed to warm up to room temperature. 
 
3.3.6 Microscope images of protein suspended in HPFP 
The various particles were initially dispersed by pipette mixing in HPFP (~ 
5mg/mL) and were observed for 2 min. with a Nikon OPTIPHOT 2-POL optical 
microscope with an attached MTI CCD-72X camera (Nikon, Tokyo, Japan).  Pictures 
were taken 30 and 60 seconds after initial dispersion in HPFP. 
 
3.3.7 Particle size analysis 
Particle sizes for the wet milled, spray dried and TFF particles were measured by 
static light scattering (SLS) with a Malvern Mastersizer-S (Malvern Instruments, 
Ltd.,Worcestershire, UK).  Typical obscuration values ranged from 11 to 13%, 
corresponding to a BSA concentration of ~ 1mg/mL. 
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3.3.7.1 Particle size analysis of dried BSA particles 
The dried powders were first suspended in HPFP at a concentration of 5 mg/mL 
and sonicated for 2-3 min.  Approximately 5 drops of the sonicated suspension were 
dispensed into a 15 mL vessel containing HPFP and a magnetic stir bar and the particle 
sizes were analyzed by SLS.  The dried powders were also suspended in acetonitrile at a 
concentration of 5 mg/mL and sonicated for 2-3 min.  Approximately 2 mL of the 
sonicated suspension was dispersed into a 500 mL acetonitrile bath and the particle sizes 
were analyzed by SLS. 
 
3.3.7.2 Particle size analysis of TFF particles suspended in HFA   
Vials containing TFF particles suspended in HFA 227 were cooled in a -80ºC 
freezer.  The metering valve was then removed from the vial and approximately 5 mL 
aliquots of the suspension were then dispensed into a 500 mL acetonitrile bath for particle 
size analysis.    
 
3.3.8 Dynamic light scattering 
Particles of BSA suspended in acetonitrile were analyzed by a custom-built 
dynamic light scattering (DLS) apparatus 49.  The scattering angle was set to 90º and the 
data were analyzed using a digital autocorrelator (Brookhaven BI-9000AT) and a non-
negative least-squares (NNLS) routine (Brookhaven 9KDLSW32).  The suspension 
concentration was 0.5 mg/mL which gave a measured count rate of approximately 150 
kcps.  Measurements were made over a period of 2 min. 
 
3.3.9 Moisture content in pressurized metered dose inhalers 
Moisture contents in the vials of each formulation were tested with an Aquatest 8 
Karl-Fischer Titrator (Photovolt Instruments, Indianapolis, IN) according to the method 
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described by Kim et al. 50.  A 19 gauge needle was inserted through the septum of the 
titration cell with the needle tip placed below the reagent, and each formulation was 
measured in triplicate.  For all formulations tested the moisture content was 
approximately 500 ppm.  The pure HFA was found to have a moisture content of 250 
ppm.  The total amount of moisture to the amount of protein particles was 7% (w/w).   
 
3.3.10  Optical density measurements of protein 
The μQuant spectrophotometer was used to measure turbidity at 350 nm to 
characterize BSA aggregation.  Dry powders of BSA were reconstituted in 10 mM KPO4 
buffer (pH 7.5) to 1 mg/mL and 3 x 300 uL aliquots of each formulation were placed in a 
96 well Falcon plate which was set in the spectrophotometer. 
 
3.3.11  Quantitation of BSA 
The amount of BSA was measured using the Micro BCA Protein Assay following 
protocols provided by Pierce (Rockford, IL).  Each sample was measured in triplicate 
with relative standard deviations (%RSD) < 2%.  The absorbance of the solutions was 
measured at 562 nm in a 96 well plate spectrophotometer (μQuant Model MQX200; 
Biotek Instruments Inc., Winooski, VT).  Untreated BSA was used to prepare the protein 
standards at concentrations between 2 and 30 μg/mL. 
 
3.3.12  Dose delivered through the valve (DDV) determination 
The protein suspensions in HFA were actuated once through the firing adaptor of 
a dosage unit sample tube (26.6 mm ID x 37.7 mm OD x 103.2 mm length; 50 mL 
volume; Jade Corporation, Huntingdon, PA) 51.  The firing adaptor was removed, and 40 
mL of DI water was added to dissolve the protein.  The sampling tube was shaken and 
allowed to sit for at least 30 min. to assure that the protein was dissolved in water.  The 
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protein concentration was determined using the Micro BCA protein assay in conjunction 
with the μQuant spectrophotometer.  The glass vial containing the HFA protein 
suspension was weighed before and after each actuation to assure that the proper dose 
had been released.  The measurement was repeated 3 times to get an average dose 
delivered through the valve (DDV) for each formulation.   
 
3.3.13  Aerodynamic diameter characterization of protein aerosol 
To characterize the aerodynamic properties of the particles, an eight-stage 
Anderson cascade impactor (ACI) (Thermo-Anderson, Smyrna, GA) with an attached 15 
cm spacer and an air flow-rate of 28.3 L/min was used to quantify mass median 
aerodynamic diameter (MMAD), geometric standard deviation (GSD), fine particle 
fraction (FPF), and emitted dose (ED).  Initially 3 shots were sent to waste, and the next 5 
shots were made into the ACI.  The interval between shots was between 15-30 s to 
prevent cooling of the metering chamber and subsequent moisture condensation.  After 
the last dose was discharged, the glass vial was removed from the impactor and the valve 
stem and actuator were rinsed separately with a known volume of DI water.  Each plate 
of the impactor was placed in a separate container with a known volume of DI water and 
soaked for 30 min. to assure complete dissolution.  The protein concentrations were then 
measured with the Micro BCA Protein Assay. 
The ad  of the protein particles were also determined in triplicate with an 
Aerodynamic Particle Sizer (APS) 3321 (TSI, Shoreview, MN).  The throat and spacer 
from the ACI were placed over the inlet of the APS and the airflow rate through the inlet 
was 5 L/min.  Each formulation was shot once through the spacer and throat.  The 
particle size range by mass was determined with the Aerosol Instrument Manager (AIM) 
software provided by TSI.   
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3.3.14  Geometric diameter characterization of protein aerosol 
To obtain aerosolized particles for SEM (Hitachi Model S-4500, Hitachi Ltd, 
Tokyo, Japan) analysis, double carbon adhesive tape was applied to stage 3 of the ACI.  
Each formulation was actuated once through the ACI with an air flow rate of 28.3 L/min.  
The carbon tape was removed from stage 3 and applied to an aluminum SEM stage, 
which was transferred rapidly to a Pelco Model 3 sputter-coater to minimize exposure to 
moisture.  Total exposure to the atmosphere was less than 1 minute.  The SEM 
micrographs were then characterized with imaging software (Scion, Frederick, MD) to 
determine the particle size distribution of at least 100 particles. 
The aerosolized particles were also characterized by SLS.  Each formulation was 
actuated once through the ACI spacer and throat.  The aerosol exited the outlet of the 
throat downwards 5 cm directly above the laser beam of the Malvern Mastersizer S.  For 
each formulation 100 measurements of the aerosolized spray were made every 5 ms.  The 
recorded measurements were then averaged to give the final profile of the aerosolized 




3.4.1 Suspension stability of the BSA particles in HFA 
Prior to forming suspensions of BSA in HFA 227, the morphologies of the dried 
BSA particles prepared by TFF, wet milling and spray drying were observed by SEM 
(Figure 3.2).  For BSA prepared by TFF, interconnected rods ~50 - 100 nm in diameter 
were observed with a web structure (Figure 3.2A and B).  Similar morphologies were 
observed previously for lysozyme produced by TFF at 223 K 29.  The BSA particles 
prepared by wet milling (Figure 3.2C) were in the form of cubes with 400-800 nm 
dimensions.  Lastly, spray dried BSA at a feed concentration of 10 mg/mL produced 
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spheres 3-6 μm in diameter with corrugated surfaces (Figure 3.2D).  Additionally, the 
bulk powder of the TFF particles before adding HFA had a low tapped density of 0.0064 
g/cm3 and required a mass of only ~100 mg to fill the entire volume of the vial (Figure 
3.2E).  Alternatively, the same mass of dried wet milled and spray dried particles formed 
a thin layer at the bottom of the vial (data not shown). 
The various dried BSA particles were suspended in HFA 227 at 0.70% (w/w) 
corresponding to a volume fraction in the vial vφ  of 0.0077 (Figure 3.3), as determined 
from the true density of BSA pρ  = 1.3 g/cm
3 52.  For the TFF powder, the particles filled 
the entire volume of the vial immediately upon adding HFA (Figure 3.3A) and did not 
settle even after 1 year in storage.  For a control with an extremely low vφ  of only 
0.070% (w/w) (Figure 3.3B) the TFF particles still filled approximately half the HFA 
volume.  For the wet milled BSA particles, the suspension initially appeared to be 
uniform (like Figure 3.3A), but the particles settled to the bottom after only 5 min. 
(Figure 3.3C).  The spray dried particles dispersed well with shaking, but creamed after 
only 2 min. (Figure 3.3D).   
Since the wet-milled particles settled in HFA 227 (1.41 g/cm3) 53, the wet milling 
raised ρ to above 1.3 g/cm3.  On the contrary, the wet milled particles creamed in HPFP 
(1.59 g/cm3) 53.  Thus, it was estimated that pρ  ~ 1.50 g/cm
3, the average of the two 
solvent densities.  Therefore, the true density reported for BSA appeared to be a skeletal 
density that did not account for internal pores.  Upon wet milling removal of the pores 
raised ρ.  
 
3.4.2 Characterization of the flocs in a surrogate solvent HPFP at ambient 
pressure 
Because the vapor pressure of HFA 227 is above ambient at 25ºC (~500 kPa) 53,  
the flocs were not studied in situ by light scattering and microscopy.  Instead, the 
particles were characterized at ambient pressure in HPFP, a surrogate nonvolatile solvent, 
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with a similar polarity and polarizability as HFA 22753-55.  According to light 
microscopy, the TFF particles in HPFP were in the form of loosely packed flocs of rods 
(Figure 3.4A and B).  The rods formed 200-300 μm flocs with subdomains on the order 
of 25 μm within 5-30 s. after dispersing the particles by pipette mixing (Figure 3.4A and 
B).  The SLS measurements were consistent with the microscopy images in HPFP with 
d(v,50) values between 215-259 μm (Figure 3.5).  For wet milled (Figure 3.4C) and the 
spray dried (Figure 3.4D) particles, 100 μm flocs formed in 30 seconds and grew to over 
200 μm in 60 seconds.  These flocs were more densely packed and composed of larger 
primary particles than those formed from TFF particles.  About 50% of the wet milled 
particles by volume were between 1-10 μm with a secondary peak between 30-200 μm 
(Figure 3.5).  For the spray dried particles a single peak centered at 10 μm was observed 
(Figure 3.5).   The smaller sizes for light scattering versus microscopy may have been 
produced by shear from stirring.   
 
3.4.3 Characterization of particles suspended in acetonitrile 
The various dried BSA particles were also suspended in a more polarizable 
solvent acetonitrile to gain fundamental knowledge about the dispersibility, primary 
particle size and flocculation properties.  Upon suspending the particles in acetonitrile a 
milky uniform dispersion formed (Figure 3.3E), but the particles settled after 3 days 
(Figure 3.3F).  The dispersion/settling behavior shown in Figure 3.3E and F was also 
observed for wet milled and spray dried particles in acetonitrile (data not shown) with 
settling in ~3 days and ~30 min., respectively.   
The BSA particles suspended in acetonitrile were also characterized by SLS after 
sonication for 2 min.  As shown in Figure 3.6 the d(v,50) values were 330 nm, 410 nm 
and 6.3 μm for the TFF, wet milled and spray dried BSA particles, respectively, 
consistent with the original sizes in the SEMs in Figure 3.2.  Even without sonication, 
significant dispersion of the TFF particles was observed with peaks at 330 nm and 20 
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μm, with approximately 50% of the particles by volume below 1 μm (Figure 3.6).  In 
SLS particle sizing results are based on the equivalent volume of a sphere.  In the case of 
the TFF nanorods a measured particle diameter of 330 nm would have an equivalent 
volume of 0.019 μm3.  In the case of the nanorods with 100 nm diameters, the length of 
the rod would be 2.4 μm which is consistent with the SEMs in Figure 3.2A and B.  These 
experiments in acetonitrile demonstrated that the particles may be dispersed with little 
aggregation over 1 hr. to determine the primary particle size 
To determine if exposure of the TFF particles to acetonitrile caused 
morphological changes, the dispersions in ACN were frozen by drip freezing into liquid 
nitrogen.  The acetonitrile was then removed by lyophilization leaving fluffy particles 
with an approximate tapped density of 0.012 g/cm3 (Figure 3.7A).  When the particles 
were redispersed in acetonitrile the measured particle size profile was d(v,50) = 330 nm 
which was similar to the profile in Figure 3.6 of the original TFF dispersion, indicating 
the particles did not aggregate irreversibly.  As observed by SEM, the morphology in 
Figure 3.7B was 50-100 nm diameter rods, similar to the interconnected rods of the 
original TFF powder in Figure 3.2A, and consistent with the sizes from light scattering 
results in Figure 3.6.  Thus exposure to acetonitrile does not alter the morphology 
significantly.   
 
3.4.4 TFF particle characterization after recovery from HFA 
To further understand the flocs of TFF particles in the HFA, the particles were 
characterized after HFA evaporation.  Isolation of the particles from HFA by 
lyophilization could not be achieved since the freezing point (-131ºC) of HFA 227 is too 
low to for conventional shelf lyophilizers 53, 56.  Alternatively, the HFA was cooled to -
80ºC, well below its boiling point of -16ºC 53, and completely evaporated at atmospheric 
pressure.  The TFF particle residue only occupied approximately 1 mL (tapped density of 
0.10 g/cm3, Figure 3.8A), an order of magnitude less than that of the starting TFF bulk 
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powder (Figure 3.2E).  The particle morphology after HFA exposure resembled rods with 
100 nm diameters (Figure 3.8B), similar to the original TFF particles in Figure 3.2A.  
Therefore, exposure to HFA 227 followed by sonication did not significantly alter the 
primary nanorod particle morphology.  However, the densified aggregates of the 
nanorods formed by capillary forces upon evaporation (Figure 3.8A) of HFA were not 
redispersible when reintroduced into HFA or into acetonitrile.   
A second approach was used to harvest the TFF particles from HFA for further 
characterization at ambient pressure.  A 2 mL aliquot of the cold TFF suspension was 
mixed directly with 500 mL of acetonitrile at 25oC.  The suspensions were sonicated and 
analyzed by SLS.  The flocs deaggregated nearly completely to individual primary 
particles with over 80% of the volume distribution between 100 nm and 1 μm. (Figure 
3.9).  The distributions nearly matched those of the original TFF particles in acetonitrile 
(Figure 3.6).   
In a third approach to analyze the TFF particle suspensions, the valve of the 
pMDI was submerged into acetonitrile and actuated.  Submerging the actuator prevented 
the mixture of HFA droplets and particles from being exposed to ambient moisture and 
prevented HFA evaporation from effectively compacting the aerosolized particles.  A 
slightly turbid dispersion was formed with an approximate particle concentration of 0.5 
mg/mL, too low for detection by SLS, but not for DLS.  From DLS, the particle size was 
1-2 μm (Figure 3.10) much smaller than the 250 μm floc size in HFA.  Therefore, both 
the second and third approach indicate the loosely flocculated nanorods in HFA may be 
broken up into primary nanorods, which will be shown to be beneficial for lung delivery.   
 
3.4.5 Molecular stability of BSA exposed to HFA 227 as determined by optical 
density 
As a means to determine the molecular stability of BSA against forming 
aggregates in the HFA 227, the optical density (OD) of the BSA exposed to HFA 227 
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was measured.  The HFA 227 was removed by cooling the HFA suspension to -80ºC and 
allowing the HFA 227 to completely evaporate at atmospheric pressure.  Aggregates of 
protein molecules did not appear to form according to OD measurements at 350 nm of 1 
mg/mL BSA 27, 57.  The OD was the same at 0.042 for aqueous solutions in 10 mM 
phosphate pH = 7.4 buffer prepared from bulk and TFF powder, both before and after 
storage in HFA 227 for 1 week.  In the glassy state, BSA is less susceptible to 
aggregation 56, 58.  The total moisture to BSA content was 7% (w/w) for the suspended 
BSA particles in HFA 227 as determined by Karl-Fischer titration.  Even at particle 
moisture contents of 8% (w/w), BSA glass transition temperatures gT  range between 80-
100ºC 59.  Thus the temperature was well below Tg, assuming the HFA 227 did not 
contribute to plasticization.   
 
3.4.6 Particle characterization after actuation through the pMDI    
The suspension must be stable for consistent dosing with a pMDI, which is 
commonly characterized by the dose (mass) delivered through the valve (DDV) (Table 
3.1).  The concentration was 10 mg/mL or 0.7% (w/w) in each HFA suspension.  
Therefore, the theoretically delivered dose per actuation would be 1 mg with the 100 μL 
valve.  For the BSA TFF particles, the DDV values were 92% and 63% of the theoretical 
delivery dose for the sonicated and unsonicated TFF particles, respectively (Table 3.1).  
For the milled and spray dried suspensions with rapid settling, the DDV was only 30-
31% of the theoretical loading.  Here, the formulation was actuated less than 5 seconds 
after vigorous shaking.  Therefore, these suspensions were not tested further for aerosol 
properties. 
As shown in Table 3.2 and Figure 3.11A and B, the ad  determined from the 
Anderson cascade impactor (ACI) and the Aerodynamic Particle Sizer (APS) were in 
good agreement and ranged from 3 to 4 μm, within the optimal 1-5 μm range for 
pulmonary delivery.  As determined by the ACI, the fine particle fraction (FPF) (particles 
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less than 4.7 μm) was unusually high 35 for an HFA suspension, ranging from 38 to 47%, 
compared to 5 to 30% for typical suspensions 35, producing a fine particle dose/actuation 
of approximately 300 μg (Table 3.1).  The emitted dose (ED) (amount of drug that exited 
the actuator) was approximately 70% of the DDV upon actuation (Table 3.1 and Figure 
3.11A).   
The particles were recovered from the ACI for SEM analysis.  The peak drug 
mass in the ACI was deposited on stages 3 and 4, with ad  between 2.0-4.7 μm (Figure 
3.11A).  Therefore, particles were collected on stage 3 ( ad  = 3-4 μm).  The particles 
were porous and composed of rods with diameters less than 500 nm (Figure 3.12A and 
B), similar in morphology to the original nanorods in Figure 3.2A.   
The SEMs were analyzed by Scion software to determine the volume average 







DVol  (3.3) 
 
where d  is the measured diameter of the particle.  Approximately 200 of the BSA 
particles which consisted of aggregated nanorods were measured in 5 different images.  
The diameter of each particle was determined by averaging the longest and shortest 
diameter of each particle.  The volD  for BSA was approximately 9 μm (Table 3.2).  The 
gd  of the aerosolized particles were also measured by SLS.  An effective refractive index 
en  was calculated according to the Bruggeman mixing rule 
62 based on the volume 
fraction of BSA in the aerosolized particle gφ  (Appendix A).  From the gd  and the ad  
(Table 3.2), the particle density gρ  can be defined by 
41  
 
gga dd ρ=  (3.4) 
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where gρ  = 0.19 g/cm
3.  The resulting gφ  = pg ρρ / = 0.14.  With n  = 1.45 and 1.00 for 
pure BSA and air, respectively, en  = 1.1.  As shown in Table 3.2 the volume average 
d(v,50) particle sizes varied by less than 1 μm from the values determined from the SEM 
micrographs.  The consistent gd  values measured by SLS and SEM, and likewise for ad , 
indicate that TFF particles form large porous particles, and with the optimal size range 
for pulmonary delivery upon aerosolization.   
When the TFF particles were actuated above 10 mM phosphate buffer (pH = 7.4) 
the particles were visually observed to dissolve in less than 5 seconds.  The high surface 
area favors rapid dissolution, which could be advantageous for rapid dissolution rates of 




The attractive van der Waals forces play a key role in the floc formation, as 
depicted in the summary in Figure 3.1 14, 45, 63.  According to the Derjaguin-Landau-
Verwey-Overbeek (DLVO) theory, particle stability depends on counteracting the 
attractive van der Waals forces by electrostatic and/or steric repulsion 14, 45, 63.  If 
attractive van der Waals (VdW) forces are dominant at all separation distances, particles 
flocculate and may then settle 14.  Currently, electrostatic stabilization in HFAs is not well 
understood 11, but atomic force microscopy (AFM) measurements indicate that 
electrostatic forces may be negligible compared to attractive VdW forces 11, 64.  The 
understanding of steric stabilization in HFAs is in its infancy 36, 39.  While novel 
surfactants are being discovered, developed and approved 38, 39, alternative means to form 
stable suspensions in HFAs without surfactants would be useful 11.   
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3.5.1 Suspension Stability for Porous or Hollow sphere Particles 
The destabilizing van der Waals attractive forces between suspended particles are 
weaker for porous particles or hollow particles with thin solid shells 21, 40.  These particles 
can be stable for hours in HFAs, compared to non-porous 1-5 micron particles, which 
often flocculate and settle rapidly in less than 1 minute 21, 40 (see Figure 3.2).  Dellamary 
et al. 21 suggested that the increased suspension stability resulted from a weaker attractive 
VdW energy potential vdwΦ  between the particles, but quantitative calculations were not 
presented 11.    
As shown in Appendix A, the van der Waals energy vdwΦ  is directly proportional 
to the Hamaker constant 121A .  In order to compare values of vdwΦ  it is necessary to 
choose a separation distance, h , between particles.  Table 3.3 gives the h  where 
vdwΦ becomes equivalent to the thermal energy 3/2 kBT at 298K.  An increase in h  
required to overcome thermal energy indicates stronger attraction between particles.  In 
Table 3.3, the porous particles with φ  = 0.5 had a calculated 121A  (Eq. A.3 in Appendix 
A) that was nearly a factor of 4 lower than for the non-porous particles.  Consequently, h  
was a factor of 3 smaller.  The hollow spheres from TEM images 21 were estimated to 
have 2-5 μm diameters and ~100 nm thick shells.  Although the 121A  for the hollow 
sphere particles with solid shells was the same as for the non-porous particles, the 
calculated h  was still lower by a factor of 2 as a consequence of the differences in the 
geometries (Eq. A.6 in Appendix A).  Therefore, the vdwΦ  calculations quantify the 
benefits of weaker attraction for porous particles or for particles with hollow cores.  A 
reduction in vdwΦ  or in h  to overcome thermal energy can reduce the rate of flocculation 
over orders of magnitude as described by the stability ratio 45, 63, 65.   
Although, the porous or hollow sphere particles can effectively prevent 
flocculation, the particles are still subject to settling by gravity 11, 21.  If porous or hollow 
sphere BSA particles were suspended at vφ  = 0.0077, the particles would occupy ~ 10% 
of the suspension and could potentially settle into a dense sediment.  As shown in Table 
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3.4, the calculated settling rate for a single hollow sphere particle with a solid shell is 6.4 
x 10-4 mm/s indicating that the particles would settle a distance of 2 cm in ~ 9 hrs.  The 
settled particles would then potentially aggregate irreversibly leading to decreased FPFs 
upon aerosolization 34.   
 
3.5.2 Flocculation of TFF rods 
To understand the space filling nature of the flocs composed of TFF rods, the 
volume fraction of the particles in the floc, fφ , was calculated with Eq. 3.2.  The volume 
of a TFF cylindrical rod, pV  = 0.019 μm
3, was calculated from the equivalent volume of 
a sphere with particle diameter d(v,50) = 0.33 μm, which was measured by SLS (Figure 
3.6 ) in acetonitrile.  For a rod with volume 4/2 LDVp ⋅= π  and D  = 0.10 μm (Figure 
3.2A and B), L  is determined as 2.4 μm and thus r = 24.  For r ~ 20, the predicted fφ  in 
Eq. 3.2 is ~1 order of magnitude lower than for spherical particles with equivalent flocd , 
fD , and where pd  for spheres scales as 
3/1
pV  for rods. 
To determine the effect of fD on fφ  , the density of a floc fρ  and fφ  were also 
determined experimentally from the visually observed floc settling rate, fU , according to  











f  (3.5) 
 
where Lρ  and μ are the liquid density and  viscosity, respectively, and 
flocd  = 250 μm 
for TFF flocs and 100 μm for spray dried and milled flocs (Figure 3.6).  After solving for 
fρ  in Eq. 3.5, fφ  may be determined by the straightforward material balance 
)( LpfLf ρρφρρ −⋅+=  
66, 67.  As seen in Table 3.4, fφ  for the TFF particles is 1-2 
orders of magnitude lower than for the cube and spherical wet milled and spray dried 
particles.  From Eq. 3.1 and 3.2 the calculated fD  values are in a narrow range from 2.5 
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to 2.6 in each case.  Although the milled and TFF particles have nearly equivalent flocd  
and fD  values (Table 3.4), the r/1  scaling in Eq. 3.2 for rods accounts for the 1 order of 
magnitude decrease in fφ , for a given Vp, which is consistent with the theoretical 
prediction above. 
As illustrated in Figure 3.1B, the open nanorod flocs with low fφ  filled large 
amounts of space in HFA and stacked upon each other like tumbleweeds to prevent 
settling.  The volume fraction of flocs in the HFA suspension, flocsφ , is given by 
fv
flocs φφφ /=  (derivation given in Appendix A) where flocsφ  determines the space filling 
capability of the flocs.  As flocsφ  approaches 1 the flocs occupy the entire volume of HFA 
(Figure 3.1B).  For the dilute vφ  = 0.00077 suspension (Figure 3.3B), the calculated 
flocsφ  was 0.38 (Table 3.4) in good agreement with Figure 3.3B.  At a loading 10 fold 
higher, vφ  = 0.0077, the entire vial was white without the appearance of spaces between 
flocs (Figure 3.3A), as expected from the low fφ .  Here it was not possible to observe a 
settling rate as the visual appearance did not change for 1 year, the maximum time tested, 
as the flocsφ  of essentially unity prevented settling.  In order for the cubic or spherical 
particles to produce flocsφ  = 1 the required mass loadings for the milled and spray dried 
particles would be 6.7% (w/w) and 33% (w/w), respectively, compared to <0.7% (w/w) 
for the TFF rods.  In contrast to the TFF rods, the hollow sphere particles would settle the 
length of the vial (~2 cm) by gravity in ~9 hours according to Stoke’s law 21 for a particle 
diameter of 5 μm and shell thickness of 100 μm.  In the settled state with a high particle 
volume fraction and contact between protein chains they are more likely to form 
irreversible particle aggregates by interparticle diffusion and sintering 68.   
The open flocs in HFA 227, that gave the stable suspensions, may be shown to be 
favored by the relatively strong attractive forces between the primary particles 45, 63.  At 
first, this may seem counterintuitive to the normal goal of lowering attractive forces to 
stabilize colloidal dispersions.  Upon addition of the HFA, the relatively strong attractive 
forces between the primary rods, vdwΦ , cause sticky collisions to “lock in” the open 
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structure rapidly to inhibit collapse of the flocs 45, 69.  For weaker attractive forces 
between primary particles, collapse has been shown to be more prevalent as particles 
sample a greater number of energetically favorable locations to reduce the interfacial 
surface area 45, 69.  Therefore, rapid flocculation from sticky collisions facilitates the 
formation of low density flocs that fill the entire vial and prevent settling.  
In contrast to the flocs in HFA 227, colloidal dispersions of primary TFF rods in 
acetonitrile settled in 3 days (Figure 3.3F).  This settling rate agreed with the predicted 
settling rate of individual effective spheres with a diameter of 330 nm from light 
scattering given in Table 3.4.  From Table 3.3, the calculated 121A  values for BSA in 
acetonitrile are 1 order of magnitude lower than in HFA 227 (Table 3.3).  Therefore, the 
stronger attractive forces between particles in HFA relative to ACN, favors formation of 
open flocs, resulting in more stable suspensions against settling. 
 
3.5.3 Aerosol formation from stable suspensions 
Although the 250 μm flocs form stable suspensions, they are too large to produce 
optimal ad .  The shear forces in the actuator are needed to break apart the flocs.  The 
calculation of these shear forces is rarely reported because the turbulence from the 
immediate onset of HFA evaporation produces complex cavitation events 61, 70.  
According to empirical models, aerosolized HFA droplets are typically 10-30 μm in 
diameter 70.  Thus we choose an HFA droplet diameter of 25 μm.  Our hypothesis is that 
the attractive van der Waals interactions between primary particles within a floc are very 
weak such that the HFA droplets may template the 250 μm flocs into 25 μm subdomains 
with the same fφ  = 0.0020 as illustrated schematically in Figure 3.1.   
To separate the subdomain from the floc, the attractive forces between the 
interacting particles within ( 1r ) and outside ( 2r ) the subdomain surface ( 3r ) must be 
overcome (Figure 3.13).  The particle density within the floc was assumed to be uniform 
at 1.1 x 1017 m-3 as determined from the fφ  = 0.0020 of the floc and pV  = 0.019 μm
3 of 
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the rod primary particle.  The total number of interacting particles was assumed to 
occupy a 25 nm thick shell between 1r  = 12.488 μm and 2r  = 12.513 μm (Figure 3.13).  
As shown in Table 3.4, at separation distances greater than 25 nm the attractive energy 
between particles is similar to the thermal energy.  This indicates that particles at 
separation distances > 25 nm would not significantly contribute to the force necessary to 
separate the subdomain.  The total number of particles in the shell was ~6, and therefore 
3 particle-particle interactions had to be separated.  The force to separate the interacting 
particles is dependent on the distance of separation of the particles (Eq. A.5).  An average 
separation distance between the interacting particles was determined as the difference of 
the geometric means determined by 2/13113 )( rrr ⋅>=<  and 
2/1
3223 )( rrr ⋅>=<  as shown 
in Figure 3.13 giving an average separation distance h  between particles in the shell of 
12.5 nm.  From Eq. A.5 the total force necessary to separate the subdomain from the floc 
is ~10-12 N (Eq. A.5) assuming that the primary particle radius is 0.165 μm.  The 
attractive force to separate the subdomain is very weak compared to the calculated shear 
force of ~10-4 N indicating that the subdomains can be easily templated by HFA droplets.  




















νμπτπ  (3.6) 
 
where dfloc is the floc diameter, τ is the viscous stress, μ and υ are the viscosity and 
kinematic viscosity of HFA 227 in the liquid state at 25oC, respectively, v is the HFA 
droplet velocity during atomization, and Le is the dimension of the largest eddy generated 
during pMDI atomization (approximated as the dimension of the turbulent flow cavity).  
The floc subdomains were estimated to be 25 μm in diameter, the size of an HFA 227 
droplet.  The viscosity and kinematic viscosity of HFA 227 were 2.44 x 10-4 Pa•s and 
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1.76 x 10-7 m2/s, respectively 14.  The velocity of the HFA droplets during atomization 
was estimated to be 30 m/s 61, and Le was 0.7 mm, the pMDI valve diameter. 
The concept of templating of the 25 μm subdomains is supported by a material 
balance on the protein between the volume of the HFA droplet, HFAV , and the volume of 
the dry aerosolized particle, Vg, (Figure 3.1B) given by 
 
HFAHFAgg VV ρρ ⋅=⋅   (3.7) 
 
where BSA concentrations are given by pvHFA ρφρ ⋅=  , and pgg ρφρ ⋅= .  It is assumed 
that the volume fraction of particles in a HFA droplet is approximately equal to vφ  as a 
result of the break up of the flocs.  Because of the high flocsφ  (Figure 3.1B and 3.3A), it is 
expected that most of the HFA droplets are likely to be filled with a subdomain.  From 
the measured gd  and ad  in Table 3.2 and gρ  = 0.19 g/cm
3 (Eq. 3.4), gφ  = 0.14.  The gφ  
is nearly 20 times greater than vφ  in the vial.  Therefore, the capillary forces in the 
shrinking HFA droplets during evaporation collapse the flocs 33.  Eq. 3.7 is refined to 








d ⋅⋅=⋅ φφ  (3.8) 
 
where d is a diameter, BSAf  = 0.7 accounts for the mass fraction of drug that is emitted 
from the actuator, and HFAf  = 0.5 accounts for the mass fraction of HFA that exits the 
actuator orifice to form aerosolized liquid droplets (relative to vapor) 61.   
From Eq. 3.8 with gd  = 9.3 μm (Table 3.2), HFAd  = 25 μm 
70, and vφ  = 0.0077 , 
the calculated gφ  = 0.21, which compares reasonably well to the experimentally 
determined gφ  = 0.14.  Also the polydispersity in the aerodynamic properties was small.  
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It would be unlikely that any other factor besides templating of the flocs with relatively 
uniform HFA droplets could explain these low polydispersities. 
The control experiment in Figure 3.8A supports this argument since the TFF 
particles remained below the meniscus of the evaporating HFA 227.  The tapped density 
of the particles was approximately 0.10 g/cm3 (Figure 3.8A) which is within a factor of 2 
of the calculated density (0.19 g/cm3) of the aerosolized particle.  Therefore, the capillary 
forces acting on the TFF particles during HFA evaporation compacted the particles into 
denser aggregates with a highly desirable value of the ad .  If needed, the ad  may be 
manipulated further by varying the valve volume and geometry and the HFA droplet 
generation.  If the particles had not collapsed partially, they would have been too large 
and light for pulmonary delivery.  Even after this collapse, the porosity and surface area 
were still relatively high and favorable for  high dissolution rates of small molecules and 




High (38-47%) fine particle fractions in HFA 227 pMDI delivery were achieved 
with flocculated BSA nanorods stable against settling for up to 1 year, without the use of 
surfactants and cosolvents.  Analysis of experimental settling rates of dilute suspensions 
indicated that the volume fraction, fφ , of the nanorods in the flocs was an order of 
magnitude lower than for flocs of spherical particles produced by wet milling or spray 
drying.  The rapid and sticky attractive collisions of nanorods facilitates the formation of 
low density flocs (250 μm) which stack upon each other to fill the entire solvent volume 
to prevent settling (Figure 3.1B).  In contrast, denser flocs of spherical particles filled 
much less space and rapidly settled within 60 s (Figure 3.1A).  The novel concept of 
purposely flocculating nanorods to prevent settling is fundamentally opposite the 
conventional approach of stabilizing colloidal dispersions of pre-formed primary particles 
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with surfactants.  The reversibility of the nanorod flocs in HFA 227 was 
demonstrated by break-up of the flocs into individual 330 nm primary rod particles upon 
transfer to the more polar solvent acetonitrile.  A material balance on a shrinking HFA 
droplet containing a 25 μm floc subdomain predicts a final volume fraction of BSA in the 
aerosolized particle in agreement with experiment.  Therefore, the attractive van der 
Waals interactions between primary particles within the floc are sufficiently weak such 
that the atomized HFA droplets initially template the 250 μm flocs into 25 μm 
subdomains.  The aerosolized particles with a ad  of 3-4 μm and gd  of ~10 μm are 
optimal for high fine particle fractions via a pMDI.  The concept of forming open flocs 
composed of aymmetric particles, for example nanorods, that are stable against settling 
without surfactants, and templating the flocs to achieve optimal das and high FPFs is of 
practical interest for wide classes of low and high molecular weight pharmaceuticals and 





                                                     A) 
 
                                        B) 
 









                                   E) 
 
Figure 3.2   TFF particles of BSA (A, B and E), milled BSA particles (C) and spray 
















Figure 3.3 Suspensions in HFA 227 of TFF particles at φV = 0.0077 (A) and φV = 
0.00077 (B), wet milled particles 5 minutes after shaking (C) and spray 
dried particles at  2 minutes after shaking (D) at φV = 0.0077, and TFF 
particles in acetonitrile at φV = 0.0077 immediately after shaking (E) and 3 




Figure 3.4 Optical microscopy images of BSA particles suspended in HPFP with TFF 
particles magnified 10x (A) and 60x (B) after 30 seconds, wet milled BSA 
particles after 30 seconds at 10x (C) and spray dried BSA particles after 30 
seconds at 10x (D) The flocs from TFF particles are more open than for wet 
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Figure 3.5   Particle sizes in HPFP measured by static light scattering for BSA nanorods 
formed by TFF, cubes formed by wet milling and spheres by spray drying.  
The large particle size for TFF nanorods indicates flocculation, consistent 
with the microscopy results in Figure 3.4. 
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Figure 3.6   Particle sizes in acetonitrile measured by static light scattering for BSA 
nanorods formed by thin film freezing (TFF), cubes formed by wet milling 
and spheres by spray drying. Closed symbols indicate sonicated powder and 





















Figure 3.7   TFF particles after suspension in ACN and lyophilization: photograph (A) 













Figure 3.9   Particle size distribution measured by static light scattering for BSA 






























Figure 3.11   ACI mass deposition profiles for device (D) and spacer and throat (S+T) and 





































Figure 3.12   BSA aerosol particles consisting of aggregates of nanorods collected from 
stage 3 of Anderson cascade impactor for BSA observed under high (A) and 






Figure 3.13  Diagram of subdomain with radius r3 held within a floc by particles 





Table 3.1 Dosage and aerodynamic properties of TFF, wet milled, and spray dried 
particle suspensions in HFA 227     
 










TFF BSA 915 ± 21 92 47 ± 4.0 318 ± 31 695 ± 133 
TFF BSA 
unsonicated 625 ± 95 63 -- -- -- 
Milled BSA 295 ± 17 30 -- -- -- 
Spray Dried 
BSA 308± 38 31 -- -- -- 
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Table 3.2   Aerodynamic particle sizes determined by ACI and APS and geometric 
particle sizes determined by laser diffraction and SEM for TFF particles of 

























3.1 ± 0.1 1.9 ± 0.1 3.2 ± 0.03 1.6 ± 0.01 9.1 ± 0.9 9.4 0.19 
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Table 3.3  Calculation of the van der Waals (VdW) interaction potential vdwΦ  of BSA 
particles in HFA 227 
 
Particle Type Particle Diameter (μm) 
Hamaker Constant 
1021 x A121 (J) 
Separation Distance 
(nm) at Φvdw = 3/2kBT 
Spray Dried-Non-
Porous 5.0 14 270 
Spray Dried-
Porous 
φ = 0.50 
5.0 3.8 100 
Spray Dried- 
Hollow Spherea 
φshell = 1.0 
5.0 14 120 
Spray Dried- 
Hollow Spherea 
φshell = 0.50 
5.0 3.8 60 
TFF Nanorods 0.33 14 23 
TFF Nanorodsb 0.33 2.6 6.9 
 
aShell thickness 100 nm 
bTFF nanorods were in acetonitrile 
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Table 3.4   Settling behavior of BSA particles prepared by TFF, wet milling, and spray 
drying and calculations for porous shell particles prepared by spray drying. 
 









flocs φf Df 
TFF 0.33a 250 0.00022 0.023 2.4 x 10-5 0.00077 0.38 0.0020 2.5 
Milled 0.41 100 0.0080b 0.13 3.7 x 10-5 0.0067 0.11 0.073 2.5 




5.0c -- 0.013d -- 6.4 x 10-4 -- -- -- -- 
 
aValue determined from the equivalent volume of a sphere measured from laser light 
scattering 
bThe density difference was determined by ρf−ρL with ρp = 1.5 g/cm3  
cDetermined from dimensions given by Dellamary et al.21  
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Chapter 4:  Templated Open Flocs of Anisotropic Particles for 
Pulmonary Delivery with Pressurized Metered Dose Inhalers 
The challenges in forming uniform and stable drug suspensions in 
hydrofluoroalkane (HFA) propellants have limited drug dosages and efficiency of 
delivery with pressurized metered dose inhalers (pMDI).  Herein, stable suspensions of 
weakly flocculated particles, in the shape of thin plates or needles, of a poorly water 
soluble drug, itraconazole (Itz), in HFA 227 are delivered efficiently with high doses, up 
to 2.4 mg/actuation.  These anisotropic particles, with aspect ratios from 5-10, pack 
inefficiently and form low density flocs that stack upon each other to prevent settling, 
with no visible settling for over two years.  In contrast, spherical particles produced by 
milling formed dense aggregates that settled within one minute.  Upon actuation of the 
pMDI, the atomized propellant droplets shear apart and thus template portions of the 
highly friable flocs.  Evaporation of the HFA droplets compacts the flocs to yield porous 
particles that possess optimal aerodynamic properties.  Thus, the respirable particles are 
formed in situ in the airways, in contrast with conventional particles which are pre-
formed to possess desired aerodynamic diameters before being suspended in the 
propellant.  High fine particle fractions (49-64%) were achieved with the stable uniform 
suspensions, even at high drug loadings up to 50 mg/mL.  This approach produces 
micron-sized particles, ideal for deep lung delivery, which are composed of nanoparticles 
that facilitate rapid dissolution to enhance the systemic absorption of poorly water soluble 
drugs.  Pulmonary delivery of stable suspensions of templated, open flocs is broadly 
applicable to a range of anisotropic particle morphologies, including plates, needles, and 
rods of poorly water soluble drugs, as well as proteins, to deliver high doses, up to 




Pulmonary delivery is an attractive route of drug administration because it is non-
invasive and offers advantages of an enormous absorptive surface area (140 m2), thin 
absorptive membrane (0.1 – 0.5 μm), highly vascularized epithelium, and avoidance of 
first pass metabolism1.  Effective treatment of respiratory diseases, such as asthma and 
chronic bronchitis, by pulmonary drug delivery methods has been well established1, 2.  
More recently, aerosol delivery of systemic drugs has resulted in several pulmonary 
insulin products3-7.  To achieve high deposition of particles in the alveoli, where drug 
absorption is most efficient as a consequence of extremely thin membranes (0.1 – 0.2 
μm)1, aerosolized particles must possess an aerodynamic diameter (da) between 1-5 μm.  
Particles larger than 5 μm tend to deposit in the throat or upper airways whereas smaller, 
sub-micron particles are often exhaled during expiration without appreciable deposition8, 
9.   
The most widely used delivery option for aerosolized particles is the pressurized 
metered dose inhaler (pMDI) because it is convenient, reliable, affordable , and provides 
effort-independent dosing 10, 11.  Formulations for use in pMDIs are commonly developed 
as suspensions due to the low solubilities of many drugs in hydrofluoroalkane (HFA) 
propellants12.  Drug particles within the appropriate size range for pMDI delivery are 
most commonly produced by milling12-15 and spray drying7, 16-18.  However, at typical 
drug loadings of 1-5% w/w12, suspensions of milled or spray dried particles in the HFA 
propellant often flocculate and settle within minutes, due to a lack of repulsive 
interactions between particles12, 17, 19.  Thus, pMDI formulations often contain additives 
such as surfactants and co-solvents to aid in suspension stability12, 20, 21.  However, 
hydrogenated tails of FDA-approved surfactants are poorly solvated by HFAs, due to its 
low polarizability.  The poor solvation has resulted in low surfactant solubilities and poor 
steric stabilization of drug particles coated by these surfactants10, 12, 22-24.  Consequently, 
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pMDI formulations are often constrained by low mass loadings (<5% w/w) and fine 
particle fractions (FPF) between 5-30%25.  The FPF is the percentage of delivered 
particles estimated to deposit in the deep lungs1.  The low FPF is caused by irreversible 
particle aggregation after settling, which increases da and reduces deep lung deposition, 
and causes inconsistent dosing between actuations.  Thus, pMDI administration has been 
primarily used to deliver high potency (low dose) drugs.  Typical respirable doses 
delivered by pMDI are only 30-200 μg/actuation1, 17, 25, relative to required doses for 
insulin and some anti-cancer agents of 1-10 mg/dose26.   
An alternative approach for enhancing the stability of primary particles in HFA-
propellants is to modify particle morphology.  Hollow particles with porous shells form 
stable suspensions in HFAs, with no visible settling up to four hours17.  Their porous 
structure allows the HFA to fill the particle, minimizing the density difference between 
the suspended particles and the surrounding HFA, significantly reducing van der Waals 
attraction forces between particles27.  Additionally, high FPFs are achieved with the 
hollow, porous particles when delivered as a pMDI,  ranging from 40-70% for a wide 
variety of drugs 17, 27-29.  Particles with a similar morphology to hollow, porous particles 
include large porous particles (LPP) 4, 18 and large porous nanoparticle (LPNP) 
aggregates 30-34, which are produced by spray drying and have sizes ranging from 10-20 
µm.  These powders exhibit FPFs as high as 60% when administered as a dry powder due 
to their low density(< 0.4 g/cm3) 4, 18, 30-32.  To extend this approach to pMDI delivery, 
large, porous, particles are stabilized as individual entities as a colloidal dispersion or 
suspension in HFA; however, over the course of several hours, they are expected to settle 
due to their large size.  Furthermore, the ability to form large, porous particles often 
requires the inclusion of significant amounts of excipients, which reduces the active 
pharmaceutical ingredient (API) potency in the composition.  API loadings in porous 
particles have been reported as high as 70%, but are typically less than 50% w/w, with 
respriable doses up to 300 µg/actuation12, 17, 28.       
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To date, suspension-based pMDIs have utilized pre-formed particles that possess 
the proper aerodynamic diameter for deep lung deposition.  Recently we introduced a 
new paradigm in which the particles are not pre-formed, but instead are templated by 
HFA droplets and formed in the airways.  Anisotropic nanorods of bovine serum albumin 
(BSA) were purposely flocculated in an HFA to produce low density flocs that stack 
upon each other and fill the entire volume of the propellant to inhibit settling35 (Fig. 4.1).  
Furthermore, the protein rods yielded stable suspensions in HFA without the need for 
surfactants or additional excipients, which is highly desirable to achieve increased doses, 
limit disruption of lung function, and avoid potential toxicity issues36, 37.  The packing 
behavior in flocs may be contrasted for spheres and rods.  The volume fraction occupied 


















≈ϕ   (4.1) 
 
where dfloc and dp are the diameter of the floc and primary particle, respectively, and Df is 
the fractal dimension, a parameter that characterizes floc structure38.  For cylindrical rods 
























≈ϕ  (4.2) 
where r, the aspect ratio, is L/D.  Thus, for a given number of particles in a given volume, 
rods with r >> 1 will form  more open, lower density flocs than spheres38-42.  The flocs 
were shown to be weakly held together by van der Waals (VDW) forces.  Actuation of 
the pMDI produced a sufficient amount of force to shear off a portion of the weak, friable 
flocs within an HFA droplet.  The droplet served as a template for the final aerosolized 
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particle.  Upon evaporation of the HFA droplet, capillary forces shrunk the flocs to 
produce porous particles that yielded the proper aerodynamic diameter to achieve high 
FPFs between 38-47% and an emitted dose of 700 µg/actuation.  Thus, the final size of 
the aerosol particle delivered into the airways was templated by the evaporating HFA 
droplet.    
Here, we extend our method of pMDI delivery of templated, open flocs of 
anisotropic particles to a poorly water soluble drug, Itz, to yield aerosol particles 
possessing optimal aerodynamic sizes for deep lung deposition.  The effects of particle 
size, shape, and aspect ratio on floc formation and structure, as well as aerodynamic 
properties upon pMDI delivery are examined.  The Itz morphologies include thin, 
rectangular plates (maximum dimension of 600 nm) and long, needle-shaped crystals 
(maximum dimension of 8 µm).  Strong, attractive VDW forces between small contact 
points in the anisotropic primary particles are shown to “lock in” an open floc structure to 
inhibit floc collapse.  In contrast, particles with an aspect ratio near unity sample a greater 
number of energetically favorable locations to reduce the interfacial surface area38, 43, 44, 
which produces denser flocs.  In the current study, the aspect ratios of the Itz particles are 
as low as 5 compared to 24 for the BSA nanorods in our previous study35.  A key 
objective was to increase the emitted dose from pMDIs to more than 2 mg/actuation to 
advance pulmonary treatment of systemic diseases.  Drug loadings were increased by a 
factor of 5, compared to our previous study35, to characterize how loading affects floc 
density, suspension stability, and aerosol properties.  The ability of the HFA droplets in 
the pMDI to shear off portions of the floc to form aerosol particles, and to compact the 
flocs upon droplet evaporation, is examined. The aerodynamic properties of the 
aerosolized particles are described and analyzed in terms of floc structures and aerosol 
particle formation mechanisms.     
The final objective was to demonstrate that these aerosolized flocculated, high 
surface area nanoparticles exhibit improved dissolution rates relative to lower surface 
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area milled aggregates.  Thus, the ability to deliver nanoparticles to the lungs as micron-
sized aggregates with the proper aerodynamic diameter has the potential to significantly 
improve drug absorption rates in the lungs.  This approach satisfies simultaneously both 
the requirements of micron-sized particles for deep lung deposition and the delivery of 
nanoparticles to facilitate efficient drug dissolution rates to enhance absorption.  
Enhanced dissolution rates are extremely important for raising bioavailability of poorly 





B.P. grade itraconazole (Itz) was acquired from Hawkins, Inc. (Minneapolis, 
MN).  Bovine serum albumin (BSA) and polyoxyethylene sorbitan monolaurate (Tween 
20) were purchased from Sigma (St. Louis, MO).  The propellant 1,1,1,2,3,3,3-
heptafluoroprane (HFA 227) was obtained from Hoechst (Frankfurt, Germany) and 
2H,3H-Perfluoropentane (HPFP) from SynQuest Labs Inc. (Alachua, FL).  A Micro BCA 
protein assay reagent kit was acquired from Pierce (Rockford, IL).  Sodium dodecyl 
sulfate (SDS), HPLC grade acetonitrile (ACN), 1,4 dioxane, and diethanolamine (DEA) 
was used as received from Fisher Chemicals (Fairlawn, NJ).  Stabilized pa grade 1,3 
dioxolane was purchased from Acros Organics (Morris Plains, NJ).  The deionized water 
(DI) was obtained by flowing distilled water through a series of 2x7 L mixed bed vessels 
(Water and Power Technologies, Salt Lake City, UT) containing 60:40 anionic:cationic 
resin blends.   
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4.2.2 Powder Preparation 
4.2.2.1 Thin Film Freezing (TFF) 
Anisotropic Itz and BSA nanoparticles were prepared by a thin film freezing 
(TFF) process described previously47.  Briefly, Itz (0.4% w/v) was dissolved in 1,4 
dioxane and dripped onto a stainless steel surface that was cooled by dry ice to maintain a 
surface temperature of 223K at a flow rate of 4 mL/min through a 17 gauge (1.1 mm ID, 
1.5 mm OD) stainless steel syringe needle.  Upon impact with the steel surface, the 
droplets spread into thin disks and froze.  The frozen disks were collected and lyophilized 
to yield a dry powder.  BSA particles were made using the same method, where the feed 
solution consisted of BSA (0.5% w/v) in 10 mM potassium phosphate buffer (pH 7.4).   
 
4.2.2.2 Controlled precipitation (CP) 
Itz particles were also prepared by a previously established controlled 
precipitation process48, 49.  Briefly, 15 g of 1,3 dioxolane containing 33.3% w/w Itz was 
injected into an antisolvent DI water (50 g), cooled on ice to a temperature of 4oC. 
Vacuum distillation was used to reduce the 1,3 dioxolane to very low residual levels in 
the aqueous dispersion.  The aqueous dispersion was then frozen drop-wise into liquid 
nitrogen and lyophilized to yield a powder.  An Itz/T20 powder was also produced by CP 
using the same method, where the antisolvent phase consisted of 0.75% w/w solution of 
Tween 20 in DI water.  After precipitation, the aqueous dispersion was centrifuged at 
10,000 rpm for 15 minutes at 4oC to separate unadsorbed polymer from the drug 
particles.  The final Itz composition in the Itz/Tween 20 powder was 95±2% w/w, 
determined by dissolving 20 mg of Itz/Tween 20 powder in 3 mL of ACN and then using 
HPLC to quantify the Itz concentration in that solution. 
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4.2.2.3 Wet Milling 
Isotropic Itz particles were prepared by milling.  Micronized Itz powder, as 
received, was suspended at 150 mg/mL in DI water and added to a ceramic container 
filled with 50 ceramic balls, approximately 1 cm in diameter.   The suspension was 
milled on a mechanical roller for 2 weeks and then lyophilized to yield a dry powder. 
 
4.2.3 Lyophilization 
A Virtis Advantage Lyophilizer (The Virtis Company, Inc., Gardiner, NY) was 
used to dry the drug powders.  For particles produced by TFF and CP, drying was 
conducted at -40ºC for 36 hrs at 300 mTorr, followed by a 12 hour linear ramp to 25ºC at 
100 mTorr, and then 24 hours at 25ºC and 100 mTorr. The milled suspension was dried at 
30oC for 12 hours at 500 mTorr. 
 
4.2.4 Particle Density 
The tapped densities of the drug powders were measured using a Vankel tap 
density meter (Varian, Palo Alto, CA).  Drug powder (100-300 mg) was placed into a 100 
mL graduated cylinder and was tapped 200 times.  The true particle densities of the 
powders were determined using a Micromemeritics AccuPyc 1330 helium pycnometer 
(Norcross, GA).  Drug powder was added to a 10 cm3 sample holder for measurements.  
Mean values and standard deviations were obtained from three measurements. 
 
4.2.5 Scanning Electron Microscopy (SEM) 
Powder samples were affixed to aluminum stages using double adhesive carbon 
conducting tape and then sputter coated with gold-palladium for 30 s using a K575 
sputter coater (Emitech Products, Inc., Houston, TX). SEM micrographs were taken using 
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a Hitachi S-4500 field emission scanning electron microscope (Hitachi Ltd., Tokyo, 
Japan) at an accelerating voltage of 10–15 kV. 
Cross-sectional views of the aerosolized flocs were obtained by sectioning the 
region of interest using a dual beam system FEI Strata 235 including both a focused-ion 
beam (FIB) and SEM. Ga+ species that were accelerated at 30 kV were employed to mill 
the particles. A beam current of ~50 pA was employed to minimize risks of overheating 
the specimen. The sample was sectioned after finding the eucentric height and aligning 
the electron-beam (for SEM imaging) and the ion-beam (for material removal with heavy 
Ga ions).   
 
4.2.6 Brunauer-Emmett-Teller (BET) surface area measurement 
A BET apparatus (Quantichrome Instruments, Nova 2000 version 6.11 
instrument, Boynton Beach, FL), using nitrogen as the adsorbate gas, was used to 
measure the specific surface areas of the drug powders.  Weighed powder was added to a 
9 mm Quantichrome bulb sample cell and degassed for 12 hours.  Six points were taken 
over a range of relative pressures from 0.05 to 0.35.  Analysis of the data was performed 
using the Brunauer-Emmett-Teller equation using Nova Enhanced Data Reduction 
Software (Version 2.13). 
 
4.2.7 X-ray Diffraction (XRD) 
The crystallinity of the dried powders was determined using x-ray diffraction 
patterns that were obtained using CuKα1 radiation with a wavelength of 1.5404 Ǻ at 40 
kV and 20 mA from a Philips PW 1720 X-ray generator (Philips Analytical Inc., Natick, 
MA).  Dried powder was pressed onto a glass slide to from a flat sample surface.  A 2Ө 
step size of 0.05o and a dwell time of 4 seconds were used from 5-40 2Ө degrees.    
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4.2.8 Preparation of HFA Suspensions 
Unless otherwise noted, pMDI suspensions were produced by loading the drug 
powders (110 mg) into glass pMDI aerosol vials (SGD Pharmacy, Paris, France) that 
were fitted with 100 μL metering valves (DF10 RC 150, Valois of America, Inc., 
Congers, NY) using a Pamasol Model P2005 compressor pump (Pamasol Willi Mader 
AG, Pfaffikon, Switzerland).  HFA 227 (11 mL) was loaded into the drug-containing 
pMDI vials using Pamasol filling equipment (Model P2008).  For the 50 mg/mL pMDI 
suspensions, 550 mg of drug powder was loaded into the pMDI vial along with 11 mL of 
HFA 227.    
 
4.2.9 Particle Size Analysis by Static Light Scattering (SLS) 
The particle size distribution of the Itz particles was measured by static light 
scattering with a Malvern Mastersizer-S (Malvern Instruments, Ltd., Worcestershire, 
UK).  The dried powder (60 mg) was pre-dispersed in a 2% Tween 20 aqueous solution 
(6 mL) and sonicated with a probe sonicator (Branson Sonifier 450, Brandon Ultrasonics 
Corporation, Danbury, CT) for ~ 2 minutes.  The dispersion was then added drop-wise 
into the sample reservoir, containing 500 mL of pure DI water, to obtain an obscuration 
between 10-15%.  Particle size distributions, weighted by volume, were calculated with a 
refractive index of 1.61 for Itz50.  Particle size measurements of flocs in HPFP were 
measured similarly.  The drug powder (20 mg) was pre-dispersed in HPFP (2 mL) and 
added drop-wise into the small volume sample cell, containing 15 mL of HPFP.  
However, due to the high porosity of the floc, an effective refractive index was 
determined in to obtain particle size distributions.  The effective refractive index was 
calculated using the Bruggeman mixing rule, as described in the Supplementary Section.   
The size distribution of the aerosolized particles, emitted from the pMDI, was also 
characterized by SLS.  The pMDI was actuated directly into the laser beam of the 
Malvern Mastersizer S and 100 measurements were taken in 5 ms intervals.  The 
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recorded measurements were averaged, on a volume basis, to yield the size distribution of 
the aerosolized particles.  An effective refractive index, calculated with the Bruggeman 
mixing rule, was used to determine the particle size distribution of the aerosol particles 
due to its high porosity. 
 
4.2.10 Particle Size Analysis by Dynamic Light Scattering (DLS) 
DLS was used to measure the particle size distribution of Itz particles when the 
drug concentration was too low to be measured by SLS.  Particle size measurements were 
performed in triplicate using a custom-built dynamic light scattering (DLS) apparatus51 at 
a scattering angle of 90° and temperature of 25 °C.  Dispersion concentrations were 
adjusted to give a measured count rate between 300-400 kcps.  Measurements were made 
over a period of 2 minutes. The data were analyzed with a digital autocorrelator 
(Brookhaven BI-9000AT) with 522 real time channels and a non-negative least-squares 
(NNLS) method (Brookhaven 9KDLSW32).   
 
4.2.11 Optical Microscopy      
Drug particles were dispersed in HPFP at a ~5 mg/mL drug loading and pipette 
onto a glass slide for observation using a Nikon OPTIPHOT 2-POL optical microscope 
with an attached MTI CCD-72X camera (Nikon, Tokyo, Japan).   
 
4.2.12 Aerosol Characterization of Drug Particles after Actuation by pMDI 
 
4.2.12.1 Dose Delivered Through the Valve (DDV) Determination  
The pMDI suspensions were actuated once through the firing adaptor of a dosage 
unit sample tube (26.6 mm ID x 37.7 mm OD x 103.2 mm length; 50 mL volume, Jade 
Corporation, Huntingdon, PA).  Then, 40 mL of an appropriate solvent, ACN or DI water 
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for Itz or BSA, respectively, were added to the tubes, which were allowed to sit for at 
least 30 minutes to ensure sufficient dissolution of drug.  The drug concentration in the 
rinse media were quantified using high performance liquid chromatography (HPLC) or a 
Micro BCA protein assay for Itz and BSA, respectively.   
 
4.2.12.2 Andersen Cascade Impactor (ACI) 
Aerodynamic characterization of pMDI aerosols was performed using an eight-
stage Andersen cascade impactor (ACI) (Thermo-Andersen, Smyrna, GA).  The ACI was 
operated with a 15 cm spacer (Aerochamber Plus®, Trudell Medical International, 
Ontario, Canada) and an air flow-rate of 28.3 L/min. Three actuations were sent to waste 
and the next five were made into the ACI.  The interval between actuations was between 
30-60 s and the pMDI was shaken between each actuation.  After the last dose was 
discharged, the valve stem and actuator were rinsed with solvent.  Each plate of the 
impactor was placed in a receptacle containing a known volume of solvent and soaked for 
at least 30 minutes to ensure complete drug/protein dissolution.  Drug and protein 
concentrations were determined using HPLC or a Micro BCA protein assay for Itz and 
BSA, respectively.  Quantification of the drug deposition on each stage was used to 
calculate mass median aerodynamic diameter (MMAD), geometric standard deviation 
(GSD), and fine particle fraction (FPF).   
The geometric diameter of the aerosolized particles was also determined using the 
ACI. Double-sided carbon adhesive tape was applied to stage 3 of the ACI stage.  The 
ACI was operated under the same conditions from above and a pMDI was actuated once 
into the impactor.  The tape was applied to an aluminum SEM stage, sputter coated, and 
imaged using SEM.  Particle sizes from the SEM micrographs were analyzed using 
imaging software (Scion, Frederick, MD).  At least 50 particles were counted for each 
sample.  The number averaged particle size obtained from image analysis was converted 








DVol   (4.3) 
 
 where d is the particle diameter. 
 
4.2.13 Dissolution 
The dissolution rates of aerosolized particles, emitted from a pMDI, were 
measured in 0.02% w/v SDS phosphate buffer (pH = 7.4) at 37oC.  The dissolution media 
(30 mL) were preheated in 100 mL dissolution vessels (Varian Inc., Cary, NC) and set in 
a VanKel VK6010 Dissolution Tester with a Vanderkamp VK650A heater/circulator 
(VanKel, Cary, NC).  To introduce the drug particles to the dissolution media, the 
dissolution vessel was fitted with a home-made silicon adaptor, lifted out of the 
dissolution apparatus, and tilted at a ~45oangle.  The silicon adaptor fit tightly around the 
dissolution vessel on one side and the actuator of the pMDI on the other side.  The pMDI 
was actuated 10 times into the dissolution vessel and the vessel was placed back into the 
dissolution apparatus.  A USP paddle method was used for the dissolution test.  Sample 
aliquots (~1.2 mL) were withdrawn at various time points up to 120 minutes.  The 
samples were filtered immediately using a 0.02 μm syringe filter.  The filtrate (0.7 mL) 
was subsequently diluted with ACN (0.7 mL) to prevent precipitation of the drug.  The 
Itz concentration in the samples was quantified by HPLC as described below. 
 
4.2.14 High Performance Liquid Chromatography (HPLC) 
Itz concentrations were quantified using a Shimadzu LC-600 HPLC system 
(Columbia, MD) equipped with a Hypersil C18 column (5 μm, 150 x 4.6mm) 
(Thermoelectron Corporation, Waltham, MA) protected by a C-18 guard column (5 mm, 
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7.5 x 4.6 mm) (Alltech Associates Inc., Deerfield, IL).  The mobile phase consisted of 
ACN, DI water, and DEA (70:30:0.05 v/v/v) and was pumped at a rate of 1 mL/min. 
Using a detection wavelength of 263 nm, the Itz peak eluted at 5.4 min.  
 
4.2.15 Quantitation of BSA 
BSA content was measured using a Micro BCA Protein Assay (Pierce, Rockford, 
IL) according to manufacturer protocols.  The absorbance of BSA solutions was 
measured at 562 nm using a 96 well plate spectrophotometer (μQuant Model MQX200; 
Biotek Instruments Inc., Winooski, VT).  BSA solutions with concentrations between 2 




4.3.1 Powder Characterization 
The morphologies of Itz particles prepared by TFF, CP, and milling were 
characterized by SEM (Fig. 4.2a-d).  Itz primary particles produced by TFF (TFF Itz) 
without any stabilizers were spherical in shape and had an average diameter of 30 nm as 
determined from SEM micrographs, consistent with the powder surface area measured by 
BET (Table 4.1).  Itz particles produced using CP without any stabilizers (CP Itz) were 1-
3 μm in size as determined from SEM, again in agreement with the sizes measured by 
BET and SLS (Table 4.1, Fig. 4.3).  The XRD patterns of both particles lacked the 
characteristic peaks of crystalline Itz, indicating an amorphous morphology (Fig. 4.4).  
However, upon addition of each of these amorphous powders to HFA 227, a change in 
particle morphology was observed by SEM (Fig. 4.2 e-f).  The originally spherical 
particles of both powders transformed into thin, plates.  The average dimensions of the 
crystallized TFF Itz particles were 600 nm x 300 nm x 60 nm, based on sizing of over 50 
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particles from SEM images.  The maximum aspect ratio of 10 was used to characterize 
these plates.  Similar sizes were observed for the crystallized CP Itz particles.  
Furthermore, the change in particle shape was accompanied by a shift in the x-ray 
diffractorgram to a crystalline pattern (Fig. 4.4).  The time for crystallization to occur was 
less than 10 minutes, as determined by a control experiment where HFA, cooled to -80oC, 
was mixed with the amorphous Itz powders and then allowed to immediately evaporate 
under ambient conditions, which took about 10 minutes for ~2 mL of HFA.  After this 
short exposure, the change in the XRD pattern to a crystalline profile was observed.  The 
same particle shape change (data not shown) and crystallization (Fig. 4.4) were also 
observed when the amorphous Itz particles were added to the HFA surrogate, HPFP, a 
non-volatile solvent with similar polarity and polarizability as HFA 22753, 54.  
Crystallization of the amorphous Itz powders may be attributed to the relatively low glass 
transition temperature (Tg) of Itz, approximately 60oC based on DSC measurements55.  
Thus a small degree of the swelling of the amorphous Itz by the HFA would be sufficient 
to lower the Tg to room temperature.  With the enhanced molecular mobility, the 
amorphous Itz relaxes to the lower energy crystalline state.  Because CP Itz particles 
were essentially the same size and shape as TFF Itz particles after HFA exposure, the 
remainder of the paper will focus on the TFF Itz particles. 
In contrast to the spherical particles produced by TFF and CP in the absence of 
any stabilizers, the morphology of Itz particles prepared by CP and stabilized using 
Tween 20 (T20) favored preferential growth in one direction to produce long, thin, 
needle-shaped particles.  The needles had widths ranging between 1-2 µm and lengths 
between 6-10 µm, as determined by SEM.  Although SLS particle sizing results are most 
accurate for spherical particles, they may still be applied for these needle-shaped particles 
by using the equivalent volume of a sphere to characterize the non-spherical particle’s 
geometry35.  For instance, the effective average particle diameter measured by SLS for 
the Itz needles was 3.08 µm (Fig. 4.3), which gives an equivalent spherical volume of 
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15.3 µm3.  Therefore, if the average width of the needles is 1.5 µm, and the shape of a 
needle is approximated as a long rectangular box with square ends, the corresponding 
length, L, would be 6.8 µm (L=15.3/1.52), consistent with the SEM micrographs.  
Therefore an aspect ratio of 5 (L/w = 7/1.5, where w is the width) was assigned to the 
needles.  Itz particles processed by wet milling produced spheres 300 nm in diameter, as 
observed by SEM and from BET and SLS measurements.  As determined from their 
XRD patterns, both CP Itz/T20 and milled Itz were crystalline (Fig. 4.4).  SEM 
morphology and XRD patterns for CP Itz/T20 and milled Itz did not change after 
exposure to HFA 227. 
 
4.3.2 Suspension Stability of Anisotropic Itz Particles in HFA 
Measured amounts of Itz powders (110 mg) were loaded into the pMDI vials. 
Prior to the addition of HFA, for the TFF Itz (tapped density=0.012 g/cm3), the powder 
filled the entire volume of the vial.  In the case of CP Itz and CP Itz/T20 (tapped 
density=0.63 g/cm3), about 75% of the vial was filled.  However, the milled particles 
only formed a thin layer at the bottom of the vial (tapped density=1.53 g/cm3).  HFA 227 
was then added to the powders to yield a 10 mg/mL suspension, corresponding to a 
volume fraction of particles in the vial, φv = 0.0077.  The TFF Itz, CP Itz, and CP Itz/T20 
particles filled the entire volume of the propellant as a homogenous, milky dispersion 
(Fig. 4.5a-c).  No settling was observed in these samples for over two years.  As a 
control, a pMDI composition was prepared using TFF Itz loaded at a φv of 0.0015, 20% 
of the original drug loading described above.  Even at this lower φv, the particles still 
filled about 70% of the volume of the propellant (Fig. 4.5d), indicating extremely low 
density flocs, similar to what was observed previously by Engstrom et al.35  To test the 
effect of drug loading on suspension stability, the TFF Itz loading was increased to 50 
mg/mL (φv = 0.039).  The resultant suspension was also homogenous in appearance, 
similar to that of the 10 mg/mL loading. No settling was observed over the lifetime of the 
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pMDI (~2 weeks).  In contrast to the particles prepared by TFF and CP, the milled 
particles settled rapidly, within 30 seconds.  Within 5 minutes, the milled particles had 
settled completely (Fig. 4.5e). 
To investigate the floc structure formed by the different anisotropic particles and 
milled Itz particles in HFA 227, analogous formulations prepared in a surrogate solvent 
HPFP were examined by optical microscopy (Fig. 4.6) at ambient pressure.  Flocs formed 
by TFF Itz and CP Itz/T20 are clearly more open than those formed by the milled 
particles, with comparable floc sizes of about 150-200 µm.  SLS measurements of TFF 
Itz particles in HPFP were performed to confirm the observed floc sizes.  A measured D50 
value of 318 µm was in agreement with the microscopy images (Fig. 4.7a).  The flocs of 
milled Itz were of similar size to those formed by the anisotropic particles; however they 
were much more densely packed.   
To demonstrate that the flocs of anisotropic particles are only weakly held 
together and can be easily broken apart by the shear during pMDI actuation, the valve of 
the pMDI was submerged in 10 mL of an aqueous Tween 20 solution (2% w/v) and 
actuated.  The resultant dispersion (~0.1 mg/mL) was barely turbid and the emitted 
particles, which were measured immediately by DLS, had an average particle size of 700 
nm, significantly smaller than the 150-318 µm floc diameter measured for TFF Itz flocs 
in HPFP (Fig. 4.7b).     
 
4.3.3 Characterization of Aerosolized Anisotropic Itz Particles from a pMDI 
DDV values provide insight into the stability of a pMDI composition.  Unstable 
suspensions prone to settling and particle aggregation may not provide efficient or 
consistent doses.  A pMDI with a drug concentration of 10 mg/mL should theoretically 
deliver 1 mg of drug/actuation with a 100 µL valve.  The DDV values for the pMDI 
suspensions of TFF Itz and CP Itz/T20 at a 10 mg/mL drug loading were 97 and 82% of 
the theoretical dose, respectively, in comparison with 92% for the BSA nanorods reported 
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in Engstrom et al.35 (Table 4.2).  Therefore, despite the smaller aspect ratios and larger 
sizes of the anisotropic Itz particles compared to the BSA nanorods, sufficiently stable 
pMDI suspensions were produced to facilitate efficient aerosol delivery.  The milled Itz 
suspension pMDI only delivered 21% of the theoretical dose, which was expected based 
on previous reports in literature12 given the poor suspension stability.  When the drug 
loading for the TFF Itz and TFF BSA pMDI suspensions was increased by a factor of 5 to 
50 mg/mL, the DDV values were between 2.3-2.9 mg/actuation.  However, the dosing 
efficiency decreased to 46 and 68% for TFF Itz and TFF BSA, respectively.   
The ability of a pMDI to efficiently deliver anisotropic Itz particles to the deep 
lungs was assessed using an Andersen Cascade Impactor (ACI) (Table 4.2).  For TFF Itz 
and CP Itz/T20 pMDI suspensions, FPFs were 56% and 49%, respectively, compared to 
47% for the BSA nanorods35.  These high FPFs resulted in fine particle doses (FPD) and 
total emitted doses (TED) ranging from 377-525 µg/actuation and 754-942 µg/actuation, 
respectively.  In contrast, milled pMDI suspensions produced a 15% FPF to yield a FPD 
and TED less than 30 and 200 µg/actuation, respectively.  Increasing the drug 
concentration in the pMDI suspensions to 50 mg/mL did not adversely affect the FPF for 
either TFF Itz or TFF BSA particles.  In each case, the FPFs actually increased to 64 and 
50%, respectively.  The high FPFs, and FPDs and TEDs as high as 1.2 mg and 2.4 mg, 
respectively, represent a considerable increase over most current commercial products12.   
The distribution of drug deposited on the ACI stages is shown in Fig. 4.8.  At both 
drug concentrations, the highest amount of drug deposition occurred on stages 3 - 5, 
within the desirable range for deep lung deposition, for the anisotropic Itz particles. 
However, increased deposition in the spacer and throat was detected for a 50 mg/mL drug 
loading compared to 10 mg/mL.  In contrast, the majority of the milled Itz particles were 
deposited in the spacer and throat region.  MMADs were calculated based on the 
distribution of drug mass on the different stages in the impactor.  Therefore, MMAD and 
GSD values between 3-4 µm and 1.8-3.3 µm, respectively, were achieved for the pMDI 
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suspensions of anisotropic particles, within the optimal 1-5 µm range for deep lung 
delivery (Table 4.3).  Aerosolized milled Itz particles had an MMAD of 6 µm and GSD 
of 2.9 µm.   
The geometric diameters and morphologies of the anisotropic Itz particles emitted 
by the pMDI were determined by recovering the particles from stage 3 of the ACI (da = 
3.5-4.7 µm), which had high deposition levels.  The particles were imaged using SEM 
(Fig. 4.9).  Similar to observations by Engstrom et al.35, the actuation of the pMDI 
suspension of anisotropic particles produced large, porous aggregates of relatively 
monodisperse size that clearly are composed of the individual nanoparticles originally 
loaded into the pMDI vial.  All pMDI suspensions of anisotropic particles, which 
possessed the same drug loading (10 mg/mL), emitted aerosol particles of comparable 
size, ~10 µm.  In contrast, aerosolized milled particles were about a factor of two smaller 
than the aerosolized anisotropic Itz particles.  The average geometric particle sizes 
observed by SEM (analysis of ~50 particles) were in excellent agreement to those 
measured using light scattering (Table 4.3).  The densities of the aerosolized particles, ρg, 
were calculated using the following equation, which relates da (set at 4 µm, 
corresponding to stage 3 of ACI ) to geometric diameter, dg 4:   
 
gga dd ρ=  (4.4) 
 
Values for ρg ranged between 0.1-0.2 g/cm3 for the aerosolized anisotropic 
particles with a 10 mg/mL drug loading and between 0.04-0.09 g/cm3 for the 50 mg/mL 
drug loading (Table 4.3). 
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4.3.4 Dissolution of Aerosolized Anisotropic Itz Particles from a pMDI 
To demonstrate the ability of the aerosolized flocs of anisotropic particles to 
deaggregate into its constituent nanoparticles upon deposition in the lungs, the pMDI 
containing TFF Itz was actuated above dissolution media and the aerosolized particles 
were trapped and suspended in the media, which contained 0.02% w/v SDS.  From SLS, 
the initial D50 of 9.0 µm was the same as the geometric diameters measured for the 
aerosolized particles in the previous section (Fig. 4.10).  However, the size decreased to a 
D50 of 2.7 µm upon sonication over 2 minutes, indicating that the aerosolized flocs 
deaggregated and/or dissolved.  The dissolution study shows that the aerosolized flocs of 
anisotropic TFF Itz nanoparticles dissolve more rapidly than a pMDI composition of 
milled nanoparticles of equal drug loading, achieving 55% dissolution after 2 hours, 
compared to only 25% for the aerosolized milled particles (Fig. 4.11a).  The improved 
dissolution rate of the aerosolized TFF Itz flocs can be further explained by the SEM 
images of the two aerosol particles after actuation into dissolution media.  The SEM 
images clearly show that the aerosolized TFF Itz flocs deaggregated into smaller entities 
relative to the original aerosol particle, while the milled Itz flocs appear to be the same 




4.4.1 Role of van der Waals forces in suspension stability 
Attractive VDW forces are used deliberately in this study to form the open space-
filling flocs that produce stable suspensions in HFAs, as described in detail in this section 
and in a recent study35.  This approach is the opposite of the traditional method in which 
the goal is to stabilize individual pre-formed particles against flocculation.  VDW 
attractive forces are dominant for pure drug particles without a surfactant in HFA, 
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compared to electrostatic and steric forces.  Electrostatic stabilization is not well 
understood in HFAs because of ion paring resulting from the low dielectric constants.  
Atomic force microscopy (AFM) studies in HPFP have shown that electrostatic forces are 
negligible compared to VDW forces in HFA systems54, 56.  As a consequence of the low 
polarizabilities of HFAs, traditional surfactants for chlorofluorocarbons are not solvated 
sufficiently well to provide steric stabilization10, 12.  Novel surfactants with enhanced 
solvation in HFAs are being designed using simulation and AFM studies to address this 
problem24, 57, 58.   
To circumvent the lack of electrostatic and steric stabilization available in HFAs, 
spherical porous particles (LPPs, LPNPs) and hollow, porous particles (pulmospheres), 
have been designed to minimize VDW attractive forces.  These porous particles are 
typically larger than 5 μm in diameter.  The solvent penetrates the pores within the 
particles to lower the VDW attraction between particles, and thus the rate of particle 
aggregation.  The porosity of the particle also improves its buoyancy, which minimizes 
settling.  Both of these factors facilitate efficient aerosolization of these pre-formed 
particles, which is necessary to achieve desired aerodynamic properties for deep lung 
deposition.  These suspensions may remain stable in HFAs for several hours, whereas 
solid particles of the same size rapidly flocculate and settle within minutes17, 18.  The 
lower attractive forces are due to a lower effective Hamaker constant, A121, for porous 
particles compared to solid particles35.  For highly porous particles, the penetration of 
propellant within the particle lowers the particle’s effective Hamaker constant, according 
to Bruggeman’s mixing rule.  As the effective Hamaker constant becomes more similar to 
that for the propellant, A121 decreases, thus reducing VDW forces (See Supplementary).  
The comparison of ΦVDW for the different particle types was performed by calculating the 
separation distance, h, that corresponded to a ΦVDW equal to the thermal energy 3/2 kBT 
at 298 K.  A larger h required to overcome thermal energy indicates a stronger attraction 
between particles.  Calculated separation distances clearly demonstrate that increasing the 
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particle porosity will significantly reduce VDW attractive forces (Table 4.4), as described 
previously12, 17, 28. 
Relative to hollow and porous particles, the VDW forces are stronger for the 
primary particles prepared by TFF and CP due to their low porosities (Table 4.4).  
According to Eq. 4.2, the thin plates of TFF Itz and CP Itz and long needles of CP 
Itz/T20, with large aspect ratios >1, form open flocs that do not pack efficiently.  The 
strong VDW attractive forces promote rapid flocculation.  However, the contact area 
between primary particles is relatively small because of the high aspect ratios and poor 
packing.  The VDW forces at the contact sites prevent the flocs from compacting to 
denser flocs to reduce the surface areas59.  For spheres that pack efficiently, dense flocs 
form and settle rapidly within minutes.  The formation of open space-filling flocs of the 
anisotropic particles is the basis for particle stability in the HFA, as seen in Fig. 4.5, 
relative to unstable spherical particles. 
 
4.4.2 Effect of particle size, shape, and drug loading on suspension stability in 
HFA 227  
The effect of particle size and shape on floc structure may be quantified by 
comparing the following characteristics: (1) volume fraction of particles within a floc 
(φf), (2) volume fraction of flocs in the HFA propellant (φfloc), and (3) Df.  Values for φf 
were calculated based on observed floc settling rates, Ufloc.  A modified Stoke’s settling 









floc                              (4.5) 
 
where ρL and µ are the liquid density and viscosity, respectively, g is the gravitational 
constant, and dfloc was estimated from the optical microscope images in Fig. 4.6.  The 
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material balance )( LpfLfloc ρ−ρϕ+ρ=ρ , where ρp is the true density of the primary 
particle, was then used to determine φf 60, 61.  As seen in Table 4.5, the settling rate for CP 
Itz/T20 flocs was faster than that for TFF Itz flocs, likely due to their larger ρp.  Milled 
particles settled the most rapidly, two orders of magnitude faster than the anisotropic 
particles, given the formation of dense aggregates with a high φf as seen in Fig. 4.6.  
Because the measured settling rate was over four orders of magnitude higher than that for 
a 300 nm particle from Eq. 4.5, the particles definitely aggregated.  Therefore, both the 
TFF Itz plates and the CP Itz/T20 needles possessed a φf at least two orders of magnitude 
lower than milled particles. The low φf is in good agreement with the floc structures 
observed in Fig. 4.6, in contrast with the dense flocs from the milled particles.  
Furthermore, a slower settling rate yielded a lower φf for the plates than for the needles.  
The lower φf was consistent with the smaller size and higher aspect ratio for the plates, as 
seen in Eq 2. as well as Fig. 4.6.   
The corresponding φfloc values are obtained by φv/φf 35, where φv is the particle 
volume fraction in HFA (based on drug loading).  The φfloc describes the space-filling 
capabilities of the flocs within the HFA volume.  Values of φfloc for TFF Itz and CP 
Itz/T20 particles were one order of magnitude greater than for the milled particles, again 
indicating that the flocs composed of anisotropic particles fill more space.  For a 
concentration of 2 mg/mL, the  dispersion still occupied about 70% of the propellant 
volume (Fig. 4.5).  This experimental observation is in excellent agreement with the φfloc 
of 0.65, which was calculated based on the floc settling rate.  The trends observed in φf 
and φfloc were consistent with the calculated Df values, obtained using Eq. 4.2.  A Df less 
than 2 corresponds to an extremely open, low density floc.  Higher Df values correspond 
to increasingly tight more dense floc, and a close-packed packed floc is assigned a Df 
value of 3 38.  For Eq. 4.2, the volume of a cylinder was used to obtain an effective 
spherical diameter to determine Df 39.  The same approach was used for the plate-shaped 
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particles.  Flocs of TFF ITZ and CP Itz/T20 particles yielded Df values of 2.3 and 2.2, 
respectively, whereas flocs of milled particles yielded a Df value of 3.0.      
Anisotropic particles, with aspect ratios as low as 5-10, were found to produce 
stable suspensions in HFA 227, as was the case for the BSA nanorods35.  Despite the 
lower aspect ratio, the floc structure for the TFF Itz plates and CP Itz/T20 needles was 
similar to those of the TFF BSA nanorods with an aspect ratio of 24 35.  All of the 
anisotropic particles formed flocs with very low φf values and Df values between 2.3-2.5.  
Despite the factor of two lower aspect ratio of CP Itz/T20 needles compared to TFF Itz 
plates, the larger size of the needles gave a slightly lower Df and packing density, as 
described by Eq. 4.2.  No visible settling was observed in the suspensions of the three 
different types of anisotropic particles in HFA 227 over 2 years (10 mg/mL drug 
loading), indicating that the VDW attractive forces are sufficient to prevent collapse of 
the flocs.  Furthermore, increased drug loadings up to 50 mg/mL did not adversely affect 
suspension stability, since φf was still an order of magnitude lower than for the milled 
particles at a 10 mg/mL loading.  These results indicate that the space-filling, open flocs 
stack upon each other to prevent settling, even at a high drug loading. 
 
4.4.3 Effect of particle size, shape, and drug loading on aerosol properties  
Although the open, space-filling flocs of anisotropic particles form stable 
suspensions in HFA, the diameter of ~150 μm would be too large for efficient deep lung 
deposition.  Recently, a mechanism was presented by Engstrom et al.35 to explain how 
these large flocs are sheared apart to produce respirable particles that may be delivered to 
the deep lung.  The shear forces generated during actuation template the flocs within ~25 
µm HFA droplets.  These forces easily overcome the  attractive VDW interactions 
between the primary particles within the flocculated particles, as illustrated in Fig. 4.1 35, 
given the small contact area between the primary particles.  As the HFA droplets 
evaporate, capillary forces compact the flocs to produce porous aerosol particles.  This 
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compaction is illustrated in Appendix C Fig. C.1, where the volume of 100 mg of TFF Itz 
powder, with a tapped density of 0.012 g/cm3 was compacted significantly upon HFA 
evaporation to yield a powder with a tapped density of 0.16 g/cm3.  The powder density 
after HFA evaporation was identical to the calculated density for the aerosolized TFF Itz 
particle, ρg, which was calculated using Eq. 4.4 based on experimentally measured da and 
dg values.  Thus, the final size of the aerosol particle was determined by the floc 
structure, the templating of the flocs within the HFA droplets, and compaction of the 
flocs during HFA evaporation.  
For TFF Itz particles, actuation from the pMDI with the valve submerged in a 2% 
w/v Tween 20 solution yielded particles with sizes near those of the primary TFF Itz 
plates.  They were considerably smaller than the flocs measured in HPFP, which did not 
deaggregate into primary colloidal particles.  The shear generated upon actuation and 
HFA droplet formation contributes to the break up of the large flocs into smaller flocs.  In 
addition, the Hamaker constant for water, 3.7*10-20 J 62, 63, is larger than for HFA 227 and 
closer to the Hamaker constant for Itz.  Thus, the resulting VDW forces between primary 
particles in the aqueous solution are weaker and the flocs deaggregate into primary 
particles, as observed in previous studies35.  Because of the small area of the contact 
points between the anisotropic particles, deaggregation took place more readily after 
actuation into water than would be the case for spherical particles with a larger area of 
these contact points. 
The ability to break down the large ~150 µm friable flocs into respirable particles 
was evident in the favorable aerodynamic properties listed in Tables 4.2 and 4.3.  pMDI 
suspensions of the TFF Itz plates and the CP Itz/T20 needles both produced higher DDVs 
and FPFs versus the milled Itz composition(Table 4.2).  The DDV and FPF values of the 
CP Itz/T20 pMDI were slightly lower than those for the TFF Itz pMDI.  The CP needles, 
with average needle lengths of 7 µm, may not fill the pMDI metering chamber as 
efficiently as the smaller TFF plates.  The geometric sizes of the aerosol particles of both 
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the TFF Itz and CP Itz/T20 were about 10-11 µm with a ρg of 0.10-0.16 g/cm3, 
comparable to values for the aerosolized TFF BSA rods in Engstrom et al35.  Therefore, 
for a given drug loading , the aerosol properties of the pMDI compositions produced by 
the  templating/compaction mechanism were similar for different types of drugs and 
anisotropic shapes, as long as the level of anisotropy was sufficient for low φf  values and 
high suspension stability. 
Upon increasing the drug loading by a factor of 5 for 50 mg/mL, the dose 
efficiency (%DDV) decreased significantly, by at least 30% for the TFF Itz and TFF 
BSA, even though there was no observable change in suspension stability.  However, the 
FPFs for the two concentrated pMDIs remained high.  Perhaps the inflow of the flocs into 
the metering chamber is less efficient with a higher overall volume fraction of primary 
particles, than for the lower 10 mg/mL loading.  Therefore, the drug concentration in the 
metering chamber may not be equal to the drug concentration in the rest of the vial.  This 
behavior, along with potential of sticking to or clogging of the valve due to the high 
particle concentrations, may explain the reduced dosing efficiencies.  However, the 
particles that are able to fill the metering chamber are still subjected to the same 
templating mechanism as described above, keeping FPFs high.  As a consequence of the 
higher drug loading, the geometric sizes of the aerosolized particles increased by about 
50%.   
Aerosol particles produced by the templated open floc method yields extremely 
high emitted and respirable doses, up to 2.4 and 1.2 mg/actuation, respectively, compared 
to a maximum respirable dose of 300 µg for the hollow, porous particles12.  For porous 
and hollow particles, drug mass/particle can be limited by high porosity as well as the 
need for high excipient levels.  Furthermore, the total particle loading in the pMDI can be 
limited by the lack of efficient steric stabilizers.  If the loading is to high, the particles 
may not form uniform suspensions.  For our flocs, the drug mass/aerosolized particle is 
very high because the individual anisotropic particles contain no excipients and are 
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uniformly distributed throughout the entire aerosolized particle.  The homogenous 
distribution of drug throughout the entire aerosolized particle is shown in Appendix C 
Fig. C.3, where a slice of an aerosolized particle was shaved off using a focused ion beam 
(FIB) and imaged using SEM to view the interior particle morphology.   
 
4.4.4 Dissolution of aerosolized particles in the lungs 
In addition to improving suspension stability, the delivery of flocs of sub-micron 
particles enhances particle dissolution rates in the lungs compared to the more 
traditionally delivered solid, 5 µm particles (or a 5 µm dense aggregate of particles)64, 65.  
Particles that require long dissolution times are subject to more rapid clearance by 
macrophages in the lungs, especially for particles 1-5 um in size, or cause irritation to the 
lungs.  Therefore, rapid dissolution rates are beneficial for efficient drug absorption, 
especially for poorly water soluble drugs.  Enhanced dissolution rates may be achieved 
by particle size reduction, which increases the surface area, and decreases the boundary 










     (4.6) 
 
where M is the mass of undissolved drug, D is the diffusion coefficient, and ∆C is the 
difference in equilibrium concentration of the drug adjacent to the particle surface and in 
the bulk. 
To address the bioavailability of poorly water soluble drugs, LPNP aggregates 
have previously been shown to dissociate rapidly into constituent nanoparticles that 
dissolve rapidly when added to a liquid medium30.  However, these LPNP particles had a 
maximum drug loading of 10% w/w with the remainder composed of polymer and/or 
phospholipid.  In contrast, the flocs in the current study were pure drug. 
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For our highly porous aerosolized flocs produced by TFF, solvent permeates 
throughout the entire floc to enhance dissociation into the primary anisotropic particles, 
thereby increasing the available surface area for dissolution.  The high BET surface area 
of the TFF powder will lead to high surface area flocs for high dissolution rates.  
Therefore, dissolution rates correspond more closely to that of the primary nanoparticles, 
as opposed to the larger open flocs.  The ability of the TFF Itz aerosolized flocs to 
dissociate into entities with sizes on the order of the individual anisotropic nanoparticles 
was demonstrated in Fig. 4.11b, where particles roughly resembling the constituent 600 x 




The novel concept of templating suspensions of open flocs of anisotropic particles 
in HFAs without surfactants, to produce particles for efficient deep lung delivery via 
pMDIs35, has been extended to poorly water soluble drugs and higher drug loadings. 
Plate- and needle-shaped drug particles, with aspect ratios between 5-10, pack 
inefficiently and formed low density flocs that stacked upon each other to prevent settling 
for over two years at a 10 mg/mL drug loading.  For highly concentrated and stable 
pMDI suspensions, with a drug loading of 50 mg/mL, total emitted doses (TED) reached 
2.4 mg/actuation, a significant improvement over typical  pMDIs with doses of  600-1000 
µg/actuation1, 12.  Aerosolization of the templated flocs produced high FPFs between 49-
64%.  The aerosolized particles were templated during HFA droplet formation and 
compacted during evaporation to yield optimal aerodynamic diameters for deep lung 
delivery, in contrast with the conventional approach of delivering pre-formed particles.  
Furthermore, the delivery of high surface area micron-sized porous flocs of nanoparticles 
to the lungs, as opposed to a solid, micron-sized particle was shown to enhance drug 
dissolution rates.  Therefore, the delivery of micron-sized flocs of nanoparticles with a 
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pMDI offers both efficient deep lung deposition as well as rapid dissolution, which is 






Figure 4.1 Schematic describing the mechanism by which anisotropic particles form 
stable suspensions in HFA for efficient pulmonary delivery via a pMDI.  
The anisotropic particles form loose, open flocs that stack upon each other 
and do not settle, to give an overall volume fraction of flocs in suspension of 
φflocs.  Upon pMDI actuation, a portion of the floc is sheared within an 
HFA droplet to yield a volume fraction of particles within the floc of φf.  
HFA evaporation compacts the floc to produce the aerosol particle, in which 












Figure 4.2 SEM micrographs of Itz particles made by (a) TFF (TFF Itz), (b) CP without 
stabilizers (CP Itz), (c) CP using Tween 20 as a stabilizer, 96% w/w Itz (CP 
Itz/T20), (d) and wet milling.  Micrographs of TFF Itz and CP Itz after HFA 




















   






Figure 4.3 Particle size measurements of CP Itz, CP Itz/T20, and milled Itz particles 






























Figure 4.4 X-ray diffraction patterns for Itz particles prepared by TFF, CP, and milling 
before HFA 227 exposure.  The diffractogram of TFF Itz particles after 











Figure 4.5 Photographs of pMDI suspensions 5 minute after shaking: (a) TFF ITZ, (b) 
CP ITZ, (c) CP ITZ/T20, (d) TFF ITZ-dilute, and (e) milled Itz.  All Itz 
loadings were 10 mg/mL (1% w/w) except for the dilute suspension in (d), 

































Figure 4.6 Optical microscopy images of Itz particles suspended in HPFP.  Images of 








































Figure 4.7 Particle size measurements of (a) TFF Itz in HPFP (D50 = 318 um) measured 
by SLS and of (b) TFF Itz particles after actuation by a pMDI, with the 




















TFF Itz (10 mg/mL)
TFF Itz (50/mg/mL)
CP Itz/T20 (10 mg/mL)
Milled Itz (10 mg/mL)
FPF
 
    
Figure 4.8 Anderson Cascade Impactor deposition profiles for pMDI suspensions of 
TFF Itz, CP Itz/T20, and milled Itz, accounting for drug deposited in the 
spacer and throat (S+T), and stages 0-F.  A 10 mg/mL and 50 mg/mL drug 
loading was examined for pMDI suspensions of TFF Itz particles.  The fine 
particle range was determined by the mass of drug deposited on stages 3-F. 
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Figure 4.9 SEM images of aerosolized Itz particles collected from stage 3 of an ACI 
after actuation of a pMDI (10 mg/mL drug loading) through the ACI:  (a-b) 


















   
 
pMDI actuated (above water)
pMDI actuated (above water, sonicated)
 
 
Figure 4.10 Particle size measurements of TFF Itz pMDI actuated above water with (D50 
= 2.7 μm) and without sonication (D50 = 9.0 μm), measured by SLS.   
 
 












































(b)      (c)   
 
 
Figure 4.11 (a) Dissolution profile of Itz particles in pH 7.4 phosphate buffer with 
0.02% w/v SDS after aerosolization from a pMDI for TFF Itz milled Itz. 
SEM images of Itz particles collected from dissolution media after 5 
minutes of stirring for the suspension pMDI of (b) TFF Itz, and (c) milled 





Table 4.1 BET surface area measurements and the effective spherical diameter, Deff, 
corresponding to that specific surface area for Itz particles prepared by TFF, 
CP, and milling prior to addition of HFA 227. 
 
Dry Powder Sample BET Surface Area (m2/g)  Deff (μm) 
TFF Itz  136 ± 5  0.034 
CP Itz  9 ± 0.6  0.690 
Milled Itz  24 ± 0.5  0.192 
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Table 4.2 Dosages and aerodynamic properties for pMDI suspensions of Itz and BSA 
particles for two drug loadings, 10 mg/mL and 50 mg/mL.   
 










TFF Itz  
(10 mg/mL) 965 ± 35 97 56 ± 3 525 ± 23 942 ± 13 
CP Itz/T20 
(10 mg/mL) 836 ± 44 82 49 ± 2 377 ± 7 754 ± 16 
Milled Itz  
(10 mg/mL) 212 ± 152 21 15 ± 3 29 ± 8 194 ± 18 
TFF Itz  




915 ± 21 92 47 ± 4 318 ± 31 695 ± 133 
TFF BSA 
(50 mg/mL) 2910 ± 370 68 50 ± 3 1202 ± 38 2446± 155 



















Table 4.3 Aerodynamic (MMAD) and geometric (from SEM and SLS) particle sizes 
and densities of the aerosolized Itz and BSA particles from a pMDI.  pMDI 
suspensions were prepared at a 10 mg/mL and 50 mg/mL drug loading. 
 
Sample MMAD (μm) GSD(μm) Dv,Avg  (SEM) (μm) 
Dv,50 (SLS) 
(μm) ρg  (g/cm
3) 
TFF Itz  
(10 mg/mL) 3.8 ± 0.3   1.9 ± 0.1  9.89 9.44 ± 1.53 0.16 
CP Itz 
(10 mg/mL) --- --- 10.1 9.88 ± 1.07 0.16 
CP Itz/T20 
(10 mg/mL) 3.9 ± 0.5 1.8 ± 0.08 12.8 11.01 ± 1.25 0.098 
Milled Itz  
(10 mg/mL) 6.0 ± 0.7  2.9 ± 0.6  3.95 
3.33 ± 0.29 /   
10.67 ± 0.29* 1.02 
TFF BSA 
(10 mg/mL)** 3.1 ± 0.1  
1.9 ± 0.1 
 9.40 9.10 ± 0.9 0.19 
TFF Itz  
(50 mg/mL) 3.1 ± 0.1 1.9 ± 0.06 --- 15.2 ± 2.41 0.040*** 
TFF BSA 
(50 mg/mL) 3.7 ± 0.3 3.3 ± 0.10 13.7 14.7 ± 1.87 0.085 
* bimodal distribution – the size at which the maximum of each of the peaks was 
observed 
** taken from Engstrom et al35 
***calculated by using the Dv,50 (SLS) and MMAD in Eq. 4.3 
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Table 4.4 Calculation of VDW interaction potentials for drug particles of different 
morphologies in HFA 227, where R is the radius, L is the length, w is the 
width, and y is the height of the particle. 






(nm) at ΦVDW = 3/2kBT 
Solid Itz sphere R= 2.5 33 1 1129 
Porous Itz sphere 
ϕf = 0.50 
R  = 2.5* 8.9 1 300 
Hollow, porous Itz 
sphere 
ϕshell = 0.50 
R = 2.5* 
shell thickness = 0.10* 8.9 1 
96 
 
TFF Itz plates** L x w x y 0.6 x 0.3 x 0.06 33 10 150 
CP Itz/T20 
needles** 
(approx. as cylinder) 
R= 0.75;  L = 6.8 33 5 955 
Milled Itz 
spheres*** R = 0.15 33 1 68 
*taken from Engstrom et al. 35  
**particle dimensions estimated using SEM images 




Table 4.5 Settling behavior of ITZ particles prepared by TFF, CP, and milling.  A floc 
diameter, df, of 150 μm, was used based on optical microscopy images.  
 
Sample UExperimental (mm/s) 
ρp (g/cm3) dfloc (µm) φv φflocs φf Df 
TFF Itz  
plates 0.0118 1.30 150 0.0015 0.65 0.0024 2.35 
CP Itz/T20 
needles 0.043 1.36 150 0.0010 0.15 0.0068 2.27 
Milled Itz  
spheres 1.27 1.5 100 0.0077 0.011 0.70 3.00 
TFF BSA* 
rods 0.023 1.30 250 0.00077 0.38 0.0020 2.50 
*taken from Engstrom et al.35 
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Chapter 5:  Controlled Assembly of Biodegradable Plasmonic 
Nanoclusters for Near-Infrared Imaging and Therapeutic Applications 
Metal nanoparticles with surface plasmon resonance (SPR) in the near-infrared 
region (NIR),  are of great interest for imaging and therapeutic application 1-6.  Presently, 
widely available gold nanoparticles that absorb in  the NIR are typically larger than 50 
nm7-13, above the threshold size of approximately 5.5 nm required for efficient renal 
clearance from the body14.  Because these nanoparticles are not biodegradable, concerns 
about their accumulation and long-term toxicity14, 15 have restricted their translation into 
clinical practice.   Herein, we describe the assembly of biodegradable clusters smaller 
than 100 nm from sub-5 nm constituent gold particles. The nanoclusters manifest intense 
NIR absorbance and strong optical contrast in live cells.  Nanocluster size and spacing 
between constituent gold nanoparticles are controlled by regulating particle concentration 
during cluster formation, as well as controlling interactions between ligand-coated gold 
cores and a biodegradable polymer binder.  Nanoclusters deaggregate completely into 
sub-5 nm primary gold particles upon degradation of the polymer binder under 
physiologically relevant conditions in solution and in live cells.  This general concept for 
the assembly of hybrid polymer/inorganic nanoclusters combines advantages of the 
biodegradability of a polymer binder/stabilizer with the strong imaging contrast and 






Various plasmonic particles including nanoshells7-9, nanorods10, 11, nanocages12, 13, 
and nanoroses16, which scatter and absorb in the NIR region (650-900 nm), where soft 
tissues and blood are most transparent, may be used for molecular-specific imaging, 
therapy and multi-modal application8, 13, 17-21.  Intravenous administration of nanoparticles 
provides an effective method for rapid delivery throughout the body.  In general, particles 
with diameters between 6-100 nm exhibit sufficiently long blood residence times for 
accumulation at disease sites, such as cancer and cardiovascular plaques22-24.  However, 
the potential accumulation and long-term toxicity of these inorganic nanoparticles are a 
major roadblock in their translation to clinical practice for systemic targeting of diseases.  
Particles smaller than ~6 nm are removed too rapidly by the kidneys to achieve sufficient 
accumulation, although this clearance is highly desirable from a toxicity stand point14.  
Furthermore, the synthesis of ultra-small functionalized nanoparticles <6 nm is 
challenging14, as the strength of plasmon resonances rapidly decreases with size25.  The 
discrepancy in the particle size needed for imaging and therapy versus efficient excretion 
from the body creates a serious conflict in biomedical applications.   
Herein, we present a flexible platform for the kinetically-controlled assembly of 
sub-5 nm gold particles to produce ~100 nm metal/polymer biodegradable nanoclusters 
with strong NIR absorbance for multimodal application.  The nanoclusters are bound 
together with a biodegradable triblock copolymer of polylactic acid and polyethylene 
glycol, PLA(2K)-b-PEG(10K)-b-PLA(2K), that degrades under physiological conditions 
to release the constituent clearable gold nanoparticles. Thus, these clusters have the 
potential to satisfy the requirements of sufficient blood residence time for clinical 
application, followed by effective clearance from the body after biodegradation (Figure 
5.1A).  The close-spacing between gold nanoparticles within the nanoclusters facilitates 
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strong NIR scattering and absorption.  Both nanocluster size and physical properties, 
especially interparticle spacing, are controlled by varying particle volume fractions 
during solvent evaporation.  The changes in electrostatic, van der Waals (VDW), 
depletion, and steric interactions upon concentrating the gold nanoparticles and polymer 
micelles govern the kinetic assembly of the nanoclusters, as well as their disassembly 
after polymer degradation.   Without the presence of a polymeric stabilizer, clusters of 
lysine-26-28, cysteine-29, or glutathione-30 capped gold nanoparticles, produced by varying 
pH, demonstrate no control over cluster size, forming irregular micron-sized aggregates.  
Polymer-templated self-assembly has been used to produce small clusters of  metal 
nanoparticles31-34.  However, metal loadings and interparticle spacings have rarely been 
sufficient to provide strong NIR absorbance, and further, the templating agents are often 
highly specialized.  In contrast, our wide-ranging kinetically-controlled assembly 
platform requires only common copolymers as binders and simple capping ligands on 
gold, such as citrate and/or lysine, which are acceptable for in vivo application.   
 
5.2 METHODS SUMMARY 
 
5.2.1 Nanocluster synthesis:  
Gold nanoparticles (~4 nm) stabilized with citrate ligands were synthesized based 
on a well known method35 (See Appendix C).  To add lysine ligands to the citrate-capped 
gold nanoparticles, a 1% lysine in pH 8.4 phosphate buffer (10 mM) solution was added 
to 1.2 mL of a 3.0 mg/mL colloidal gold solution to yield a final lysine concentration of 
0.4 mg/mL.  The dispersion was stirred for 12 hours26, 28.  PLA(2K)-PEG(10K)-PLA(2K) 
(Sigma Aldrich Co., St. Louis, MO ) (60 mg) was added to the aqueous dispersion of 
ligand capped gold nanoparticles, yielding a final polymer concentration of 50 mg/mL.  
The dispersion was sonicated in a bath sonicator for 5 minutes.  Unless otherwise 
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indicated, the polymer/gold dispersion was placed under an air stream and dried to 
completion over 2 hours.  The dried film was redispersed with 10 mL of DI water to yield 
a blue dispersion at ~0.30 mg Au/mL.   
 
5.2.2 Nanocluster deaggregation: 
To characterize deaggregation in solution, an aliquot of the nanocluster dispersion 
(1.0 mL) was acidified with 0.1N HCl to pH=5, and monitored using UV-vis 
spectrophotometry and TEM.  Nanocluster deaggregation was assessed in a murine 
macrophage cell line, (J477A.1, American Type Culture Collection, Manassas, VA), in 
which the cells were cultured in a 12-well plate in phenol-free DMEM media (Gibco, 
Grand Island, NY) supplemented with 5% fetal bovine serum (Hyclone, Logan, UT) and 
antibiotics (Gibco, Grand Island, NY) and incubated at 37°C in a 5% CO2 environment 
for 1 week.  The nanoclusters were filtered through a 0.45 µm filter (Corning, Corning, 
NY), spun down, and resuspended in DMEM medium prior to their addition to each well 
(0.4 mg cells/well).  Incubation of the cells with the nanoclusters occurred over 24 hours, 
after which the excess, un-engulfed nanoparticles were removed by aspiration and the 
cells were allowed to proliferate to 72 or 168 hours time points.  Optical measurements 
were taken at 24, 72, and 168 hours.  The cells were washed three times in 1x phosphate 
buffered saline (PBS), harvested, and centrifuged at 110x g for 3 minutes.  The 
supernatant was discarded. The cells were resuspended in 10 μL of PBS, placed on a 
microscope slide, and imaged using a combination of darkfield reflectance and 
hyperspectral imaging.  Darkfield reflectance microscopy images of the cells and 
nanoclusters were taken with a Leica DM6000 upright microscope and the hyperspectral 
images were acquired with a PARISS spectral imager (Lightform Inc.).  The same 20x, 
0.5 NA objective and a 75 W Xe light source were used for both imaging modalities.  
The hyperspectral system was calibrated using a standard wavelength calibration lamp 
(low pressure Hg, Lightform, Inc.).  All hyperspectral spectra from cells were normalized 
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by the spectrum of the Xe excitation light source on a pixel by pixel basis.  RGB images 
were taken with a Q-imaging Retiga EXi CCD camera with color LCD attachment.  
Images were white balanced with a Spectralon (Labsphere, North Sutton, NH), and the 
acquisition settings were chosen such that all samples were acquired under identical 
conditions. 
 
5.2.3 TEM of cells:  
To acquire TEM images of cells, 3x104 macrophage cells were seeded overnight 
on Aclar Embedding Film (Electron Microscopy Sciences, Hatfield, PA).  All samples 
for TEM imaging were treated identically and were run in parallel to the samples used for 
optical imaging.  At each time point (24 hrs, 96 hrs, 168 hrs), the cells were fixed in a 1% 
glutaraldehyde, 1% paraformaldehyde solution for 1 hour at room temperature and then 
washed 3 times in PBS.  Subsequently, cells were stained with 2% osmium tetroxide in 
water for 10 minutes then washed for 10 minutes in water.  The sample was then 
dehydrated using increasing ratios of ethanol to acetone solutions, and finally embedded 
in an epoxy-acetone mixture and allowed to bake at 60°C for 24 hours.  Ultrathin sections 
were sliced using a Leica Ultracut microtome (Leica, Deerfield, IL) and imaged with a 
Tecnai G2 TEM at a voltage of 80 kV.        
 
5.3 RESULTS AND DISCUSSION 
 
To control cluster growth, we have mediated interactions between gold particles, 
capped with a mixture of citrate and lysine ligands, with the biodegradable polymer, 
PLA(2K)-b- PEG(10K)-b-PLA(2K), as shown in Fig. 5.1B.  The initial dispersed gold 
particles were ruby red, with an average diameter of 4.1±0.8 nm (Fig. 5.2A, Table 5.1).  
However, the dispersion turned blue after addition of the biodegradable polymer, in 
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conjunction with evaporation of ~80% of the solvent.  Complete solvent evaporation 
produced a smooth blue film, indicating absorption in the red.  Reconstitution of the film 
with deionized (DI) water to a concentration of ~0.3 mg/mL yielded a dark blue 
dispersion of sub-100 nm clusters composed of primary gold nanoparticles as shown by 
scanning electron (SEM) and transmission election microscopy (TEM) (Fig. 5.2).  TEM 
images titled at various angles reveal closely-spaced primary gold nanoparticles 
throughout the cluster.  The hydrodynamic diameter measured by dynamic light 
scattering (DLS) was 83.0±4.6 nm, by volume (Fig. 5.3A, Table 5.1), in agreement with 
the TEM results.  In the SEM image, a polymer-rich shell a few nanometers thick is 
apparent on the exterior of the clusters, which likely provides steric stabilization of the 
nanoclusters.   
Thermogravimetric analysis indicated that the nanoclusters contained only 20 ± 
5% organic material (polymer and ligands), 10-15% of which was polymer.  These low 
polymer loadings favor close-spacing of the gold primary particles. Measured 
interparticle distances between constituent gold particles within the cluster were 
estimated to be 1.80±0.6 nm based on the more discernible particles in the periphery of 
TEM images (Appendix C Figure C.1) and are consistent with the calculated length scale 
of a lysine-lysine dipeptide in solution of 1.49 nm27.  The ability to simultaneously 
control cluster size and spacing of gold nanoparticles within the nanocluster was achieved 
by manipulating particle volume fractions upon solvent evaporation, as well as the 
electrostatic, VDW, depletion, and steric interactions between the gold primary particles 
and the polymer (see Appendix C).  Furthermore, the depletion interactions facilitate, 
along with the propensity of hydrophilic PEG blocks to migrate to the exterior of the 
clusters towards the interface with water, low polymer loadings in the clusters.   
The extinction spectra changed markedly upon cluster formation (Fig. 5.3B).  The 
initial red dispersion of gold nanoparticles had a maximum absorbance at 520 nm, 
characteristic of isolated gold spheres.  For the blue nanocluster dispersion, a broad, 
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relatively constant, absorbance was observed in the NIR region from 700 to 900 nm, 
which is important for in vivo applications.  The extinction coefficient at the maximum 
absorbance, ε703, was 0.020 cm2/μg for a 56 μg/mL gold dispersion.  Assuming that the 
gold nanoparticles are in a closest-packed state (based on SEM and TEM images in Fig. 
5.2B-E), the estimated particle extinction cross section was ~10-14 m2 (see Appendix C), 
comparable to the value for nanoshells19, nanocages13, nanorods19, and nanoroses16.  The 
high NIR absorbance observed for nanoclusters is attributed to a combination of the 
following factors: close interparticle spacing between constituent gold nanoparticles, non-
uniform spatial distribution of the constituent particles within the nanocluster, roughness 
of the nanocluster boundary surface, and finally, any deviation in the overall aspect ratio 
of the entire nanocluster from that of a sphere.  The close spacing between gold particles 
is well within the fraction of the particle diameter known to produce significant red-shift 
in the SPR19, 36-39.  TEM images (Fig. 5.2) also show that short oligomers of primary 
particles and sub-clusters may be discerned, indicative of a non-uniform volume-packing 
distribution of the constituent particles.  When combined with strong plasmonic coupling, 
this non-uniform distribution significantly enhances the red-shift of the SPR19, 37.  The 
NIR absorbance per total particle mass is much higher compared to previous composite 
particles with smaller amounts of gold nanoparticles templated with liposomes, block 
copolymer micelles, or DNA34, 40, 41.      
Nanoclusters with strong NIR absorbance were also produced by clustering more 
negatively charged citrate-capped gold nanoparticles, which possess a zeta potential of -
44.0±4.9 mV, compared to -30.1±2.4 mV for the lysine/citrate-capped nanoparticles 
(Table 5.1).  The remainder of the paper will focus on the lysine/citrate-capped 
nanoclusters due to their slightly smaller sizes. 
The initial stability and degradation of the nanoclusters were examined at pH 7.4 
and 5, simulating normal cellular environments and the interior of cellular lysosomes, 
respectively 42.  After storage for 168 hours (1 week) in pH 7.4 buffer, the DLS peak 
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shifted modestly towards smaller sizes (Fig. 5.3A). This limited degradation is consistent 
with the long half-life of PLA (MW=2K) of about 4 weeks at neutral pH.  Upon 
incubation in pH 5 buffer for one week, nearly complete nanocluster deaggregation was 
observed by TEM.  The mean particle size of the deaggregated particles was 4.3±0.1 nm 
(Fig. 5.3C, Table 5.1), comparable to the initial size of the ligand-capped gold particles of 
4.1±0.8 nm (Appendix C Figure C.2).  Upon degradation of the polymer, the electrostatic 
repulsion between the gold particles is sufficient to overcome the attractive VDW forces 
to enable deaggregation.  The extinction spectra of the nanocluster dispersions undergo a 
substantial shift towards the original spectra of the colloidal gold spheres, along with a 
change in the color of the dispersion back towards red (Fig. 5.3B).  The discrepancy 
between the absorption spectra of the deaggregated particles compared to that of the 
initial colloidal gold dispersion is attributed to the presence of a small number of clusters 
still present in the dispersion.  Deaggregation to constituent nanoparticles was also 
observed for the clusters produced using citrate-only capped nanoparticles (Table 5.1).    
After demonstrating the ability of the nanoclusters to deaggregate in solution, 
interactions of the nanoclusters inside living cells were examined.  Scattering spectra 
from image pixels (Fig. 5.4A,B), dark-field reflectance (DR) (Fig. 5.4C and D, a-c), and 
hyperspectral images (Fig. 5.4C and D, d-f) were acquired at 24, 96, and 168 hours after 
cells were treated with nanoclusters.  High nanocluster uptake was evident in the DR 
images, where nanoclusters strongly scattered illumination light (Fig. 5.4C, a).  The 
scattering intensity decreased over time as macrophages divided and nanoclusters were 
distributed between daughter cells (Fig. 5.4C, a-c).  A significant increase in the red-NIR 
scattering signal of the labeled cells was seen compared to unlabeled cells (Fig. 5.4A, B), 
consistent with the high scattering efficiency of the nanoclusters in solution (Fig. 5.4A, 
red curve). The relative intensity of the red-NIR scattering signal decreased after 96 hours 
and the scattering from labeled cells showed a marked blue shift to ~550 nm that is 
consistent with scattering from the constituent lysine/citrate-capped gold nanoparticles 
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(Appendix C Fig. C.3).  Hyperspectral images showed a gradual progression from very 
strong scattering in the 650-700 nm region at t=24 hours to a less intense scattering signal 
predominantly in the 500-550 nm region at t= 168 hours (Fig. 5.4C, d-f). As expected, 
the scattering for the control macrophages did not significantly change with time.  The 
biodegradation of nanoclusters inside live cells was further confirmed by TEM. After 24 
hours, large ~100 nm nanoclusters were observed throughout the cell interior (Fig. 5.4E, 
a-b). However, after 168 hours, cells contained only particles less than 5 nm in diameter 
(5.4E,c-d). These TEM results are in excellent agreement with optical measurements and 
deaggregation results in solution, providing unambiguous proof of essentially complete 
biodegradation of the initial ~100 nm nanoclusters into sub-5 nm primary particles 
(Appendix C Fig. C.2).  
In this study we developed a general assembly platform for the design of hybrid 
polymer/gold nanoclusters smaller than 100 nm with strong absorbance in the NIR.  In 
contrast to other plasmonic nanoparticles under development for biomedical applications, 
these nanoclusters degrade under physiological conditions to components that can be 
easily excreted from the body.  Thus, these nanoclusters can provide strong optical cross-
sections required for imaging and therapy, prolonged blood residence times for systemic 
delivery, as well as effective clearance from the body to facilitate the translation of 
plasmonic nanoparticle applications into clinical practice.  This nanocluster assembly 
method is applicable to gold particles with varying surface charge, which plays an 
important role in clearance. Furthermore, it can be extended to the multiplexing of 











Figure 5.1 Schematic of synthesis and degradation of gold nanoclusters.  (A) 
Illustration of a biodegradable nanocluster, which is composed of 4 nm 
primary gold particles held together with a biodegradable polymer.  Upon 
polymer degradation, catalyzed by low pH in endosomal compartments of 
cells, the nanocluster deaggregates into primary gold nanoparticles.  (B) 
Schematic of nanocluster formation process, in which primary gold 
nanoparticles aggregate in the presence of a micelle-forming polymer in a 
controlled manner to yield sub-100 nm clusters.  Polymer adsorption to the 
nanoparticle surface and an increase in the volume fraction of particles, φ, 
via solvent evaporation promotes cluster formation.  Long PEG loops on the 
polymer extend into the aqueous environment and provide steric 










Figure 5.2 Electron microscopy characterization of gold nanoclusters. (A) TEM of 
initial 4 nm lysine/citrate-capped gold nanoparticles before clustering.  (B) 
SEM and (C-E) TEM micrographs of nanoclusters templated using 
PLA(2K)-PEG(10K)-PLA(2K) at a 16/1 polymer/Au ratio (w/w).  For TEM 
micrographs, the TEM stage was tilted at an angle of -40o, 0o(no tilt), and 












Figure 5.3 Degradation of gold nanoclusters in solution. (A) Particle size distribution, 
measured by DLS, of the nanoclusters in pH 7.4 media immediately after 
preparation and after 168 hours (1 week) of incubation.  (B) UV-vis 
absorbance spectra and photographs of the (a) colloidal dispersion of 
lysine/citrate-capped gold nanoparticles, (b) biodegradable nanoclusters 
(pH=7.4), and (c) deaggregated nanoclusters (pH=5).  (C) Number 
distribution of nanocluster sizes after deaggregation in pH=5 media, as 
determined by image analysis of TEM micrographs (over 200 particles 
measured).  Inset : TEM micrograph of nanoclusters after incubation at 





Figure 5.4 Biodegradation of gold nanoclusters inside live cells.  Scattering spectra 
(normalized by area under the curve) of (A) nanoclusters in live cells and 
(B) control cells without nanoclusters.  The spectra were taken after 24, 96, 
and 168 hours of incubation time. (C,D) Dark-field reflectance (DR) images 
of cells treated with nanoclusters and control cells over time (a-c) and 
corresponding color coded images indicating the scattering peak position at 
each pixel in the field of view (d-f).  The scale bar in the dark-field images 
is 20 µm.  The color bar was used to obtain images in (C and D, d-f). Pixels 
that did not have an identifiable peak in a corresponding spectrum were not 
assigned a color.  (E) TEM images of cells treated with nanoclusters at low 
magnification (a,c) and high magnification (b,d) at 24 hours (a,b) and 168 
hours (c,d).  Boxes in (a) and (c) are magnified in (b) and (d), respectively.  
Scale bars in (a) and (c) are 2 um and scale bars in (b) and (d) are 100 nm.  
DR images were taken with a Leica DM6000 upright microscope and 
hyperspectral measurements were acquired with a PARISS spectral imager 
(Lightform Inc.) using a 20x, 0.5 NA objective and a 75 W Xe light source.  
TEM images were taken with a Tecnai G2 TEM at an accelerating voltage 
of 80 kV.   
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Table 5.1 Characterization of gold primary particles and nanoclusters with lysine and 
citrate ligands. Absorbance measurements were recorded at gold 
concentrations of ~56 μg/mL.  All nanoclusters were formed at 100% 
evaporation using the polymer PLA(2K)-b-PEG(10K)-b-PLA(2K).  Average 
diameters, Davg, for nanoclusters were determined by DLS.  Davg for primary 
particles and deaggregated particles (Davg deag) were measured by image 
analysis of TEM micrographs. 
 
Ligand Absorbance (750 nm) 
Davg, primary 
particle (nm) 
Davg, cluster pH=7.4 
(nm) 
Davg, deag, pH=5 
(nm) 
Lysine/citrate 1.10 4.1 ± 0.8 83.0 ± 4.6 4.4 ± 0.8 
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Chapter 6:  Kinetic Assembly of Near-IR Active Gold Nanoclusters 
Using Weakly Adsorbing Polymers to Control Size 
 
Clusters of metal nanoparticles, with an overall size less than 100 nm and high 
metal loadings for strong optical functionality, are of interest in various fields including 
microelectronics, sensors, optoelectronics and biomedical imaging and therapeutics.  
Herein we assemble ~5 nm gold particles into clusters with controlled size, as small as 30 
nm and up to 100 nm, which contain only small amounts of polymeric stabilizers.  The 
assembly is kinetically controlled with weakly adsorbing polymers, PLA(2K)-b-
PEG(10K)-b-PLA(2K) or PEG (MW = 3350), by manipulating electrostatic, van der 
Waals (VDW), steric, and depletion forces. The cluster size and optical properties are 
tuned as a function of particle volume fractions and polymer/gold ratios to modulate the 
interparticle interactions.  The close spacing between the constituent gold nanoparticles 
and high gold loadings (80-85% w/w gold) produce a strong absorbance cross section of 
~9×10-15 m2 in the NIR at 700 nm.  This morphology results from VDW and depletion 
attractive interactions that exclude the weakly adsorbed polymeric stabilizer from the 
cluster interior. The generality of this kinetic assembly platform is demonstrated for gold 
nanoparticles with a range of surface charges from highly negative to neutral, with the 
two different polymers.  
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6.1 INTRODUCTION 
Optical and electronic properties of 1D1, 2D, and 3D clusters of metal 
nanocrystals, 20 to 500 nm in diameter, have been studied extensively, especially for 
applications involving sensors, memory devices, microelectronics2-4, and more recently, 
for cellular imaging and therapy5-9.  For a variety of applications, robust and broadly 
applicable synthetic strategies are needed to pack high levels of functionality (i.e. high 
metal loadings) into clusters with an overall size smaller than ~30 to 100 nm.  Most often, 
clusters are formed by thermodynamic self assembly.  Rotello and co-workers developed 
a “bricks and mortar” technique for the templated assembly of metal nanoparticles into 
clusters using polymers, proteins, and DNA2, 10 and Glotzer et al. have demonstrated 
assembly with polymer-tethered nanoparticles11.  Gold nanoparticles have been 
assembled in the cores of block copolymer micelles12-15 and on the surface of micelles16, 
17.  Amphiphilic gold Janus spheres, containing hydrophobic and hydrophilic domains 
self-assemble into clusters18-21 upon manipulation of pH or solvent quality.  For clusters 
formed thermodynamically, high concentrations of templating agents and strong 
interactions between these agents and the particles are typically required to drive the self-
assembly.  Consequently, these agents are usually highly retained in the final cluster and 
limit the metal loading, typically well below 50% w/w.   
An alternative approach is to form clusters of metal nanoparticles by kinetic 
assembly to achieve extremely high metal loadings by manipulating van der Waals 
(VDW), electrostatic, and steric interactions.  For example, variation of pH or ionic 
strength of dilute dispersions of citrate-capped gold nanoparticles screens electrostatic 
repulsion and induces cluster growth22, 23.  Similarly, lysine-24-27 and cysteine-28 capped 
gold nanoparticles at high loadings aggregate reversibly in response to changes in charge 
with pH.  Gold nanoparticles coated with associating proteins, such as biotin and 
streptavidin29, or with complementary DNA strands30, 31 also form clusters.  However, in 
each of these cases, uncontrolled growth often yields irregularly shaped aggregates 
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greater than several hundred nanometers in diameter.  Therefore, a conflict arises in both 
thermodynamically- and kinetically-controlled assembly between the need for sufficient 
levels of stabilizers to arrest growth to produce small sub-100 nm clusters, while 
simultaneously achieving high metal loadings for high functionality. 
Metal nanoparticles with high NIR absorbance are of great interest in biomedical 
imaging and therapy because soft tissues and water are relatively transparent from 650 to 
900 nm.  The surface plasmon resonance (SPR) of a spherical gold particle exhibits a 
maximum at 530 nm, but undergoes a red shift to the NIR for particles with a hollow or 
non-spherical geometry, such as nanoshells32-34, nanorods35, 36, and nanocages37, 38.  These 
particles are typically 50-100 nm in diameter.  NIR absorbance has rarely been achieved 
for particles smaller than 50 nm, where it becomes challenging to synthesize the types of 
asymmetric morphologies needed for strong red-shifts39.  Significant NIR absorbance 
also has been demonstrated in vitro and in vivo for the assembly of 40 nm gold spheres, 
conjugated with antibodies, by receptors in cancer cells into clusters5, 6, 40.  Small gold 
clusters that have been formed by equilibrium self assembly methods often contain high 
concentrations of templating agents,  which result in particle separations greater than one 
particle diameter and thus small red shifts41, 42. 
Nanoparticle components may be assembled into clusters with properties that are 
challenging to achieve including, sizes below 50 nm3, 7, 12, 43, strong optical absorbance7, 
43, multifunctionality7, and/or biodegradability9, 43.  Recently, there has been great interest 
in the development of sub-30 nm particles, which penetrate cell membranes and leaky 
vasculature in cancerous tumors more efficiently than particles >50 nm44-48.  
Furthermore, these small nanoparticles elicit profound changes in biological pathways in 
targeted cells.  Sub-30 nm particles have been reported for gold nanocages49 and 
multifunctional nanocluster hybrids containing gold and iron oxide, referred to as 
nanoroses7.  Despite their small sizes, both types of nanoparticles absorb strongly in the 
NIR.  The nanorose clusters, composed of nanocomposite primary particles, are formed 
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by kinetic assembly during the reduction of gold precursors onto iron oxide 
nanoparticles.  They exhibit intense magnetic relaxivity as well as NIR absorbance7.  To 
further advance the functional properties in nanoclusters, especially biodegradability, we 
recently introduced a physical, rather than chemical, method for the kinetically controlled 
colloidal assembly of ~5 nm gold spheres into ~100 nm NIR plasmonic clusters stabilized 
by PLA(2K)-b-PEG(10K)-b-PLA(2K).  These clusters were shown to biodegrade nearly 
completely in solution and in macrophage cells back to the original 5 nm primary 
spheres, which are small enough for renal clearance 9.  This physical, kinetic, colloidal 
assembly method is general and likely to enable synthesis of many types of clusters over 
a wide size range.    
Herein we assemble kinetically sub-5 nm gold particles into clusters of controlled 
sizes, as small as 30 nm and up to 100 nm, stabilized by small amounts of a weakly 
adsorbing polymer, either PLA-b-PEG-b-PLA or PEG 3350.  The physical cluster 
assembly process, introduced recently in Tam et al.9, is illustrated in Fig. 6.1.  The gold 
nanoparticles are nucleated rapidly at high volume fractions in the presence of a weakly 
adsorbing polymer to form small clusters9.  The nucleation and growth of the gold 
clusters is controlled by increasing gold and polymer concentrations simultaneously, 
either by solvent evaporation or by mixing of a concentrated gold dispersion with a 
concentrated polymer solution.  A mechanism is presented to describe the cluster growth 
and gold particle spacing in terms of the electrostatic, VDW, steric and depletion forces.   
The combination of high gold particle volume fractions and exclusion of the weakly 
adsorbed polymeric stabilizer from the cluster interior towards the exterior surface are 
utilized to produce low polymer loadings and closely spaced gold particles for strong 
NIR absorbance.  In contrast, high polymer loadings and larger gold particle spacings are 
typically obtained in equilibrium assembly processes that rely on strong interactions with 
templating agents, such as micelles12-17, 50, 51.  Finally, the small amount of polymer on the 
exterior surface provides sufficient steric stabilization to prevent unregulated cluster 
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growth, in contrast with previous studies without polymer stabilizers23-28.  Relative to our 
previous study9, the size of the clusters is over three fold smaller, and furthermore, a 
wider range of ligands (to modify particle charge), polymers, and polymer/gold ratios are 
examined.  An advantage of this kinetic assembly approach is its use of readily available 
polymer stabilizers and simple ligands on the gold surface, such as citrate and lysine, in 





HAuCl4•3H2O was purchased from MP Biomedicals LLC (Solon, OH) and 
Na3C3H5O(COO)3 •2 H2O and NaBH4 were acquired from Fisher Scientific (Fair Lawn, 
NJ).  L(+)-lysine was obtained from Acros Chemicals (Morris Plains, NJ).  PEG 
(MW=3350) was ordered from Union Carbide (Danbury, CT) and PLA(2K)-b-
PEG(10K)-b-PLA(2K) was purchased from Sigma Aldrich (St. Louis, MO).   
 
6.2.2 Nanocluster formation 
Gold nanoparticles (3.8-nm) stabilized with citrate ligands were synthesized based 
on a well known method52.  Briefly, DI water (100 mL) was heated to 97oC.  While 
stirring, 1 mL of 1% HAuCL4•3H2O, 1 mL of 1% Na3C3H5O(COO)3 •2 H2O, and 1 mL 
of 0.075% NaBH4 in a 1% Na3C3H5O(COO)3•2 H2O solution were added in 1 minute 
intervals.  The solution was stirred for 5 minutes and then removed to an ice bath to cool 
to room temperature.  The gold particles were then centrifuged at 10,000 rpm for 10 
minutes at 4oC to remove any large aggregates.  Centrifugal filter devices (Ultracel YM-
30, Millipore Co.) were used to removed unadsorbed citrate ligands as well as 
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concentrate the gold dispersion to ~3.0 mg Au/mL. Gold concentrations were determined 
using flame atomic absorption spectroscopy (FAAS).   
In most cases, lysine ligands were added to the citrate stabilized gold 
nanoparticles by adding a 1% lysine in pH 8.4 phosphate buffer (10 mM) solution to 1.2 
mL of the colloidal citrate-capped gold solution to yield a final lysine and gold 
concentration of 0.4 mg/mL and 3.0 mg/mL, respectively.  In the cases where a 1.0 
mg/mL gold solution was used to produce nanoclusters, the 3.0 mg/mL stock gold 
solution was diluted using deionized (DI) water.  The dispersion was stirred for at least 
12 hours25, 53.  PLA-b-PEG-b-PLA was added to the aqueous dispersion of ligand capped 
gold nanoparticles to yield polymer/gold ratios ranging from 1/10 – 40/1.  The 
dispersions were then sonicated in a bath sonicator for 5 minutes.  Unless otherwise 
noted, the concentration of the gold solutions used in this study to produce nanoclusters 
was 3.0 mg/mL with a polymer/gold ratio of 16/1.   
In some cases, the polymer/gold dispersion was placed under an air stream and a 
certain percentage of the solvent, between 50-100%, was evaporated.  When the 
dispersion was not dried to completion, it was quenched with DI water after the chosen 
amount of solvent evaporation.  Upon quenching, the concentration of the dispersion was 
approximately an order of magnitude lower than that of the original gold stock prior to 
solvent evaporation.  In the case of 100% solvent evaporation, which took place over 
~20-30 minutes, the dried film was redispersed with 10 mL of DI water to yield a blue 
dispersion of ~0.30 mg Au/mL.  Nanoclusters were also formed using a mixing 
procedure, in which highly concentrated solutions of gold colloid and polymer were 
mixed together using a probe sonicator (Branson Sonifier 450, Branson Ultrasonics 
Corporation, Danbury, CT) with a 102 converter and tip operated in pulse mode at 35 W. 
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6.2.3 Nanocluster characterization 
Nanocluster morphology was observed by transmission electron (TEM) and 
scanning electron microscopy (SEM).  TEM was performed on a FEI TECNAI G2 F20 
X-TWIN TEM using a high-angle annular dark field detector.  TEM samples were 
prepared using a “flash-freezing” technique, in which a 200 mesh carbon-coated copper 
TEM grid was cooled using liquid nitrogen and then dipped into a dilute aqueous 
nanocluster dispersion.  The TEM grid was dried using a Virtis Advantage Tray 
Lyophilizer (Virtis Company, Gardiner, NY) with 2 hours of primary drying at -40oC 
followed by a 12 hour ramp to +25oC and then 2 hours of secondary drying at 25oC.  
Separation distances between primary particles within the nanoclusters were measured by 
analyzing TEM images using Scion Image software (Frederick, Maryland).  A Zeiss 
Supra 40VP field emission SEM was operated at an accelerating voltage of 5−10 kV. 
SEM samples were prepared by depositing a dilute aqueous dispersion of the 
nanoclusters onto a silicon wafer.  The sample was dried in a hood, washed with DI water 
to remove excess polymer, and dried again.  UV−visible spectra were measured using a 
Varian Cary 5000 spectrophotometer for a 1 cm path length.  Dynamic light scattering 
(DLS) measurements of hydrodynamic diameter and zeta potential measurements were 
performed in triplicate on a Brookhaven Instruments ZetaPlus dynamic light scattering 
apparatus at a scattering angle of 90° and temperature of 25 °C54.  Dispersion 
concentrations were adjusted with either DI water for DLS measurements or pH=7.4 
buffer (10 mM) for zeta potential measurements to give a measured count rate between 
300-400 kcps.  For DLS measurements, all dispersions were filtered through a 0.2 µm 
filter and probe sonicated for 2 min prior to measurement.  The data were analyzed using 
a digital autocorrelator (Brookhaven BI-9000AT) with a non-negative least-squares 
(NNLS) method (Brookhaven 9KDLSW32).  A distribution of hydrodynamic diameters 
was obtained based on the Stokes-Einstein equation for the diffusion coefficient of a 
sphere. All distributions were weighted by volume.  Reported average diameters 
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correspond to the D50, or diameter at which the cumulative sample volume was under 
50%.  For zeta potential measurements, the average value of at least three data points was 
reported.  Thermogravimetric analysis (TGA) was used to determine the amount of 
adsorbed ligand mass on the primary gold nanoparticles and the final polymer/gold ratio 
of the nanoclusters.  TGA was performed using a Perkin–Elmer TGA 7 under nitrogen 
atmosphere at a gas flow rate of 20 mL/min. Excess, unadsorbed organic material, either 
ligands and/or polymer, was removed from particles, either colloidal gold or 
nanoclusters, by centrifuging the dispersions at 10,000 rpm for 5 minutes at 4oC.  For the 
colloidal gold particles, which were too small to settle efficiently during centrifugation, 
centrifugal filter devices were used to separate and filter the particles from the smaller 
unadsorbed ligands.  The supernatants were discarded and the pellets were dried to a 
powder.  The powder samples were held at 50°C for 120 minutes to remove any moisture 
in the sample and then heated at a constant rate of 20 °C/min from 50°C to 800 °C and 
held at 800°C for 30 minutes.  The loss in mass after heating accounted for the organic 
component of the particles.  Flame atomic absorption spectroscopy (FAAS) was used to 
determine the gold concentration in the dispersion and the yield for the gold particles that 
were incorporated into the clusters.  A GBC 908AA flame atomic absorption 
spectrometer (GBC Scientific Equipment Pty Ltd) was used to determine the amount of 
gold present in a sample.  All measurements were conducted at 242.8 nm using an air-
acetylene flame.  To determine clustering efficiency, a dispersion of nanoclusters of 
known concentration was centrifuged at 10,000 rpm for 10 minutes at 4oC.  FAAS 
measurements were conducted on the supernatant.   
 
6.2.4 Determination of stability ratio and half-life for aggregation 
The stability of the nanoparticles may be quantified using a stability ratio, W, 
defined as the ratio of the rate of fast, diffusion controlled aggregation to slow, 
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kinetically-controlled aggregation23, 55.  Alternately, W may also be determined using the 









kW ==    (6.1) 
 
where kf and ks are the rate constants for fast and slow flocculation, respectively, and t1/2,f 
and t1/2,s are the half-lives for fast and slow flocculation, respectively.  The half life for 










=        (6.2) 
 
where η is the solution viscosity, kB is the Boltzmann constant, T is temperature, and N0 is 
the initial number density of nanoparticles. Slow flocculation half-lives were estimated 
experimentally based on the observed time required for a visual color change in the 
nanocluster dispersion to occur, tcol.  The observed tcol may be used to estimate half-lives 
using the assumption that a color change corresponds to the collision of 11 particles56 and 
solving the equation for second order reaction kinetics, 1/N(t) = kt + 1/N0, to yield:    
 
10/tt cols,2/1 =        (6.3) 
 






6.3.1 Effect of particle volume fraction on nanocluster size and optical properties 
The amount of ligands on the surface of the gold particles was determined prior to 
the formation of nanoclusters.  For the red citrate-capped gold nanoparticles, the average 
diameter was 3.8 ± 1.0 nm (data not shown) and the zeta potential was -44.0 ± 4.7 mV 
(Table 6.1) at a pH of ~7.2.  The citrate coverage on the gold nanoparticles was estimated 
to be about 6.3% w/w, based on calculations assuming saturated ligand coverage on the 4 
nm gold particle surface, in good agreement with the 7% w/w citrate measured by 
TGA(See supplementary).  The adsorption of lysine to gold did not significantly change 
the particle size, which was 4.1 ± 0.8 nm (Fig. 6.2a), nor the pH of the gold dispersion.  
Lysine contains two NH3+ charges and one COO- charge over a pH range from 3 to 10 25 
(Appendix D Fig. D.1).  The ligand exchange with the positively charged lysine increased 
the zeta potential to -30.1 ± 2.4 mV (Table 6.1), indicating about 30% of the adsorbed 
citrate was exchanged(See supplementary).  The citrate/lysine-capped particles were 
coated with 11% total ligand, according to TGA results, compared with 7% for the 
citrate-only stabilized nanoparticles.  The color did not vary for the citrate-only and 
citrate/lysine-capped gold nanoparticle dispersions for ~1 month, corresponding to a very 
high W of ~7×109 (Table 6.2) for an N0 of ~1021 particles/m3 and t1/2,f of 3.93×10-5 s, 
which is based on a gold loading of 3 mg/mL.  The high stability is due to strong 
repulsive charges on the ligands of the particles, in good agreement with previous reports 
in literature25, 57.   
To form gold clusters, interactions between citrate/lysine gold particles were 
mediated with a weakly adsorbing polymer, either PLA-b-PEG-b-PLA, as shown in Fig. 
6.1, or PEG (MW=3350) homopolymer.  Without any solvent evaporation, the addition 
of either polymer to the ligand-capped gold particles at a 16/1 polymer/gold ratio (gold 
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concentration = 3 mg/mL) did not produce a color change over a period of one hour, 
indicating that clusters of closely-spaced gold were not formed9.  After an hour, the color 
slowly changed.  A one hour stability (tcol =1 hr) corresponds to a maximum W of 
~4×105, as determined from Eqs. 1-3 (Table 6.2).  To more fully probe the kinetics of 
nanocluster formation, the nanocluster size was monitored as a function of solvent 
evaporation by quenching cluster growth with the addition of DI water after a specified 
level of solvent evaporation.  The harvested nanoclusters were observed by TEM (Fig. 
6.2) and their sizes determined by DLS (Fig. 6.3a).  For PLA-b-PEG-b-PLA, the 
formation of dimers and trimers was detected, indicating nucleation, after 50% solvent 
evaporation (Figs. 6.2, 6.3a), which occurred over ~5 minutes for a 1.4 mL sample.  This 
time corresponds to a maximum W of ~2.5×105, as t1/2,s could have been even smaller 
than 5 minutes.  These small oligomers produced a shoulder in the DLS size distribution.  
When the suspension, from which 50% of the solvent had been evaporated, was allowed 
to sit over the course of one week, still no color change was observed, indicating that the 
oligomers did not grow to produce larger clusters.  However, additional solvent reduction 
to 60% evaporation, approximately one minute later, led to clusters 35-60 nm in size, as 
seen both by TEM and DLS.  Further solvent evaporation, to 80% and 100%, produced 
additional growth, with D50 values of 60 nm and 80 nm, respectively, with low 
polydispersities between 1.1-1.8 (See supplementary for calculation).  From 50 to 95% 
evaporation, the cluster size was monotonic with the extent of evaporation.  Yields of 
gold in the clusters, or the percent of the loaded primary particles that are incorporated 
into clusters after quenching the growth, was determined using FAAS (Table 6.3).  After 
60% and 100% solvent evaporation, 95.1% and 99.7%, respectively, of the initially 
loaded gold nanoparticles by mass were incorporated into clusters.  Therefore, cluster 
yields, as well as size, continued to increase with the extent of solvent evaporation.  The 
ability to tune the cluster size over a wide range and to achieve low polydispersities is of 
great scientific and practical interest.   
 214
Extents of solvent evaporation greater than 60% resulted in a color change of the 
dispersion to blue, but it was difficult to observe the kinetics given the dark, opaque 
dispersions at the high volume fractions.  Thus, the spectra were measured after the 
clusters were quenched by dilution.  The red shifts in the absorbance to the NIR were 
consistent with the morphologies observed by TEM and the sizes measured by DLS.  
Before polymer was added, the characteristic spectrum for individual gold particles 
exhibited a maximum at 530 nm (Fig. 6.3b).  For the dimers and trimers (Fig. 6.2b), the 
red-shift was modest as expected41, 42, 58.  Much larger shifts were observed for 60% 
evaporation (Fig. 6.3b), where sizable clusters of 35-60 nm were observed by TEM and 
DLS, as expected from theoretical calculations41, 42, 58.   The NIR absorbance continued to 
increase as the extent of evaporation and nanocluster size increased.   
Complete solvent evaporation produced a smooth blue film on the glass surfaces 
of the vials, indicating a shift in the absorbance spectra of gold to the NIR.  
Reconstitution of the film with DI water yielded a dark blue dispersion of sub-100 nm 
clusters composed of primary gold nanoparticles (Fig. 6.2).  SEM images of nanoclusters 
formed after 100% solvent evaporation reveal a polymer-rich shell a few nanometers 
thick surrounding the exterior of each cluster.  The spectra of the nanoclusters formed 
after 100% solvent evaporation exhibited a broad, relatively constant, absorbance in the 
important NIR region from 700 to 900 nm, corresponding to an extinction coefficient at 
the maximum absorbance, ε703, of 0.017 cm2/μg for a 56 μg/mL gold dispersion.  
Assuming that the gold nanoparticles occupy ~72% of the cluster volume (based on SEM 
and TEM images in Fig. 6.2), characteristic of a closest-packed volume fraction, the 
estimated particle extinction cross section was 9.0×10-15 m2 (See supplementary), 
comparable to the value for nanoshells41, nanocages38, nanorods41, and nanoroses7.  The 
mean spacing between primary gold particles within the clusters was estimated to be 1.80 
± 0.6 nm based on the more discernible particles in the periphery of TEM images, well 
within the range of interparticle spacing known to produce a significant red-shift in the 
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SPR (Appendix D Fig. D.2)1, 41, 42.  The ability of the gold nanoparticles to pack tightly 
together is supported by TGA results, which indicated that after 100% solvent 
evaporation, nanoclusters contained only 20 ± 5% organic material.  From the known 
amount of ligand reported above, 10-15% of this material was polymer.  The ability to 
reproducibly produce nanoclusters using 100% evaporation, with respect to both size and 
optical properties, is shown in Appendix D Fig. D.3.  The zeta potentials of the resultant 
nanoclusters of citrate-only and citrate/lysine-capped nanoparticles were -13.0 ± 3.3 mV 
and -16.3 ± 4.0 mV, respectively, approximately half that of the initial colloidal gold 
nanoparticles (Table 6.1).  Interestingly, the zeta potential of clusters formed using 
citrate-only and citrate/lysine-capped gold, stabilized with PLA-b-PEG-b-PLA, had 
similar zeta potential values, somewhat larger than that of the pure polymer.  The value 
of -8.0 ± 0.2 mV for the PLA-b-PEG-b-PLA polymer is attributed to the ionized PLA end 
groups. 
Nanoclusters were also formed using PEG (MW=3350), instead of PLA-b-PEG-
b-PLA, as the stabilizing polymer. The PEG-stabilized clusters were, on average, ~1.5 
times larger than those stabilized using PLA-b-PEG-b-PLA, as reported by DLS and 
TEM (Fig. 6.4a-c).  Similar to observations for PLA-b-PEG-b-PLA-stabilized clusters, a 
reduction in solvent evaporation from 100% to 60% yielded a ~30% reduction in cluster 
size and slightly lower NIR absorbances.  The strong NIR absorbance of the PEG-
stabilized clusters indicated that tight packing of gold nanoparticles within the cluster was 
achieved (Fig. 6.4d).  In fact, the clusters formed at 60% solvent evaporation show a 
slightly stronger NIR peak than the clusters formed after 60% solvent evaporation using 
PLA-b-PEG-b-PLA, likely due to the larger cluster size.  Similar trends were obtained for 
nanoclusters produced using citrate-only capped gold nanoparticles and PEG 3350 (data 
not shown).  
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6.3.2 Clusters of lysine/citrate particles with PLA-b-PEG-b-PLA formed by 
mixing 
Assembly of nanoclusters was also demonstrated without solvent evaporation by 
mixing together highly concentrated gold and polymer solutions.  The resulting 
concentrations of gold particles and polymer corresponded to those achieved by certain 
solvent evaporation extents.  For example, a 6 mg/mL dispersion of gold nanoparticles 
was mixed with a 100 mg/mL polymer solution to produce clusters that were equivalent 
to the concentrations achieved after 50% evaporation.  However, the cluster sizes were at 
least 2.5 times larger than those where the particle volume fractions were increased 
gradually by solvent evaporation (Fig. 6.5a). Because of their larger sizes, nanoclusters 
produced by this method displayed even more shifted NIR absorbance (Fig. 6.5b).  
Similar trends in optical properties were observed when clusters of citrate-only-capped 
gold nanoparticles were produced using this mixing method (Appendix D Fig. D.4).  The 
high viscosities of the extremely concentrated polymer solutions, ranging from 9×10-4 Pa 
s (~10 times that of water) to 0.8 Pa s (~900 times that of water) for solutions 
corresponding to 60% and 90% solvent evaporation (Appendix D Fig. D.5), respectively, 
resulted in inadequate mixing rates, poorer polymer diffusion, and thus the larger 
clusters.   
 
6.3.3 Clusters formed with citrate-only capped particles and PEG-SH coated 
particles 
Nanoclusters were produced using gold nanoparticles capped with two other types 
of ligands: negatively charged citrate, and neutral PEG-SH to compliment the above 
studies which used lysine (positively charged) and citrate ligands, simultaneously.  
Clusters of gold primary particles capped with either citrate or a citrate/lysine mixture 
exhibited strong NIR absorbance (Fig. 6.6).  However, nanoparticles capped with PEG-
SH did not produce a significant red-shift, although the shift was larger for PEG-SH with 
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a MW of 0.13K versus 5K.  PEG-SH 5K has a reported radius of gyration of 3.1 nm59.  
Therefore, the corresponding particle separations between two PEG-SH coated particles 
of at least 6.2 nm is larger than the diameter of a gold primary particle and the strongly 
bound PEG-SH 5K ligands prevented the gold nanoparticles from packing together 
tightly enough for a strong red shift.  
Relative to citrate/lysine-capped particles, very similar behavior was observed for 
clusters assembled with citrate-only capped gold nanoparticles and PLA-b-PEG-b-PLA 
upon solvent evaporation, according toDLS, TEM, and UV-vis/NIR measurements 
(Appendix D Fig. D.6).  Again, there was a very strong correlation between cluster size 
and NIR absorbance. However, the clusters did not form until ~ 85% solvent evaporation, 
as compared to 60% for citrate/lysine capped gold (Fig. 6.7).  The greater repulsion for 
the citrate-only-capped particles, as is evident in the more negative zeta potentials, 
appeared to delay cluster formation.  The slightly smaller sizes and larger SPR red-shifts 
of the nanocluster composed of citrate/lysine nanoparticles may be influenced by the 
attractive electrostatic attraction between the positive and negative charges on the lysine 
(Appendix D Fig. D.1)25.  These interactions may further promote polymer exclusion 
from the cluster interior.  
 
6.3.4 Tuning cluster size with polymer/gold ratio  
To demonstrate the ability to tune the cluster size, the gold loading was lowered 
to 1.0 mg/mL, compared to 3.0 mg/mL in our previous study9, and the polymer/gold ratio 
was varied over a wide range for 100% solvent evaporation.  Cluster sizes decreased 
considerably as polymer/gold ratios were reduced from 16/1 to 1/1 (Fig. 6.8a), with an 
average diameter of 28.4 nm for the 1/1 ratio.  Despite the reduction in cluster size, 
clusters produced at a polymer/gold ratio between 1/1 to 16/1 still exhibited a broad and 
intense NIR absorbance, similar to that shown in Fig. 6.3b.  However, for polymer/gold 
ratios below 1/1, the absorbance did not shift significantly from that of colloidal gold 
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(Fig. 6.8b).  For a given polymer/gold ratio, similar results were obtained for the cluster 
size and spectra for the higher gold loading of 3.0 mg/mL, as shown in Appendix D Fig. 
D.7, although the sizes were slightly smaller for the 1.0 versus the 3.0 mg/mL loading.  
As an example of the extent by which the cluster sizes could be tuned, the much smaller 
clusters formed with a 1/1 polymer/gold ratio at a gold loading of 1.0 mg/mL versus a 
16/1 polymer/gold ratio at a 3.0 mg/mL loading is shown in TEM micrographs (Fig. 6.8c-
d).  Additionally, a small decrease in the absorbance spectra was observed for clusters 
formed at a 40/1 polymer/gold ratio and a 3.0 mg/mL gold loading (Appendix D Fig. 
D.7b).   Here, an extremely high polymer concentration of 1200 mg/mL was generated 
when the level of solvent evaporation reached 90%, resulting in excessive polymer that 
likely interfered with close-spacing between the gold nanoparticles, and thus, lowered the 
red shift42.  This interference was not present for lower polymer/gold ratios.  Further 
decreasing gold loadings as low as 0.19 mg/mL and increasing the polymer/gold ratio up 
to 260/1 led to the formation of increasingly larger clusters with reduced NIR absorbance 
(Appendix D Table D.1, Fig. D.8).  Nanoclusters produced at a 1/1 gold/polymer ratio 
and a 1.0 mg/mL gold concentration were approximately 85% gold w/w, comparable to 
80% w/w gold in nanoclusters formed with a 16/1 gold/polymer ratio and a starting gold 




6.4.1 Interaction potential and stability ratio 
The kinetic assembly of nanoparticles into clusters may be controlled by adjusting 
the stability ratio for a pair of particles, which is dependent upon the total interaction 
potential between particles:  
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depletionstericVDWticelectrostatotal VVVVV +++=    (6.4) 
The first two terms are described by DLVO theory, as discussed in the 
supplementary section.  The addition of a weakly or non-adsorbing polymer introduces 
attractive depletion interactions, which arise from the exclusion of polymer from the gap 
region between two particle surfaces.  The depletion potential for hard sphere colloids 
















++−−+πρ−= ∞   (6.5) 
 
where H is the distance between particle surfaces, r is the polymer radius, a is the 
nanoparticle radius, and ρ∞ is the number density of polymer particles in solution.  If the 
polymer forms micelles, the micellar properties are used (See supplementary). The ability 
of depletion forces to cause particle flocculation, and even phase separation, in colloid-
polymer mixtures is well known both experimentally and theoretically63-65.  The kinetic 
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where u is a dimensionless variable defined as (H-2a)/a, and the ratio D∞/D(u) is the 










=∞    (6.7) 
The first parts of the discussion section compare the kinetically controlled 
nanocluster assembly with previous studies based on the terms for Vtotal and the 
 220
manipulation of the particle concentrations.  A quantitative expression is not presented 
herein for Vsteric, given the complexity of hydration of PEG at high concentrations where 
gels are formed.   
 
6.4.2 Cluster assembly in the absence of polymer (VDW and electrostatic forces) 
In the absence of a polymer, the VDW and electrostatic terms play a primary role 
in cluster formation, whereas steric and depletion interactions are small.  Electrostatic 
repulsion of the nanoparticles may be weakened by a change in pH or salinity to reduce 
the charge.  For dilute dispersions of gold coated with citrate (0.1 mg gold/mL), the 
growth from attractive VDW forces may be controlled over a period of hours to form 
clusters >100 nm in size22, 23.  For these dilute conditions, the clusters are typically 
relatively low density with a low fractal dimension.   In contrast, clusters formed at high 
particle concentrations are more likely to be composed of gold particles with close 
spacing that favors strong NIR absorbance.  However, for concentrated gold dispersions 
(20-50 mg/mL), it becomes difficult to balance the electrostatic repulsion and VDW 
attraction to control the growth, and substantial aggregation has been observed over a 
period of several minutes25.  For instance, when gold nanoparticles are capped with lysine 
ligands, a change in pH simultaneously produces both positive and negative charges 
(Appendix D Fig. D.1) that result in electrostatic attraction and irregularly shaped 
aggregates up to several microns in diameter22, 24-27.  Additional concepts in kinetic 
assembly are needed to better control Vtotal and thus the particle size and gold spacing 
 
6.4.3 Cluster assembly in the presence of polymer 
The key challenge in this study was to control nanocluster size and gold particle 
spacing within the clusters by manipulation of the particle concentration pathways and 
Vtotal.  High gold particle concentrations (>>0.1 mg/mL) were utilized in order to achieve 
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sufficiently close gold particle spacing for strong NIR absorbance.  However, they can 
also cause unmitigated cluster growth.  This dilemma was addressed by the addition of a 
weakly adsorbing polymer to manipulate the electrostatic, steric, and depletion forces. 
The polymer initiates nucleation and growth, while simultaneously providing steric 
stabilization, but with low final polymer loadings2, 17, 50. 
The initial citrate-only and citrate/lysine-capped gold nanoparticles in this study 
were extremely stable, evidenced by large negative zeta potentials of -44 and -30 mV, 
respectively, and a Vtotal of at least 23 kBT (Fig. 6.9) (See supplementary).  Nanocluster 
formation was initiated by raising the polymer and gold particle concentrations either by 
solvent evaporation or mixing to raise the adsorption of the polymer on gold.  The weakly 
adsorbed polymer decreases the local dielectric constant near the charged ligands and 
thus weakens the ion hydration, causing ion pairing.  This decrease in particle charge is 
directly evident in the decrease in the zeta potential with the addition of polymer (Table 
6.1).  The decrease in electrostatic repulsion causes a marked decrease in the 
experimentally determined W (Table 6.2) from ~1010 for the citrate/lysine-capped 
primary particles to ~105 after the addition of polymer and 50% solvent evaporation.  At 
this condition, the polymer adsorption did not reduce the particle charge enough to 
produce clusters larger than dimers or trimers within several hours.   
At an extent of 50% solvent evaporation, the charge on an individual gold particle 
was regressed from the theoretical W in Eq. 6.6, given the known experimental W 
described above (Table 6.2).  In this regression, Vtotal included electrostatic, VDW, and 
depletions terms, as described in the supplementary section.  All of the properties were 
known except the surface potential (and thus surface charge) on a gold nanoparticle.  The 
reduction in the regressed surface charge of 1.6 after 50% solvent evaporation, relative to 
that of the initial colloidal gold particles, was found to be comparable to the reduction in 
zeta potential given in Table 6.1.  The loss in charge is further characterized by the large 
decrease in Vtotal to about 11 kBT (Fig. 6.9), which may be attributed to the significant 
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drop in Velectrostatic upon charge reduction caused by the polymer, as VVDW did not change.  
Thus, this large decrease in Velectrostatic, and consequently Vtotal, produced a decrease in W 
at 50% solvent evaporation of 5 orders of magnitude, relative to the initial colloidal gold 
particles (Fig. 6.10).  It was not possible to regress any changes in the particle charge 
with higher extents of solvent evaporation because the dispersions were too turbid to 
determine W experimentally.  The regressed charge at 50% was used to calculate the Vtotal 
and thus W for greater solvent evaporation levels.  Vtotal decreased as solvent evaporation 
increased, primarily due to a reduction in Velectrostatic.  Using Eq. 6.6, the steady decrease 
in Velectrostatic, and thus Vtotal, with solvent evaporation (i.e. increasing particle volume 
fraction) was found to cause a further decrease in W (Fig. 6.10).  The Velectrostatic decreases 
with an increase in the number density of charged gold nanoparticles as the extent of 
evaporation increases.  For electro-neutrality, the resulting increase in counter-ion 
concentration reduces the Debye length according to Appendix D Eq. D.10.  However 
this change in Velectrostatic changes W by less than an order of magnitude, significantly 
smaller than the changes observed with polymer induced ion pairing.  Therefore, the 
initial cluster growth is driven primarily by the attractive VDW forces upon reduction of 
particle charge and electrostatic repulsion upon weak polymer adsorption63, 66. As the 
number of closely-spaced gold particles in the cluster increases, the number of water 
molecules in the coordination shells about each particle decreases, given that the gold 
surface is hydrophobic.  This decrease in hydration may further contribute to ion pairing 
and weakened electrostatic repulsion.   
The smaller clusters produced using PLA-b-PEG-b-PLA as a stabilizer versus 
PEG homopolymer may be attributed to the stronger adsorption of the more hydrophobic 
PLA-b-PEG-b-PLA15, 67, which produces greater charge reduction and thus more rapid 
nucleation.  The larger number of nuclei and greater steric stabilization for reduced 
growth would lead to small clusters.  Furthermore, the presence of micelles for PLA-b-
PEG-b-PLA may provide greater steric stabilization than the homopolymer in the early 
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stages of growth.  Similarly, smaller clusters formed for the less charged citrate/lysine-
capped gold versus citrate-only capped gold (Fig. 6.7) may also be attributed to more 
rapid nucleation.  In addition, the attractive electrostatic interactions between the lysine 
ligands may enhance polymer exclusion from the cluster interior.   
The decrease in Velectrostatic to drive cluster growth may also be achieved simply by 
adding salts.  However, without the steric and depletion contributions to the potential, 
control over the final cluster size for high initial gold particle concentrations has not been 
successful22, 23.  Thus, manipulation of these additional terms with polymer concentration 
and structure is important to achieve greater control over kinetic self-assembly.  The 
nucleation of clusters via an adsorbed polymer to reduce the surface charge and 
simultaneously provide steric stabilization enables significantly improved control over 
cluster growth even with the high gold particle concentrations.  
 
6.4.4 Spacing between gold particles in the nanoclusters 
The final polymer weight fraction in the clusters was only on the order of 10 to 
15% w/w according to TGA, even with starting polymer/gold ratios well above unity, for 
example our most common case of 16/1.  The small spacing between the gold particles of 
only 1.80 nm (Appendix D Fig. D.2) for PLA-b-PEG-b-PLA stabilized nanoclusters is 
considerably smaller than the size of a PLA-b-PEG-b-PLA polymer micelle, measured to 
be 10-14 nm (Appendix D Fig. D.9) or the Rg of the PEG homopolymer of 6.1 nm68.  
Thus, the polymers were excluded from the cluster interior. Various properties of gold 
contribute to the low polymer loadings, which favor small interparticle distances.  The 
Hamaker constant is 60 kBT for Au versus only 0.6 kBT for the PEG, calculated using 
Lifshitz theory11.   The gold surface is not highly hydrophilic given that polypropylene 
oxide adsorbs more strongly to gold than PEG67.  Thus, the gold particles are strongly 
attracted to each other by VDW and hydrophobic forces.  Additionally, the polymer 
chains are depleted from the overlap regions in the interior of the clusters towards the 
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cluster exterior in order to raise their conformation entropy, as described by Eq. 6.5.  
These depletion forces, along with the propensity for hydrophilic PEG segments to orient 
towards the aqueous exterior, drive the weakly adsorbed and hence highly mobile 
polymer away from the cluster interior and towards the exterior cluster interface with 
water and into bulk water.  This mechanism is supported by the polymer shell observed in 
the SEM image (Fig. 6.2f), as well as the low polymer loadings.  Thus, the hydrophilic 
PEG segments of the polymer, which are oriented preferentially towards the exterior 
cluster interface, extend into the aqueous environment and provide steric stabilization.  In 
essence, the close spacing of the gold particles is driven by the strong VDW attraction 
between the gold particles and the depletion forces which exclude the polymer.   
In the case where a strongly adsorbing polymer is used to regulate cluster 
formation and growth, the polymer is often retained at significantly higher levels within 
the final cluster than in the present study.  Prud’homme et al. have developed a “flash 
nanoprecipitation” method to achieve relatively high 35% w/w particle loadings in 
clusters by inducing high supersaturation with rapid “micro-mixing” to kinetically control 
nucleation and growth50, 51.  The polymer adsorption was sufficiently strong to passivate 
the surface of nucleating particles under high supersaturation conditions to produce 
clusters as small as 80 nm50.  However, the resultant clusters did not exhibit a red-shift 
into the NIR due to the strong interactions between the polymer and the gold, which 
likely prevented close-packing between the gold particles.  
 
6.4.5 Condensation versus coagulation  
Size distribution moments calculated from DLS results (Fig. 6.3a) suggest that the 
nanoclusters were formed more by condensation than by coagulation, yet some 
coagulation was present (See supplementary, Table 6.3).  A high yield of 95% of gold in 
the cluster was observed after only 60% solvent evaporation.  Here, exhaustion of 
primary particles slows down nanocluster growth by condensation. The substantial 
 225
growth in cluster size from 60% to 100% solvent evaporation cannot be caused by the 
remaining 5% gold, since the mass of the clusters is proportional to the diameter cubed.  
Thus, coagulation was the primary cause of growth at this stage.  Close inspection of the 
TEM images in Fig. 6.2 shows that the larger nanoclusters, formed after larger extents of 
evaporation (i.e. greater than 60%), are more irregular in shape relative to a spherical 
geometry.  In fact, one may even discern that the larger clusters are partially composed of 
smaller, 35-60 nm, clusters, indicating a small degree of coagulation.  By quenching the 
nanocluster dispersion with DI water soon after cluster formation, after only 60% solvent 
evaporation, the potential for additional coagulation was reduced, thus preserving smaller 
nanocluster sizes and low polydispersities.  
 
6.4.6 Tuning cluster size with polymer/gold ratio  
A reduction in the polymer/gold ratio from 16/1 to 1/1 resulted in a marked 
decrease in cluster size from ~80 nm to ~30 nm (Fig. 6.8), as well as a reduction in 
polymer loading from 20 to 15%, as shown by TGA.  This decrease is the opposite of 
what is expected for steric stabilization alone, indicating other factors were operative.  
For lower initial polymer/gold ratios and thus polymer concentrations, the lower 
adsorption onto gold produces a smaller degree of ion pairing and thus a larger Velectrostatic 
.  The greater repulsion will favor slower growth as observed.  Furthermore, the lower 
polymer concentration reduces the collision frequency between polymer chains and gold 
clusters, leading to less trapping of polymer in the clusters.  Rheological factors are also 
present.  The viscosity of PLA-b-PEG-b-PLA solutions increases markedly with 
concentration in the dilute to semi-dilute transition (Appendix D Fig. D.5).  During gold 
cluster formation via solvent evaporation, the viscosity of the dispersion will increase 
sooner for higher polymer/gold ratios, increasing the amount of entangled polymer that 
may get trapped within the gold clusters.  This behavior was observed as the 
polymer/gold ratio was raised from 1/1 to 16/1, and was even more prevalent for the 40/1 
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polymer/gold ratio (Appendix D Fig. D.7).  Coagulation was particularly evident at this 
highest ratio, according to size distribution moment calculations (μ1=1.55, μ3=0.81).  To 
examine the effect of polymer gelation, a 50 mg/mL solution of PLA-b-PEG-b-PLA 
without gold particles was dried by solvent evaporation.  The precipitate was redispersed 
to give large aggregates (> 500 nm) that did not break up into block copolymer micelles, 
indicating that gelation was not fully reversible (Appendix D Fig. D.9).    For the 
formation of gold clusters, the gelation of the polymer may make the polymer less 
available for steric stabilization.  Finally, the depletion attraction forces mediate cluster 
growth both during condensation and coagulation.  For smaller polymer/gold ratios, the 
depletion attraction will decrease, which would favor smaller clusters, as observed (Fig. 
6.8a).  As the volume of the gap region increases between particles, the depletion 
attraction also increases.  Thus, the depletion attraction will be larger for two 20 nm, 
growing clusters than for two primary colloidal 5 nm gold particles. Thus depletion 
attraction may play a larger role in the later coagulation stage than for the initial growth 
of the smallest embryos.  
 
6.4.7 Comparison to thermodynamic self assembly methods 
The mechanism by which our nanoclusters are formed is fundamentally different 
from equilibrium-based processes, in which particles are assembled into the cores of 
micelles or at the interface between the core and the corona.  In the case of 
thermodynamic self-assembly, the polymer-gold interactions are inherently stronger and 
play a much more dominant role, leading to higher polymer loadings and larger gold 
spacings. 
The loadings into micelles are governed by entropic and enthalpic interactions 
between the solute and the micelle core, as well as the interfacial free energy between the 
core and corona of a micelle, intFΔ  
69.  The change in free energy for mixing solute 
molecules and micelles is given by 69  
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intmm1 FHSTF Δ+Δ+Δ−=Δ  (6.8) 
 
where ΔSm and ΔHm are the change in entropy and enthalpy upon mixing, respectively.  
The amount of work required for expansion of the interface between the core and corona 
upon imbibing a solute molecule increases as the micelle size decreases, due to larger 
Laplace pressures.  This interfacial term becomes especially significant for micelles 
smaller than 200 nm69.  The loadings of small molecules such as pharmaceuticals in the 
cores of micelles are often less than 25% by weight69 and typically less than 10%.  The 
loading of a gold particle in a micelle will be even lower because ΔSm  will be less 
favorable, given the high molecular weight of the particle.  For example, loadings of only 
< 2% w/w of ~2.4 nm gold particles in ~20 nm polymer micelles has been observed using 
small angle x-ray scattering (SAXS)70. Thus,  thermodynamic assembly methods are not 
likely to incorporate sufficient gold loadings to yield a strong red-shift in the SPR for 
clusters, especially for sizes smaller than 50 nm.  
The kinetic nanocluster assembly method in the present study is not restricted by 
the thermodynamic constraints of micelle encapsulation.  Clusters were formed by 
purposely aggregating gold nanoparticles with a weakly adsorbing polymer to control 
nucleation and growth by manipulation of the electrostatic, steric, and depletion 
interactions.  The strong van der Waals interactions between the gold particles were the 
primary driving force for cluster growth.  Furthermore, depletion effects promote 
exclusion of the polymer to the cluster surface.  These interactions lead to much higher 
loadings than for thermodynamic assembly of gold particles with micelles. 
 
6.4.8 Application to biomedical imaging and therapeutics   
Gold nanoparticles with intense NIR absorbance, including nanoshells32-34, 
nanorods35, 36, and nanocages37, 38, have received extensive attention as biomedical 
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imaging and therapeutic agents.  However, while these particles are within the optimal 
size range of 6-100 nm to exhibit sufficiently long blood residence times for 
accumulation at disease sites, they are above the threshold size of 5.5 nm required for 
efficient clearance by the kidneys 71 72.  Furthermore, the metallic bonds between the gold 
atoms in these particles do not biodegrade.   In contrast, our gold nanoclusters, using 
PLA-b-PEG-b-PLA as the stabilizer , were shown to biodegrade nearly completely in 
solution and in macrophage cells back to the original 5 nm gold spheres9.   The ability to 
further tune the size to 30 nm and to vary composition, as demonstrated in the current 
study, broadens the scope of biodegradable nanoclusters significantly.   
 
6.5 CONCLUSIONS  
A general kinetic self-assembly method has been introduced to tune the size of 
hybrid polymer/gold nanoclusters, as small as 30 nm, with closely-spaced gold particles 
along with unusually low polymer loadings.  These properties are achieved by the 
combination of high initial gold particle volume fractions and the depletion of the weakly 
adsorbed polymeric stabilizer from the cluster interior.  Either solvent evaporation or 
mixing may be utilized to produce high initial gold particle and polymer concentrations 
simultaneously to manipulate growth.  Here, the polymer adsorbs weakly on the gold and 
thereby reduces the electrostatic repulsion to nucleate cluster growth.  The growth is 
arrested by small amounts of polymer on the exterior cluster surface, as characterized by 
SEM and TGA, which provide steric stabilization and minimize coagulation.   The 
closely-spaced particles provide intense NIR absorbance even in clusters as small as 30 
nm, a size which is of great interest for manipulation of biological pathways and 
signaling at the cellular level56.   This kinetic assembly platform may be used to tune the 
size, morphology, and optical properties of a widespread variety of clusters with high 
metal loadings, simply by varying the particle concentration pathways to adjust the 
colloidal forces.  Additionally, the method has been generalized for initial gold particles 
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with varying surface charge.   In contrast, higher polymer loadings along with more 
widely spaced metal particles are often obtained in nanoclusters formed by 
thermodynamic self-assembly, which requires stronger metal particle-polymer 
interactions.  Kinetically-controlled nanocluster assembly using physical methods offers 
broad opportunities for the design of nanoclusters for sensors, optoelectronics and 
biomedical applications, including multi-modal imaging/therapeutic systems, cell-







Figure 6.1 Schematic of kinetically controlled assembly process of nanocluster 
formation, in which primary gold nanoparticles aggregate in the presence of 
a weakly adsorbing polymer, PLA-b-PEG-b-PLA micelles, in a controlled 
manner to yield sub-100 nm clusters.  Weak polymer adsorption increases 
counter ion binding and reduces the surface charge on the gold nanoparticles 
to facilitate cluster nucleation.  Cluster growth is facilitated by increasing 
the volume fraction of particles,φ, via solvent evaporation.  PEG blocks on 
the polymer extend into the aqueous environment and provide steric 
stabilization to clusters.   
 
 
Figure 6.2 TEM images of nanoclusters produced after (a) 0%, (b) 50%, (c) 60%, (d) 
80%, (e) 100% solvent evaporation. (f) SEM image of nanoclusters 
produced after 100% solvent evaporation.  The nanoclusters were formed at 
an initial gold concentration of 3 mg/mL and a PLA-b-PEG-b-PLA 
























































Figure 6.3 (a) Particle size measurements, by DLS, and (b) UV-vis absorbance spectra 
for nanoclusters composed of citrate/lysine-capped gold nanoparticles 
produced after different extents of evaporation.  Nanoclusters were 
produced at a starting gold concentration of 3 mg/mL and bound together 



















                     
















   






Figure 6.4 (a) Particle size measurements, by DLS, TEM images of nanoclusters after 
(b) 60% and (c) 100% solvent evaporation, and (d) UV-vis absorbance 
spectra of nanoclusters composed of citrate/lysine-capped nanoparticles 
assembled using PEG homopolymer (MW=3350).  The starting gold and 



















































Figure 6.5 (a) Particle size distribution, as measured by DLS, and (b) UV-vis spectra of 
clusters of citrate/lysine-capped nanoparticles made with the mixing 
protocol.  The conditions of cluster formation are equivalent to that for 
clusters formed by solvent evaporation at a starting gold concentration of 3 
mg/mL and a PLA-b-PEG-b-PLA/Au ratio of 16/1.  In (b), the UV-vis 



























Figure 6.6 UV-vis absorbance spectra for clusters made with gold primary particles 
capped with different ligands.  The clusters were produced using a starting 
gold concentration of 3 mg/mL and bound together using PLA-b-PEG-b-
PLA at a 16/1 polymer/Au ratio.  The clusters were formed under 100% 
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Figure 6.7 Hydrodynamic diameter (D80) and absorbance values for nanoclusters 
composed of primary particles capped with citrate (■) or a combination of 
citrate and lysine (●) ligands.  The clusters were produced using a starting 
gold concentration of 3 mg/mL and bound together using PLA-b-PEG-b-
PLA at a 16/1 polymer/Au ratio. 
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Figure 6.8 (a) Particle size distribution, as measured by DLS, and (b) UV-vis 
absorbance spectra of nanoclusters of citrate/lysine-capped nanoparticles 
produced with varying PLA-b-PEG-b-PLA/gold ratios at an initial gold 
concentration of 1 mg/mL and 100% solvent evaporation. TEM images of 
nanoclusters: (c) 16/1 polymer/gold ratio and an initial gold concentration of 
3 mg/mL and (d) a 1/1 polymer/gold ratio with an initial gold concentration 


































Figure 6.9 Van der Waals and total interaction potentials describing the stability of 
citrate/lysine- capped gold nanoparticles in the absence of PLA-b-PEG-b-
PLA and after the addition of PLA-b-PEG-b-PLA.  Effects of solvent 




















Figure 6.10 Stability ratio of a system of citrate/lysine-capped gold nanoparticles in the 
absence and presence of PLA-b-PEG-b-PLA determined using DLVO 
theory, as a function of particle volume fraction.  
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Table 6.1 Zeta potentials of gold primary particles and nanoclusters capped with 
citrate or a combination of citrate and lysine ligands.   
 
Ligand Zeta potential (mV) 
Citrate 
(primary particle) -44.0 ± 4.9  
Citrate/lysine 
(primary particle) -30.1 ± 2.4 
PLA(2K)-b-PEG(10K)-b-PLA(2K) -8.0 ± 0.2 
Citrate/lysine  
16/1 PLA-b-PEG-b-PLA /Au 
(nanocluster – 100% evaporation) 
-16.3 ± 4.0 
Citrate 
16/1 PLA-b-PEG-b-PLA /Au 
(nanocluster – 100% evaporation) 




Table 6.2 Calculated stability ratios for nanoclusters produced using citrate/lysine-
capped nanoparticles at a 16/1 PLA-b-PEG-b-PLA /Au ratio and a starting 
gold concentration of 3 mg/mL.  
 
Evaporation Extent (%) N0 
(particles/m3) 
t1/2,f (s) tcol (s) t1/2,s (s) W 
0, no polymer 5×1021 3.93×10-5 2.59×106 256634 6.60×109 
0, polymer 5×1021 1.51×10-4 3.60×103 356 3.97×105 
50 1×1022 1.30×10-4 300 30 2.50×105 
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Table 6.3 Size distribution moments and cluster yields, as determined by FAAS, for 
nanoclusters produced using different extents of evaporation. The initial 
gold concentration was 3 mg/mL and the PLA-b-PEG-b-PLA /gold ratio 
was 16/1.    
 
 
Sample Cluster yield (%) μ1 μ3 
Citrate/lysine-capped nanoclusters 
100% evaporation 99.7 1.11 0.93 
Citrate/lysine-capped nanoclusters 
80% evaporation 96.8 1.04 0.97 
Citrate/lysine-capped nanoclusters 
60% evaporation 95.1 1.09 0.93 
Citrate-capped nanoclusters  
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7.1.1 Amorphous Cyclosporin Nanodispersions for Enhanced Pulmonary 
Deposition and Dissolution  
Stable dispersions of amorphous, 300 nm cyclopsorin (CsA) nanoparticles, 
containing only 10 wt% excipient, were produced using controlled antisolvent 
precipitation.  The stable dispersions, when nebulized to mice, produced efficacious drug 
concentrations in both the lung tissue and blood stream and remained within the 
therapeutic window.  This accomplishment is particularly useful for lung transplant 
recipients or for those patients requiring non-steroid asthma treatment, where the 
effectiveness of CsA has been limited due to a narrow therapeutic window.  Nebulization 
of CsA nanoparticle dispersions circumvents problems in solution-based pulmonary 
formulations that often cause irritation to lung tissues due to the use of organic solvents 
or large amounts of excipients.  Furthermore, nebulization of the drug generated much 
higher lung tissue concentrations (10.5 μg drug/g lung tissue) than oral and parenteral 
administration routes reported in literature, while maintaining lower systemic 
concentrations (370 ng/mL), below the toxicity level.  Thus, the development of an 
aerosolized nanoparticle formulation  to target the deep lungs will not only make CsA a 
more viable option for treatment of lung diseases, but this methodology can also be 
applied to other drugs that have narrow therapeutic windows.   
Successful nebulization of nanoparticles to the lungs requires that the length scale 
of the drug particles be significantly less than that of the carrier droplets, in order to 
facilitate uniform distribution of drug particles throughout the aerosolized droplets.  The 
aerosolized water droplets possessed optimal aerodynamic properties for deep lung 
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deposition, achieving high fine particle fractions up to 77%, whereas the small size of the 
drug particles favored enhanced dissolution.  Thus, nebulization of nanoparticle 
dispersions simultaneously enables efficient deep lung deposition and dissolution in the 
lung tissue.  The amorphous CsA nanoparticles generated in-vitro supersaturation levels 
up to 18 times the equilibrium solubility.  Finally, to better understand the absorption of 
poorly water soluble drugs in the lungs, a model was developed to characterize the effects 
of particle size, morphology, solubility, and drug dose on the two mechanisms that 
regulate drug absorption: drug dissolution and permeation through tissues.  For example, 
the absorption half-life for a 3 μm drug particle with a solubility of 1 μg/mL is predicted 
to decrease from 500 to 5 minutes with an increase in supersaturation to 100 μg/mL, 
indicating that the absorption of this poorly water soluble drug is dissolution-rate limited.  
Increased absorption rates may be achieved by the formation of an amorphous drug form1 
or a particle size reduction to 300 nm.  Thus, the model indicates that modification of 
drug properties to enhance drug dissolution can significantly affect drug absorption times.  
The flexibility of the model allows it to be applied in the development of other 
pulmonary poorly water soluble drug formulations to predict how particle size and 
morphology impact absorption rates, as well as if absorption rates will be sufficient to 
avoid clearance by macrophages.   
 
7.1.2 Templated Open Flocs for the Delivery of Nanoparticles to the Lungs Using a 
Pressurized Metered Dose Inhaler (pMDI)  
Anisotropic nanoparticles, in the shape of rods, thin plates, and needles (aspect 
ratios ranging between 5-24), suspended in a HFA propellant without the inclusion of 
surfactants or cosolvents were stable against settling for two years at a 10 mg/mL drug 
loading.  The anisotropic particles formed highly open, low density, space-filling flocs in 
HFA which stacked upon each other to prevent settling.  Rapid and sticky attractive 
collisions, driven by van der Waals attractive forces, between the anisotropic particles, as 
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well as the inefficient packing of these particles, are believed to facilitate the formation of 
the low density flocs.  In contrast, isotropic particles (spheres or cubes) produced by 
milling or spray drying formed dense aggregates that settled within one minute.  
Aerosolization of the floc suspension with a pMDI produced high fine particle fractions 
(47-64%) with an emitted dose up to 2.4 mg/actuation.  These desirable aerodynamic 
properties and high doses were facilitated by the ability to produce highly stable 
suspensions, even at increased drug loadings up to 50 mg/mL.     
The aerosolized particles were templated during HFA droplet formation and 
compacted during evaporation to yield optimal aerodynamic diameters for deep lung 
delivery, in contrast with the conventional approach of delivering pre-formed particles.  
The attractive van der Waals interactions between primary particles within the floc were 
demonstrated to be sufficiently weak such that the atomized HFA droplets could shear off 
portions of the floc within the droplet upon pMDI actuation.  Upon evaporation of HFA, 
capillary forces compact the templated flocs to produce porous particles with optimal 
aerodynamic properties for pulmonary delivery.  Thus, the final size of the aerosol 
particle was templated by the evaporating HFA droplet.  Furthermore, the delivery of a 
high surface area micron-sized porous floc of nanoparticles to the lungs, as opposed to a 
solid, micron-sized particle was shown to enhance drug dissolution rates.  Therefore, the 
delivery of a micron-sized floc of nanoparticles using a pMDI offers both efficient deep 
lung deposition as well as rapid dissolution, which is beneficial to enhance the absorption 
of poorly water soluble drugs in the lungs.  This novel concept for forming extremely 
stable suspensions of open flocs of anisotropic particles, and templating and compacting 
the flocs to produce particles for efficient pMDI deep lung delivery was demonstrated for 
the poorly water soluble drug, itraconazole, and the water soluble protein, bovine serum 
albumin, and thus is applicable to a wide variety of drugs.   
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7.1.3 Controlled Kinetic Assembly of Biodegradable Plasmonic Nanoclusters for 
Near-Infrared Imaging and Therapeutic Applications 
A general kinetic self-assembly method has been introduced to tune the size of 
hybrid polymer/gold nanoclusters, as small as 30 nm and up to 100 nm in diameter, in 
which the 5 nm constituent gold nanoparticles are closely-spaced together and contain 
unusually low polymer loadings.  These properties are achieved by the combination of 
high initial gold particle volume fractions during the clustering process and the exclusion 
of a weakly adsorbed polymeric stabilizer from the cluster interior due to depletion 
attraction forces.  Either solvent evaporation or a mixing process may be utilized to 
produce the high initial gold particle and polymer concentrations that are required to 
simultaneously manipulate cluster growth and optical properties.  Here, the polymer 
adsorbs weakly on the gold and thereby reduces the electrostatic repulsion to nucleate 
cluster growth.  Thus, cluster growth is simultaneously arrested by the small amounts of 
polymer on the exterior cluster surface, as characterized by scanning electron microscopy 
and thermogravimetric analysis, which provide steric stabilization and minimize 
coagulation.   The closely-spaced particles provide intense NIR absorbance in even 
clusters as small as 30 nm, a size which is of great interest for the manipulation of 
biological pathways and signaling at the cellular level2.  Furthermore, the formation of 
nanoclusters using a biodegradable polymer stabilizer enabled deaggregation of the 
clusters into its constituent, clearable particles upon polymer degradation, as 
demonstrated in physiologically relevant media as well as in live cells.  Thus, these 
nanoclusters can provide strong optical contrast required for imaging and therapy, as well 
as effective clearance from the body to minimize toxicity concerns and facilitate the 
translation of plasmonic nanoparticle applications into clinical practice.       
Additionally, this kinetically controlled nanocluster assembly method has been 
generalized for initial gold particles with varying surface charge.  In contrast, higher 
polymer loadings, along with more widely spaced metal particles, are often obtained in 
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nanoclusters formed by thermodynamic self-assembly methods, which require stronger 
metal particle-polymer interactions. This kinetic assembly platform may be used to tune 
the size, morphology, and optical properties of a widespread variety of clusters in which 
high metal loadings are desirable, simply by varying the particle concentration pathways 
to adjust the colloidal forces.  Therefore, kinetically-controlled nanocluster assembly 
using physical methods offers broad opportunities for the design of nanoclusters for 
sensors, optoelectronics and biomedical applications, including multi-modal imaging/ 
therapeutic systems, cell-specific targeting, and biodegradable clusters for rapid clearance 
from the body. 
 
7.2 RECOMMENDATIONS AND FUTURE RESEARCH 
 
7.2.1 Pulmonary delivery of nanoparticles  
The absorption of BCS class II drugs, such as itraconazole (aqueous solubility <  
1 ng/mL at neutral pH 3) by the body is generally considered to be dissolution rate 
limited, due to  extremely low aqueous solubilities.  Therefore, extensive efforts have 
been invested in the production and stabilization of amorphous nanoparticles of poorly 
water soluble drugs, with sizes as low as ~200 nm, to enhance dissolution rates in the 
lungs, and thus systemic absorption4-6.  However, a recent examination of drug 
absorption rates of poorly water soluble drugs in the lungs using the 
dissolution/permeation model described in chapter 2 of this dissertation suggests that 
continued particle size reduction or increasing supersaturation levels may not necessarily 
enhance systemic absorption rates beyond a certain point6.  According to the model, the 
absorption half-life for a crystalline 3 µm particle (solubility of 10 ng/mL) may be 
reduced by 3 orders of magnitude by raising the solubility by a factor of 10 (a reasonable 
increase upon the formation of an amorphous drug morphology1) and a reduction in 
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particle size to 230 nm.  However, a further decrease in particle size to 50 nm would not 
result in a significant improvement in the absorption rate.  Therefore, additional efforts in 
producing smaller nanoparticles would no longer be beneficial because at this point, 
absorption becomes permeation limited.  Therefore, improvements in systemic absorption 
rates would be more efficiently accomplished by incorporating permeation enhancers into 
the pulmonary composition.  Phospholipids such as dipalmitoylphosphatidylcholine 
(DPPC) and lecithin are known to enhance permeability through lung tissue7, 8.  Yang et 
al. demonstrated higher systemic rates of a nebulized itraconazole formulation containing 
lecithin compared to a similar nebulized itraconazole formulation that did not contain a 
permeation enhancer5, 6.  Therefore, it would be of interest to further examine this 
concept that the absorption of BCS class II drugs may become permeation limited once 
saturation of the fluid in the lung lining is reached, which is easily achieved due to the 
small volume of liquid in the deep lungs (~10 µL)9.  In order to thoroughly understand 
the effects of permeation enhancers in pulmonary compositions on systemic absorption 
rates, pulmonary delivery of comparable drug formulations with and without permeation 
enhancers to animals and subsequent analysis of blood levels are needed.   
Additionally, dissolution rates of aerosolized particles may be more accurately 
studied by utilizing a novel dissolution method currently being developed by Son et al.10, 
in which the dissolution rates of the particles that deposit on each plate of an aerosol 
impactor device may be studied separately.  This knowledge will provide additional 
insight into the viability of a pulmonary composition to be efficiently absorbed in the 
lungs.  Furthermore, the ability of an aerosolized composition to perform a specific 
cellular function may be tested by coating the stages of an aerosol impactor with a 
desired marker.  After aerosolization into the impactor, the specific markers may be 
analyzed to determine if a sufficient amount of drug was able to reach the desired 
location in the lungs and elicit a therapeutic effect.  This technique was demonstrated by 
Haynes et al.11, where the ability of an aerosolized cyclooxygenase-2 (COX-2) inhibitor, 
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nimesulide, to facilitate cytotoxicity and an apoptotic response against a human lung 
adenocarcinoma cell line was examined. 
For pMDI delivery specifically, additional studies on the long term storage 
stability of the pMDI suspensions on aerosol performance is recommended.  The ability 
of the flocs to form respirable particles over an extended period of time is of practical 
interest, as this knowledge influences the shelf-life of a product.  Furthermore, pMDI 
dosing to an animal model would be beneficial to demonstrate the efficacy of these novel 
aerosol pMDI compositions.  Several pMDI commercial products contain more than one 
active ingredient12, 13.  Therefore, it would also be interesting to study how floc formation 
and structure, and thus suspension stability and aerosol performance, are affected upon 
the addition of two particles with different morphologies.     
 
7.2.2 Controlled Assembly of Nanoparticle Clusters for Biomedical Imaging and 
Therapy  
Multifunctional nanoparticles that possess specific targeting capabilities have the 
potential to revolutionize health care for numerous diseases, especially cancer14, 15.  Thus, 
it is recommended that the nanocluster assembly method presented in chapter 5 of this 
dissertation be extended to the incorporation of magnetic nanoparticles and/or therapeutic 
agents.  The ability to simultaneously deliver a combination of imaging/therapeutic 
modalities is a tremendous advancement over current commercialized options because it 
would provide more efficient treatment of diseases, as well as facilitate early detection of 
diseases.  However, a key challenge in the development of such a product is to devise a 
robust strategy to load an extremely high degree of targeting, imaging, and therapeutic 
functionality into small, yet stable particles.  The generality of our nanocluster assembly 
method is highly advantageous because it is not dependent on specific chemical 
interactions for cluster formation.  Therefore, it is likely that additional materials such as 
iron oxide nanoparticles, which impart magnetic capabilities, and therapeutic agents may 
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be easily incorporated into the nanoclusters.  The effect of incorporating these additional 
materials on the size and optical properties of the cluster will need to be examined.  For 
instance, if all the constituent particles, gold, iron oxide, and a drug, are homogenously 
mixed throughout the cluster, the cluster is not as likely to maintain strong NIR 
absorbance, as the separation distance between each gold particle will likely increase.  
Therefore, the morphology of these new multifunctional nanoclusters must be carefully 
considered.  One potential method of producing a multifunctional nanoparticle would be 
to first produce nanoclusters containing only drug and iron oxide nanoparticles.  Then, 
those initial drug/iron oxide nanoclusters may be incorporated into a larger cluster with 
gold nanoparticles, bound together with a polymeric binder, to maintain strong NIR 
absorbance.  Furthermore, active targeting of these nanoclusters may be achieved by 
functionalizing the gold nanoparticles with antibodies, using methods described by 





1. Matteucci, M. E.; Brettmann, B. K.; Rogers, T. L.; Elder, E. J.; Williams, R. O.; 
Johnston, K. P., Design of Potent Amorphous Drug Nanoparticles for Rapid 
Generation of Highly Supersaturated Media. Molecular Pharmaceutics 2007, 4, 
(5), 782-793. 
2. Jiang, W.; Kim, B. Y. S.; Rutka, J. T.; Chan, W. C. W., Nanoparticle-mediated 
cellular response is size-dependent. Nature Nanotechnology 2008, 3, (3), 145-150. 
3. Peeters, J.; Neeskens, P.; Tollenaere, J. P.; Van Remoortere, P.; Brewster, M. E., 
Characterization of the interaction of 2-hydroxypropyl-beta-cyclodextrin with 
itraconazole at pH 2, 4 and 7  Journal of Pharmaceutical Sciences 2002, 91, 
1414–1422. 
4. McConville, J. T.; Overhoff, K. A.; Sinswat, P.; Vaughn, J. M.; Frei, B. L.; 
Burgess, D. S.; Talbert, R. L.; Peters, J. I.; Johnston, K. P.; Williams, R. O., III, 
Targeted High Lung Concentrations of Itraconazole Using Nebulized Dispersions 
in a Murine Model. Pharmaceutical Research 2006, 23, (5), 901-911. 
5. Vaughn, J. M.; McConville, J. T.; Burgess, D.; Peters, J. I.; Johnston, K. P.; 
Talbert, R. L.; Williams, R. O., III, Single dose and multiple dose studies of 
itraconazole nanoparticles. European Journal of Pharmaceutics and 
Biopharmaceutics 2006, 63, (2), 95-102. 
6. Yang, W.; Tam, J.; Miller, D. A.; Zhou, J.; McConville, J. T.; Johnston, K. P.; 
Williams, R. O., High bioavailability from nebulized itraconazole nanoparticle 
dispersions with biocompatible stabilizers. International Journal of 
Pharmaceutics 2008, 361, (1-2), 177-188. 
7. Liu, F.; Shao, Z.; Kildsig, D. O.; Mitra, A. K., Pulmonary delivery of free and 
liposomal insulin. Pharmaceutical Research 1993, 10, (2), 228-32. 
8. Mitra, R.; Pezron, I.; Li, Y.; Mitra, A. K., Enhanced pulmonary delivery of insulin 
by lung lavage fluid and phospholipids. International Journal of Pharmaceutics 
2001, 217, (25-31). 
9. Patton, J. S., Mechanisms of macromolecule absorption by the lungs. Advanced 
Drug Delivery Reviews 1996, 19, (1), 3-36. 
10. Son, Y. J.; McConville, J. T. In Improvements of an In Vitro Dissolution Test 
Method For Dry Inhalation Formulations, American Association of 
Pharmaceutical Scientists Annual Meeting, Atlanta, GA, 2008; Atlanta, GA, 
2008. 
 258
11. Haynes, A.; Shaik, M. S.; Chatterjee, A.; Singh, M., Evaluation of an aerosolized 
selective COX-2 inhibitor as a potentiator of doxorubicin in a non-small-cell lung 
cancer cell line. Pharmaceutical Research 2003, 20, (9), 1485-1495. 
12. Courrier, H. M.; N. Butz; Vandamme, T. F., Pulmonary Drug Delivery Systems: 
Recent Developments and Prospects. Critical Reviews in Therapeutic Drug 
Carrier Systems 2002, 19, (4 and 5), 425-498. 
13. Smyth, H. D. C., The influence of formulation variables on the performance of 
alternative propellant-driven metered dose inhalers. Advanced Drug Delivery 
Reviews 2003, 55, (7), 807-828. 
14. Larson, T. A.; Bankson, J.; Aaron, J.; Sokolov, K., Hybrid plasmonic magnetic 
nanoparticles as molecular specific agents for MRI/optical imaging and 
photothermal therapy of cancer cells. Nanotechnology 2007, 18, (32), 325101/1-
325101/8. 
15. Wang, A. Z.; Bagalkot, V.; Vasilliou, C. C.; Gu, F.; Alexis, F.; Zhang, L.; Shaikh, 
M.; Yuet, K.; Cima, M. J.; Langer, R.; Kantoff, P. W.; Bander, N. H.; Jon, S.; 
Farokhzad, O. C., Superparamagnetic iron oxide nanoparticle-aptamer 
bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem 
2008, 3, (9), 1311-1315. 
16. Aaron, J.; Nitin, N.; Travis, K.; Kumar, S.; Collier, T.; Park, S. Y.; Jose-
Yacaman, M.; Coghlan, L.; Follen, M.; Richards-Kortum, R.; Sokolov, K., 
Plasmon resonance coupling of metal nanoparticles for molecular imaging of 
carcinogenesis in vivo. Journal of Biomedical Optics 2007, 12, (3), 034007/1-
034007/11. 
17. Aaron, J. S.; Oh, J.; Larson, T. A.; Kumar, S.; Milner, T. E.; Sokolov, K. V., 
Increased optical contrast in imaging of epidermal growth factor receptor using 
magnetically actuated hybrid gold/iron oxide nanoparticles. Optics Express 2006, 
14, (26), 12930-12943. 
18. Kumar, S.; Harrison, N.; Richards-Kortum, R.; Sokolov, K., Plasmonic 
Nanosensors for Imaging Intracellular Biomarkers in Live Cells. Nano Letters 
2007, 7, (5), 1338-1343. 
19. Sokolov, K. V.; Follen, M.; Aaron, J.; Pavlova, I.; Malpica, A.; Lotan, R.; 
Richards-Kortum, R., Real-time vital optical imaging of precancer using anti-
epidermal growth factor receptor antibodies conjugated to gold nanoparticles. 
Cancer Research 2003, 63, 1999-2004. 
20. Kumar, S.; Aaron, J.; Sokolov, K., Directional conjugation of antibodies to 
nanoparticles for synthesis of multiplexed optical contrast agents with both 
delivery and targeting moieties. Nature Protocols 2008, 3, (2), 314-320. 
 
 259
Appendix A:  Templated Open Flocs of Nanorods for Enhanced 
Pulmonary Delivery with Pressurized Metered Dose Inhalers 
Bruggeman mixing rule 
For porous particles or suspensions with a BSA particle volume fraction φ , the 
effective refractive index en  and dielectric constant eε  can be calculated from the 










































φ   (A.2) 
 
where φ  can be either gφ  or fφ , the subscript A denotes air or HFA 227, and B denotes 
BSA. 
 
Attractive van der Waals equations 
The vdwΦ  is directly proportional to the Hamaker constant 121A  for one particle 
interacting with another (subscript 1) across solvent, such as HFA 227 or acetonitrile, 
(subscript 2) as a function of the particle geometry [1].  The Hamaker constant 121A  may 
be approximated by 
                                     ( )22211121 AAA −=   (A.3) 
 
where 11A  and 22A  are the pure Hamaker constants for BSA and the suspending media 
interacting across a vacuum, respectively.  These values were calculated from Lifshitz 
theory [1, 2].  To determine 11A  for porous BSA particles in HFA 227, eε  and en  were 
calculated with the Bruggeman mixing rule (Eq. A.1 and A.2) at φ  = 0.5 in HFA 227 [3, 
4].  The van der Waals attractive potential between identical spherical particles [1]        
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121−=Φ  (A.4) 
 






Fvdw =   (A.5) 
 
where R  is the spherical particle radius and h  is the separation distance between the 































vdw  (A.6) 
                                                               
where t  is the shell thickness.  For identical rods, vdwE  can be calculated for parallel   






vdw −=Φ  (A.7) 
 




121−=Φ  (A.8) 
 
where L  is the cylinder length.  The values from Eq. A.7 and A.8 were averaged to give 
equal weight to the two orientations (Table 3.3).   
Space filling floc derivation 
A vial filled with protein particles of total mass m  and primary particle density 









=  (A.9) 
 






=φ  (A.10) 
 
where Vp and Vf are the volume of a spherical primary particle and a spherical floc, 
respectively, and k  is the number of primary particles in a floc.  
The volume fraction of flocs in HFA flocsφ  is defined as 
 
V
NV ffflocs ⋅=φ  (A.11) 
 
where fN  is the total number of flocs in suspension.  kNN pf /=  where pp mmN /=  is 
the total number of primary particles in suspension and ppp Vm ρ⋅=  is the mass of a 
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Appendix B:  Templated Open Flocs of Anisotropic Particles for 
Pulmonary Delivery with Pressurized Metered Dose Inhalers 
 
Bruggeman mixing rule 
The effective refractive index, en ,and effective dielectric constant, εe, for porous 
particles or open flocs, with a particle volume fraction, φ, may be determined using the 










































ϕ−  (B.2) 
 
where φ is either φg or φf ,depending on the suspension media, the subscript A denotes the 
appropriate medium,  air or HFA 227, and B denotes the drug. 
 
Attractive van der Waals equations 
The VDW attractive potential, vdwΦ , is directly proportional to the effective 
Hamaker constant, 121A , for a pair of particles (subscript 1) interacting across a medium 
(subscript 2)1.  The Hamaker constant 121A  may be determined by 
 
                                     ( )22211121 AAA −=   (B.3) 
 
where 11A  and 22A  are the Hamaker constants for the drug and the media interacting 
across a vacuum, respectively.  A11 and A22 values were calculated using Lifshitz theory 1, 
2.  
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For porous Itz particles, 11A was determined using en  and eε  values calculated 
using the Bruggeman mixing rule (Eq. B.1-B.2) at φ = 0.53, 4.  The van der Waals 
attractive potential between two particles is dependent on the particle geometry.  For two 
identical spheres, vdwΦ  is determined by 
1           
                      
h12
RA121
vdw −=Φ  (B.4) 
 
where R is the radius and h is the separation distance between the particle surfaces.  For 
































RA  (B.5) 
 
where t  is the shell thickness.  For identical rods, vdwΦ  can be calculated for two 
configurations, parallel                      
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vdw −=Φ  (B.7) 
where L  is the cylinder length.  The two possible orientations for cylinders were given 
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Figure B.1 pMDI (a) vial prior to addition of HFA 227 and (b) after exposure to HFA 
227.   
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(a)  (b)   
 
Figure B.2 SEM image of an aerosolized (a) TFF Itz and (b) TFF BSA from a pMDI 
(drug loading of 10 mg/mL).  A focused ion beam laser was used to slice of 
a portion of the particle in order to view the morphology of the interior of 
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Appendix C:  Controlled Assembly of Biodegradable Plasmonic 




Gold particle synthesis: 
To synthesize the citrate-capped gold nanoparticles, 100 mL of DI water was 
heated to 97oC.  While stirring, 1 mL of 1% HAuCL4•3H2O, 1 mL of 1% 
Na3C3H5O(COO)3 •2 H2O, and 1 mL of 0.075% NaBH4 in a 1% Na3C3H5O(COO)3•2 
H2O solution was added in one minute intervals.  The solution was stirred for five 
minutes and then removed to an ice bath to cool to room temperature.  The gold particles 
were then concentrated using centrifugal filter devices (Ultracel YM-30, Millipore Co.) 
to 3.0 mg Au/mL. Gold concentrations were determined using flame atomic absorption 
spectroscopy (FAAS), as described below.   
 
Nanocluster characterization: 
 The nanocluster morphology was observed by scanning electron (SEM) 
and transmission electron microscopy (TEM).  A Zeiss Supra 40VP field emission SEM 
was operated at an accelerating voltage of 5−10 kV. SEM samples were prepared by 
depositing a dilute aqueous dispersion of the nanoclusters onto a silicon wafer.  The 
sample was dried and washed with DI water to remove excess polymer.  TEM was 
performed on a FEI TECNAI G2 F20 X-TWIN TEM using a high-angle annular dark 
field detector.  A dilute aqueous dispersion of the nanoclusters was deposited onto a 200 
mesh carbon-coated copper TEM grid for observation.  Separation distances between 
primary particles within the nanoclusters were measured by analyzing TEM images using 
Scion Image software (Frederick, Maryland).  UV−vis spectra were obtained with a 
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Varian Cary 5000 spectrophotometer and a 1 cm path length.  Dynamic light scattering 
(DLS) measurements of hydrodynamic diameter and zeta potential measurements were 
performed in triplicate on a Brookhaven Instruments ZetaPlus dynamic light scattering 
apparatus (scattering angle of 90°) at a temperature of 25°C[1].  Dispersion 
concentrations were adjusted with either DI water for DLS measurements or pH=7.4 
buffer (10 mM) for zeta potential measurements to yield a measured count rate between 
300-400 kcps.  Prior to all DLS measurements, the nanocluster dispersions were filtered 
through a 0.2 µm filter and probe sonicated for 2 minutes.  Data analysis was performed 
using a digital autocorrelator (Brookhaven BI-9000AT) with a non-negative least-squares 
(NNLS) method (Brookhaven 9KDLSW32).  Reported average diameters correspond to 
the D50, or diameter at which the cumulative sample volume was under 50%.  For zeta 
potential measurements, the average value of at least three data points was reported.  
Thermogravimetric analysis (TGA) was conducted using a Perkin–Elmer TGA 7 under 
nitrogen atmosphere at a gas flow rate of 20 mL/min. The samples were cleaned to 
remove excess polymer by centrifuging nanocluster dispersions at 8000 rpm for 5 
minutes at 4oC.  TGA samples were heated at a constant rate of 20 °C/min from 30°C to 
800 °C and then held at 800°C for 30 minutes.  Flame atomic absorption spectroscopy 
(FAAS) was used to determine the gold concentration in the nanocluster dispersions 
using a GBC 908AA flame atomic absorption spectrometer (GBC Scientific Equipment 
Pty Ltd).  Measurements were conducted at 242.8 nm using an air-acetylene flame.  To 
determine clustering efficiency, a dispersion of nanoclusters of known concentration was 
centrifuged at 10,000 rpm for 10 minutes at 4oC.  FAAS measurements were conducted 
on the supernatant.   
 
Hyperspectral characterization of nanoclusters in solution: 
Microscope slides were submerged in a warm, aqueous gelatin solution (3% w/v) 
for 10 minutes.  The slides were removed from the gelatin and 10 μL of a dilute 
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nanocluster dispersion (~0.01 mg/mL) were placed on the gelatin coated slide and 
covered with a cover slip.  The gelatin was allowed to cool for 2 hours, to allow the 
nanoparticles to solidify into the gelatin.  Hyperspectral images were acquired under the 
same conditions described previously. 
 
Additional Results and Discussion  
 
Proposed mechanism for nanocluster formation: 
The ability to simultaneously control cluster size and spacing of gold 
nanoparticles within the nanocluster was achieved by manipulating particle volume 
fractions upon solvent evaporation, as well as the interactions between the gold primary 
particles and the polymer binder.  In the absence of polymer, primary gold nanoparticles 
formed undesirably large aggregates (> 1 μm) upon complete solvent evaporation to form 
a film.  Thus, the polymer was needed to provide steric stabilization to the clusters.  In 
another control experiment, the addition of polymer to the colloidally stable gold 
nanoparticle dispersion without solvent evaporation resulted in a mild color change to a 
red-purple after approximately one hour.  However, clusters capable of significant NIR 
absorbance were not produced, as seen in Figure C.4, where the size of the gold particles 
did not change significantly according to DLS, and consequently, the extinction spectrum 
was essentially identical to that of the initial colloidal gold dispersion even four hours 
after the addition of the polymer.  At these dilute conditions, the polymer formed stable 
micelles with a hydrodynamic diameter of 10-14 nm (data not shown), and the 
electrostatic repulsion between ligand-capped gold particles prevented significant particle 
aggregation.  However, it is likely that the polymer addition resulted in the formation of 
dimmers and trimers, which were able to cause a mild color change[2, 3] but too small to 
elicit a strong red-shift into the NIR.  Therefore, cluster formation was likely initiated by 
the adsorption of the PLA block of the polymer to gold, as PLA homopolymer is known 
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to sterically stabilize gold nanoparticles in organic solvents[4].  Upon polymer 
adsorption, the local dielectric constant decreases and causes significant ion pairing of the 
charges on the ligands on the gold nanoparticles.  The decrease in electrostatic repulsion 
upon polymer adsorption was evidenced by a shift in zeta potential from -30.1 ± 2.4 mV 
for the lysine/citrate-capped gold nanoparticles to -14.99 ± 2.3 mV after the addition of 
polymer.       
When particle volume fractions in the polymer/gold dispersion were increased by 
only a factor of 2 (50% evaporation), only a modest red-shift in the SPR was produced, 
indicating that particle aggregation was still very limited.  However, a further increase to 
80% evaporation, which raised the gold concentration from an initial concentration of 3 
to 15 mg/mL and the polymer concentration from 50 to 250 mg/mL, produced 
nanoclusters with strong NIR absorbances.  Thus, high particle volume fractions were 
required to drive nanocluster growth.  Interestingly, the average sizes of nanoclusters 
produced after 80% and 100% solvent evaporation were similar (Figure C.4A).  Upon 
100% evaporation, approximately 99% by weight of the gold in the initial dispersion was 
incorporated within the clusters, as determined by FAAS.  The calculated moments in the 
particle size distribution measured by dynamic light scattering (μ1 and μ3 were 1.1 ±0.02 
and  0.93±0.01, respectively) indicate that the clusters were predominantly formed by 
condensation, with only a moderate amount of coagulation[5]. Thus, the lack of free gold 
nanocrystals likely causes termination in the cluster growth by condensation.    
Experimental observations during the cluster formation process may be explained 
by changes in the stability ratio, W, which is defined as the rate of slow, kinetically-






W =   (C.1) 
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where t1/2,f  and t1/2,s are the half-lives for fast and slow flocculation, respectively, and t1/2,f  




3t η=       (C.2) 
 
where η is the viscosity, and N0 is the initial number density of nanoparticles. Values for 
t1/2,s may be estimated using experimentally observed times required for the occurrence of 
a color change in solution[8].  The initial colloidal gold nanoparticle dispersion, without 
the addition of polymer, was extremely stable, with no observable change in the color of 
the dispersion for ~1 month, corresponding to a very high W of ~1010, given the low 
particle densities and strong electrostatic stabilization from the charged ligands.  The 
experimentally determined W decreased to ~105 for 50% evaporation (based on an 
estimated time of ~5 minutes to observe a color change) due to the surface charge 
reduction on the particles upon polymer adsorption and the factor of 2 increase in particle 
concentration.  Experimental values of W may also be related to the interaction potentials 
between two particles[7].  The expression for Vtotal includes the electrostatic and van der 
Waals DLVO forces, as well depletion attraction and steric repulsion 
 
stericdepletionVDWticelectrostatotal VVVVV +++=   (C.3) 
 
The “depletion” attraction is an osmotic force arising from the exclusion of 
polymer micelles from the space between two gold particles or embryonic clusters[9].  
The depletion force, along with the propensity for the hydrophilic PEG loops to drive the 
mobile, weakly adsorbed polymer away from the gold cluster interior and to the exterior 
interface with water, explains the low polymer loadings in the clusters.  Thus, the control 
of both the polymer micelle and gold particle volume fractions during evaporation 
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facilitated the attraction that led to cluster formation.  Furthermore, the cluster size is 
maintained by steric repulsion from the PEG loops on the nanocluster exterior for the 
short period until the nanoclusters are harvested.   
The nearly complete deaggregation of the clusters to the original gold primary 
particles may also be explained by the total potential, as well as positive entropy of 
mixing of the individual gold nanoparticles.  For the redispersed nanoclusters in a pure 
solvent, without excess polymer, the electrostatic repulsion becomes much stronger and 
the particles deaggregate. 
 
To determine the size distribution moments in the nanocluster population: 
Size distribution moments, μ1 and μ3, were used to determine whether cluster 

































where r1 is the arithmetic mean radius, r3 is the cube mean radius, rh is the harmonic mean 
radius, and NTot is the total number of particles in the system.  When μ1 = μ3 =1, the size 
distribution moments reflect a monodisperse system where aggregates have been formed 
by condensation.  Size distribution moments where μ1 > 1.25 and μ3 < 0.905 suggest that 
aggregates were formed by coagulation. 
 
To determine the nanocluster extinction cross section: 
For a dilute solution, absorbance (A) follows Beer–Lambert’s Law: 
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A = ε(λ) Cl   (C.6) 
 
where ε is the extinction coefficient , which is dependent on wavelength, C is the 
dispersion concentration, and l is the path length through which light travels.  For a path 
length of 1 cm, determined by cuvette dimensions, and a gold concentration of 56 μg/mL, 
the maximum absorbance, found at a wavelength of 703 nm, was 1.10.  Using Eq. C.6, 
we determined that ε703nm was 0.020 cm2/μg.  Assuming that the nanoclusters are 
spherical, with an average diameter of 100 nm, and the nanoparticles are in a closest-
packed state, the particle extinction cross section was calculated by: 
 
ε703 nm x MAu in 1 nanocluster (C.7) 
where MAu in 1 nanocluster is the mass of gold per nanocluster.  The particle extinction cross 
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Figure C.1 Histogram of separation distances between primary gold nanoparticles 
within a nanocluster.  Measurements (>130 data points) were taken using 
particles on the periphery of the nanoclusters.  Inset is a TEM image of one 



























nanoclusters (in live cells)
 
    
 
Figure C.2 Particle size distribution of primary lysine/citrate-capped Au particles (green 
curve), nanoclusters deaggregated at pH=5 (red curve), and nanoclusters 
after biodegradation in live cells (blue curve) determined by image analysis 
of over 100 particles per sample in TEM micrographs. 
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Figure C.3 Hyperspectral scattering spectra (normalized to the area under the curve) of 
biodegradable nanoclusters at pH=7.4 (dark-blue curve), deaggregated 
nanoclusters at pH=5 (green curve), and the primary lysine/citrate-capped 
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Figure C.4 (A) UV-vis absorbance and (B) particle size distribution of a solution of 
PLA-b-PEG-b-PLA with lysine/citrate-capped gold nanoparticles four hours 
after polymer addition (without evaporation) and after 80% solvent 
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Appendix D:  Kinetic Assembly of Near-IR Active Gold Nanoclusters 
Using Weakly Adsorbing Polymers to Control Size 
 
Calculation of ligand coverage: 
The saturation coverage of citrate ligands on ~4 nm gold particles was compared 
with the experimentally determined citrate/gold ratio obtained by TGA.  The saturation 
coverage of a gold particle by citrate was reported to be 4.6×10-10 mol/cm2 1, which 
corresponds to a footprint of 0.36 nm2/ citrate ligand.  The surface area of the particle was 
divided by the footprint of the ligand to determine the maximum number of citrate 
ligands that could cover the gold particle was ~140.  This amount of citrate coverage on 
the gold nanoparticle corresponds to 6.3% citrate by weight, which agrees well with the 
experimentally determined value of 7% obtained by TGA.  Therefore, the gold surface 
was saturated by citrate ligands.   
 
Calculation of polydispersity index (PDI): 
           The PDI was calculated as Mw/Mn, where Mw and Mn are the weight averaged and 
number averaged masses, respectively and may be calculated using2 
 
  (D.1) 
  (D.2) 
 
where M is mass and N is the number of particles.  PDI determinations were obtained 
using number weighted particle size distributions obtained using DLS.   
 
Calculation of displacement of citrate ligands by lysine: 
The displacement of citrate ligands by lysine on gold nanoparticles was estimated 
using the difference in zeta potentials measured for the citrate-only-capped nanoparticles, 
 282
-44 mV, versus the citrate/lysine-capped nanoparticles, -30 mV.  The charge on the 
particles, Q, was related to the surface potential, ψ0, using 
 
)a(aQ r κ+Ψεε= 100   (D.3) 
 
where εr, the dielectric constant of the aqueous medium, is 80, ε0 is the permittivity of 









=κ    (D.4) 
 
where e is the elementary charge of an electron, NA is Avagadro’s number, and I is the 
ionic strength.  I was calculated to be 0.0053M, shown in detail below, using ligand/gold 









250   (D.5) 
 
where ci is the molar concentration of ion i and  zi is the charge of an ion.  In this system, 
sodium ions are assumed to be the only free ions in solution.  Surface potential was 
estimated using the experimentally measured zeta potential for this calculation.  The ratio 
of charge for the citrate-only capped nanoparticles to that for the citrate/lysine capped 
nanoparticles was used to estimate the displacement of citrate by lysine.  
 
Calculation of size distribution moments: 
Size distribution moments, μ1 and μ3, were used to determine whether cluster 

































where r1 is the arithmetic mean radius, r3 is the cube mean radius, rh is the harmonic mean 
radius, and NTot is the total number of particles in the system.  When μ1 = μ3 =1, the size 
distribution moments reflect a monodisperse system where aggregates have been formed 
by condensation.  Size distribution moments where μ1 > 1.25 and  μ3 < 0.905 suggest that 
aggregates were formed by coagulation3. 
 
Calculation of nanocluster extinction cross section: 
For a dilute solution, absorbance, A, follows Beer–Lambert’s Law:  
 
A = ε(λ) Cl   (D.8) 
 
where ε is the extinction coefficient, C is the dispersion concentration, and  l is the path 
length through which light travels.  For a path length of 1 cm, and a gold concentration of 
56 μg/mL, the maximum absorbance, found at a wavelength of 700 nm, was 1.10.  Using 
Eq. D.8, we determined that the average ε700 nm was 0.017±0.003 cm2/μg for three 
dispersions.  Assuming that the nanoclusters are spherical, 100 nm in diameter, and in a 
closest-packed state, the particle extinction cross section was calculated by, ε700 nm x MAu, 
where MAuis the mass of gold per nanocluster, and was estimated to be 1.0×10-5 
ng/cluster (MAu = Vp×ρp×0.72, where Vp and ρp are the particle volume and density, 
respectively).  The average particle extinction cross section was calculated to be ~9.0 x 
10-15 m2. 
 
Calculation of total interaction potentials and theoretical stability ratios: 
 Total interaction potentials were calculated by summing van der Waals (VDW), 




































AV   (D.9) 
 
where A is the Hamaker constant of particles interacting in an aqueous medium and H is 
the surface to surface separation distance between particles.  The electrostatic interaction 







= ∞   (D.10) 
 
where  n∞ is the bulk ion concentration, and Γ0 is a ratio of constants related to the 
































   (D.11) 
 
where z is the valence of the electrolyte, taken to be 1 in this model, e is the elementary 
charge unit of an electron, and ψ0 is the surface potential of the gold nanoparticle.   
To construct the interaction potential curves, the necessary input parameters were 
calculated as described below.  In order to determine the bulk ion concentration, n∞, the 
number of citrate ligands per gold particle was estimated based on an experimentally 
observed W of ~7×109 for a colloidal gold suspension with no added polymer (Table 6.2).  
Using Eq. 6.6, the stability ratio W may be related to the interaction potential, Vtotal, and 
thus surface potential, ψ0.  Therefore, values for ψ0.were obtained by matching 
experimentally determined W values to an interaction potential.  The corresponding ψ0 
was calculated to be -95 mV.  This value was then used to calculate the charge on the 
particle using Eq. D.34.  The calculated particle charge was used to determine the number 
of charged citrate ligands per particle, which resulted in an estimated value of 11 charged 
citrate ligands per gold nanoparticle.  By using an initial gold concentration of 
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approximately 3 mg/ml, the number density of gold particles can be determined. From 
this value and the estimated charged citrate ligand coverage, the initial n∞ was 
approximately 5.1×1022 charged citrate molecules per cubic meter.  In order to determine 
κ, electro-neutrality was assumed, such that the ionic strength of the solution balances the 








κ =      (D.12) 
 
where zparticle is the valence of the gold nanoparticle, equivalent to the number of citrate 
ligands per particle, nparticle is the number density of gold particles, and εr is 80 in this 
case.  
The depletion contribution to the total potential is described in the text (Eq. 6.5).  
The number density of micelles, required for the depletion calculation, was dependent on 







=ρ ∞    (D.13) 
where Cp is the polymer concentration, CMC is the critical micelle concentration for the 
PLA(2k)-PEG(10k)-PLA(2k) triblock copolymer, which was reported as 7 μg/ml7, and 
Nagg is the aggregation number for the polymer, reported as 165 8.  The summation of the 
potentials determines the total interaction potential (Vtotal), which was normalized by kbT 
and then plotted as a function of surface to surface separation distance for various 
evaporation extents in Fig. 6.9.  In order to calculate the potential for a dispersion of 
nanoclusters, the reduction in surface potential due to ion pairing caused by polymer 
adsorption was regressed from experimentally determined W values using Eq. D.6, taking 
into account the electrostatic, VDW and depletion terms for Vtotal.  Since it was not 
possible to perform a regression for evaporation extents greater than 50% because of the 
excessive turbidity of the solutions, the experimental W value corresponding to 50% 
solvent evaporation, obtained from the observed time required to elicit a change in the 
dispersion color after 50% evaporation, was chosen.  The surface potential reduction 
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from ion pairing was thus determined to be approximately 1.6. This value was then used 
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Figure D.2 Histogram of separation distances between primary gold nanoparticles 
within a nanocluster produced after 100% solvent evaporation (starting gold 
concentration of 3 mg/mL and a PLA-b-PEG-b-PLA/Au ratio of 16/1). 
Measurements taken using particles on the periphery of the nanoclusters.  
Over 130 measurements were taken.  Inset is a TEM image of one of the 






















































Figure D.3 Reproducibility of nanoclusters of citrate/lysine-capped gold nanoparticles 
in terms of (a) size and (b) optical properties. Starting gold and PLA-b-PEG-
b-PLA concentrations were 3 and 50 mg/mL, respectively.  Nanoclusters 


























Figure D.4 UV-vis spectra of clusters of citrate-capped nanoparticles made with the 
mixing protocol.  The starting gold concentration was 3 mg/mL and the 






















Figure D.5 Viscosity of PLA-b-PEG-b-PLA as a function of concentration.  Viscosity 
measurements were performed using a cone and plate viscometer (TA 
Instruments AR 2000ex with a Peltier plate base and aluminum cone, with a 
diameter of 40 mm, angle of 1o 59 minutes and 56 seconds and a truncation 
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Figure D.6 (a) DLS measurements, TEM images after (b) 85% and (c) 100% solvent 
evaporation, respectively, and (d) UV-vis, absorbance spectra for 
nanoclusters composed of citrate-capped gold nanoparticles produced after 
different extents of evaporation with a starting gold concentration of 3 













































Lysine capped collloidal Au
 
Figure D.7 (a) Particle size measurements by DLS and (b) UV-vis absorbance spectra 
of clusters of citrate/lysine-capped nanoparticles formed when varying the 
PLA-b-PEG-b-PLA /Au ratio.  The starting gold concentration was 3 

















C0 =0.19 mg/mL Au
C0 = 0.38 mg/mL Au
C0 = 0.75 mg/mL Au
C0 = 1.5 mg/mL Au
C0 = 3.0 mg/mL Au
Citrate/lysine-capped colloidal Au
 
Figure D.8 UV-vis absorbance spectra of citrate/lysine-capped nanoclusters formed 
when varying the starting concentration of the colloidal gold solution.  The 
















   
   
   





Figure D.9 DLS measurement of PLA-b-PEG-b-PLA micelles prior to solvent 
evaporation and after solvent evaporation.  A 50 mg/mL polymer solution 
was prepared.  To measure the micelle size, the solution was diluted to 1 
mg/mL for analysis by DLS.  To determine the effect of solvent evaporation 
on the polymer, the solution was evaporated to dryness and then redispersed 






Table D.1 Particle sizes, as determined by DLS, of citrate/lysine-capped nanoclusters 
formed when varying the starting concentration of the colloidal gold 
solution.  The starting PLA-b-PEG-b-PLA concentration was 50 mg/mL.    
   
Sample Particle Size Range (nm) 
C0 = 0.19 mg/mL Au 74-118 (12%), 380-608 (80%) 
C0 = 0.38 mg/mL Au 82-122 (62%), 502-613 (38%) 
C0 = 0.75 mg/mL Au 44-57 (68%), 250-377 (32%) 
C0 = 1.5 mg/mL Au 56-100 (89%), 316-562 (11%) 
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